intern
group
expert
infecti
diseas
hct
public
health
work
togeth
compil
document
goal
mind
summar
current
avail
data
field
provid
evidencebas
recommend
regard
prevent
infecti
complic
among
hct
patient
serv
refer
health
care
provid
worldwid
care
hct
recipi
serv
refer
hct
recipi
nonmed
caregiv
updat
guidelin
committe
sought
summar
current
avail
data
present
concis
possibl
evidencebas
fashion
signific
chang
field
hct
sinc
public
origin
guidelin
necessit
updat
chang
includ
new
antimicrobi
agent
broader
use
reducedintens
condit
ric
increas
age
hct
recipi
frequent
use
altern
donor
stem
cell
sourc
haploident
donor
umbil
cord
blood
furthermor
field
medicin
publish
studi
continu
add
evid
regard
support
medic
care
despiteor
perhap
ofthes
chang
infect
still
occur
increas
frequenc
sever
among
hct
recipi
patient
popul
present
guidelin
committe
intend
dictat
standard
practic
although
consider
effort
gone
ensur
guidelin
global
perspect
base
current
avail
medic
evid
adher
particular
recommend
may
inconsist
nation
region
guidelin
avail
specif
procedur
medic
local
epidemiolog
condit
individu
clinician
may
follow
practic
pattern
although
deviat
recommend
nevertheless
effect
sound
purpos
report
hct
defin
transplant
bloodor
marrowderiv
hematopoiet
stem
cell
hsc
regardless
transplant
type
ie
allogen
autolog
cell
sourc
ie
bone
marrow
bm
peripher
blood
pb
umbil
cord
blood
ucb
definit
immun
compet
follow
transplant
loos
defin
abil
hct
recipi
receiv
live
vaccin
follow
recoveri
transplant
convent
thought
occur
approxim
month
follow
hct
patient
receiv
immunosuppress
therapi
activ
graftversushost
diseas
gvhd
patient
ongo
gvhd
continu
use
immunosuppress
therapi
recommend
consid
patient
immun
defici
still
risk
signific
infecti
complic
unless
otherwis
note
recommend
present
report
address
allogen
autolog
pediatr
adult
hct
recipi
recommend
intend
use
recipi
household
close
contact
transplant
infecti
diseas
specialist
hct
center
personnel
public
health
profession
recommend
prevent
strategi
rate
strength
recommend
qualiti
evid
support
recommend
tabl
principl
rate
system
develop
idsa
us
public
health
servic
use
guidelin
prevent
opportunist
infect
among
hivinfect
person
rate
system
allow
assess
strength
recommend
past
decad
modif
hct
manag
support
care
result
chang
recommend
prevent
infect
hct
patient
chang
fuel
new
antimicrobi
agent
increas
knowledg
immun
reconstitut
expand
condit
regimen
patient
popul
elig
hct
despit
advanc
infect
report
primari
caus
death
autolog
hct
patient
allogen
hct
recipi
major
chang
document
includ
chang
recommend
rate
summar
organ
document
similar
previou
guidelin
specif
prevent
exposur
diseas
among
pediatr
adult
autolog
allogen
hct
recipi
discuss
current
recommend
consid
myeloabl
condit
ric
allogen
hct
similarli
data
infecti
complic
follow
ric
compar
condit
spars
howev
increas
inform
regard
posttranspl
immun
recoveri
highlight
differ
ric
hct
includ
section
document
rearrang
attempt
follow
time
cours
potenti
infecti
risk
patient
receiv
hct
follow
background
section
inform
hematopoiet
cell
product
safeti
provid
subsequ
section
discuss
prevent
infect
specif
microorgan
follow
organismspecif
inform
section
discuss
mean
prevent
nosocomi
infect
well
do
dont
patient
follow
discharg
posttranspl
final
inform
vaccin
provid
hope
allow
reader
follow
prevent
practic
need
time
donor
select
patient
regain
immun
compet
sever
topic
new
expand
prior
document
tabl
includ
inform
multipl
organ
previous
discuss
seemingli
becom
clinic
relev
hct
patient
past
decad
data
possibl
recommend
provid
regard
follow
organ
includ
previou
document
bordetella
pertussi
polyomavirus
bk
jc
hepat
b
c
virus
hav
hbv
hcv
human
herpesvirus
hhv
human
metapneumoviru
human
immunodefici
viru
hiv
tuberculosi
nocardiosi
malaria
leishmaniasi
recognit
global
societi
sever
organ
discuss
may
limit
certain
region
world
includ
section
also
infect
may
ubiquit
occur
infrequ
pneumocysti
jiroveci
nocardia
sever
chang
note
bacteri
infect
guidelin
recommend
quinolon
prophylaxi
patient
neutropenia
expect
last
least
day
bi
addit
recommend
contact
precaut
aiii
vaccin
bi
prophylaxi
patient
gvhd
aiii
streptococcu
pneumonia
strengthen
subsect
central
lineassoci
tabl
evidencebas
rate
system
use
hematopoiet
cell
transplant
hct
guidelin
strength
recommend
strong
evid
efficaci
substanti
clinic
benefit
support
recommend
use
alway
offer
b
moder
evid
efficacyor
strong
evid
efficaci
limit
clinic
benefitsupport
recommend
use
gener
offer
c
evid
efficaci
insuffici
support
recommend
use
evid
efficaci
might
outweigh
advers
consequ
eg
drug
toxic
drug
interact
cost
chemoprophylaxi
altern
approach
option
moder
evid
lack
efficaci
advers
outcom
support
recommend
use
gener
offer
e
good
evid
lack
efficaci
advers
outcom
support
recommend
use
never
offer
categori
definit
evid
least
one
wellexecut
random
control
trial
ii
evid
least
one
welldesign
clinic
trial
without
random
cohort
casecontrol
analyt
studi
prefer
one
center
multipl
timeseri
studi
dramat
result
uncontrol
experi
iii
evid
opinion
respect
author
base
clinic
experi
descript
studi
report
expert
committe
blood
stream
infect
bacteri
section
vaccin
section
dramat
expand
chang
includ
recommend
pneumococc
conjug
vaccin
pcv
rather
polysaccharid
vaccin
pneumococc
vaccin
start
vaccin
earlier
posttranspl
addit
recommend
varivax
hpv
vaccin
nonus
zostavax
vaccin
includ
two
addit
appendic
ad
provid
inform
desensit
sulfa
drug
visitor
screen
questionnair
final
dose
appendix
merg
adult
pediatr
dose
provid
recommend
sever
newer
antimicrobi
agent
previous
avail
summari
chang
expans
document
reflect
grow
bodi
literatur
detail
infecti
complic
hct
patient
major
chang
start
page
updat
background
immun
recoveri
follow
hct
includ
differ
base
condit
regimen
stem
cell
sourc
chang
bacteri
section
quinolon
prophylaxi
recommend
patient
neutropenia
expect
last
day
bi
ad
recommend
regard
central
lineassoci
bloodstream
infect
clabsi
addit
section
infect
prevet
control
streptococcu
pneumonia
contact
precaut
aiii
prior
biii
b
antimicrobi
prophylaxi
patient
gvhd
aiii
prior
biii
c
vaccin
pcv
bi
recommend
prior
biii
chang
fungal
section
micafungin
altern
prevent
candidiasi
preengraft
bi
voriconazol
posaconazol
may
use
prevent
candidiasi
postengraft
bi
hematopoiet
cell
transplant
hct
defin
transfer
hematopoiet
stem
cell
hsc
individu
anoth
allogen
hct
return
previous
harvest
cell
individu
autolog
hct
manipul
cell
andor
recipi
goal
hct
lifelong
engraft
administ
cell
result
recipi
lymphohematopoiet
system
deriv
hct
graft
full
donor
engraft
occur
recipi
lymphohematopoiet
system
fulli
replac
progeni
hct
graft
ultim
goal
mani
hct
protocol
especi
achiev
optim
graftversustumor
gvt
activ
patient
malign
diseas
clinic
set
howev
state
mix
chimer
wherein
element
donor
recipi
lymphohematopoiet
system
surviv
may
suffici
cure
underli
condit
allogen
hct
cure
improv
outcom
wide
varieti
diseas
includ
leukemia
lymphoma
myeloprolif
disord
myelodysplast
syndrom
md
bone
marrow
bm
failur
syndrom
congenit
immunodefici
enzym
defici
hemoglobinopathi
howev
allogen
hct
associ
signific
morbid
mortal
regimenrel
toxic
rrt
infect
graft
versu
host
diseas
gvhd
recommend
regard
transplant
individu
patient
requir
care
risk
assess
take
account
diseas
statu
comorbid
previou
therapi
standard
therapi
avail
underli
diseas
donor
stem
cell
sourc
histoincompat
autolog
hct
improv
outcom
neoplast
diseas
autoimmun
condit
continu
investig
platform
gene
therapi
rrt
infect
contribut
morbid
mortal
associ
autolog
hct
howev
morbid
gvhd
gener
occur
procedur
substanti
progress
made
allogen
hct
past
year
result
improv
distinct
interrel
area
first
improv
support
care
patient
sever
immunosuppress
myelosuppress
diminish
morbid
mortal
infect
second
critic
contribut
immunemedi
gvt
effect
toward
erad
malign
diseas
facilit
engraft
well
establish
factor
promin
design
individu
hct
regimen
third
altern
donor
nonsibl
transplant
new
stem
cell
sourc
provid
hct
option
larger
percentag
potenti
candid
fourth
newer
less
toxic
prepar
regimen
develop
allow
reliabl
engraft
lower
risk
treatmentrel
mortal
trm
longterm
advers
effect
classic
transfer
hematopoiet
cell
graft
seen
mean
rescu
recipi
lymphohematopoiet
system
otherwis
lethal
myeloabl
prepar
regimen
model
prepar
regimen
use
primari
tool
erad
malign
diseas
erad
recipi
immun
system
hct
use
treat
benign
diseas
howev
care
clinic
studi
last
decad
reveal
effect
allogen
hct
erad
malign
diseas
intim
link
activ
immunoreact
cell
graft
notabl
cell
case
natur
killer
nk
cell
indirect
demonstr
graftversusleukemia
gvl
effect
come
report
increas
leukem
relaps
follow
syngen
ident
twin
hct
increas
leukemia
relaps
follow
celldeplet
hct
direct
demonstr
provid
abil
donor
lymphocyt
infus
dli
induc
remiss
substanti
number
patient
chronic
myelogen
leukemia
cml
evid
gvt
effect
also
exist
malign
effect
appear
less
potent
observ
cml
furthermor
even
hct
perform
benign
diseas
rate
degre
donor
engraft
enhanc
use
donor
leukocyt
infus
demonstr
immun
cell
also
contribut
engraft
process
thu
hct
evolv
therapi
design
primarili
provid
lymphohematopoiet
rescu
condit
form
immunotherapi
wherein
matur
immun
cell
contain
within
graft
andor
reconstitut
donor
progenitor
play
activ
role
erad
underli
neoplast
diseas
facilit
donor
engraft
expans
graft
sourc
contribut
substanti
progress
allogen
hct
tradit
allogen
hct
involv
transfer
marrow
graft
harvest
hlamatch
sibl
donor
case
histoincompat
limit
minor
antigen
reliabl
type
routin
avail
approxim
potenti
hct
recipi
match
sibl
donor
avail
effort
nmdp
unit
state
donor
registri
throughout
world
approxim
million
individu
undergon
preliminari
hla
type
last
year
result
caucasian
individu
find
suitabl
match
unrel
donor
urd
racial
ethnic
group
howev
chanc
find
suitabl
donor
use
exist
registri
substanti
less
recent
studi
demonstr
proper
hla
match
outcom
follow
match
urd
hct
approach
report
match
sibl
transplant
umbil
cord
blood
ucb
transplant
also
shown
promis
benefit
ucb
stem
cell
sourc
readi
access
abil
cross
hla
barrier
mismatch
relat
haploident
donor
graft
also
continu
role
clinic
hct
especi
patient
congenit
immunodefici
special
center
approach
continu
optim
beyond
multitud
choic
regard
donor
sourc
progress
last
year
also
demonstr
granulocyt
colonystimul
factor
gcsf
mobil
peripher
blood
stem
cell
pbsc
allograft
provid
reliabl
sourc
engraft
offer
advantag
improv
myelogen
cell
recoveri
tradit
marrow
graft
thu
fewer
infect
howev
gcsfmobil
blood
graft
also
appear
carri
greater
risk
chronic
gvhd
cgvhd
compar
marrow
graft
new
approach
develop
minim
likelihood
graft
failur
condit
toxic
gvhd
infect
addit
celldeplet
agent
eg
antithymocyt
globulin
atg
alemtuzumab
condit
regimen
associ
reduc
incid
gvhd
diminish
graft
reject
may
delay
immun
recoveri
nonmyeloabl
nma
prepar
regimen
use
cytotox
drug
lowdos
total
bodi
irradi
tbi
condit
regimen
associ
reduc
nonrelaps
mortal
nrm
provid
new
option
hct
among
elderli
patient
substanti
comorbid
choic
prepar
regimen
decis
regard
rel
merit
versu
nma
regimen
complex
involv
riskadapt
strategi
take
account
underli
diseas
patient
age
comorbid
stem
cell
sourc
histoincompat
relev
factor
summari
hct
play
central
role
treatment
varieti
benign
malign
diseas
field
continu
evolv
rapidli
new
option
donor
sourc
prepar
regimen
time
standard
treatment
mani
diseas
wherein
hct
histor
provid
mainstay
therapi
also
evolv
render
decis
whether
proceed
hct
highli
complex
requir
care
consider
individu
case
light
evidencebas
data
patient
undergo
hct
major
caus
earli
morbid
mortal
diseas
relaps
acut
gvhd
agvhd
infect
rrt
graft
failur
longterm
survivor
hct
risk
varieti
longterm
advers
effect
includ
cgvhd
infect
hypothyroid
steril
growth
failur
endocrin
disturb
cataract
avascular
necrosi
diseas
relaps
second
malign
incid
advers
effect
vari
greatli
differ
prepar
regimen
comorbid
age
transplant
whether
individu
experi
cgvhd
immun
system
recoveri
follow
hct
follow
condit
hct
recipi
typic
experi
period
profound
pancytopenia
span
day
week
depend
upon
donor
sourc
rapid
neutrophil
recoveri
vari
type
graft
approxim
recoveri
time
week
gcsfmobil
pbsc
graft
week
marrow
graft
week
ucb
graft
neutrophil
monocyt
nkcell
recoveri
follow
platelet
red
cell
recoveri
follow
b
cell
recoveri
figur
simultan
regimen
damag
mucos
surfac
therebi
provid
sourc
bloodstream
seed
commens
pathogen
inhabit
gastrointestin
tract
result
infecti
complic
immedi
posttranspl
period
usual
present
febril
neutropenia
sever
risk
relat
depth
durat
neutropenia
degre
mucos
damag
induc
recipi
nma
allogen
transplant
exhibit
substanti
heterogen
depth
durat
pancytopenia
regimen
accomplish
reliabl
engraft
without
clinic
signific
myelosuppress
regimen
minim
myelosuppress
minim
mucos
toxic
risk
infect
immedi
posttranspl
period
reduc
fact
regimen
base
lowdos
tbi
fludarabin
flu
sometim
perform
outpati
set
virtual
elimin
neutropen
complic
although
degre
myelosuppress
milder
follow
nma
regimen
depth
extent
lymphodeplet
tend
similar
prolong
period
immun
incompet
observ
recipi
nma
regimen
engraft
allogen
hematopoiet
progenitor
cell
requir
signific
recipi
immunosuppress
prevent
graft
reject
even
context
full
hla
match
regimen
essenti
complet
erad
recipi
lymphocyt
accomplish
prepar
regimen
howev
regimen
deplet
recipi
lymphocyt
occur
gradual
via
use
donor
leukocyt
infus
follow
transplant
case
vast
major
hct
recipi
experi
neartot
lymphocyt
deplet
thu
must
undergo
lymphoid
reconstitut
via
matur
lymphocyt
lymphoid
progenitor
contain
graft
furthermor
except
celldeplet
hct
graft
administ
allogen
hct
recipi
must
also
receiv
form
immunosuppress
prevent
gvhd
limit
immun
compet
unlik
recoveri
hematopoiet
lineag
typic
occur
cours
week
follow
hct
lymphocyt
recoveri
prolong
process
reestablish
immunocompet
requir
least
sever
month
patient
continu
demonstr
immun
deficit
sever
year
hct
gener
nk
cell
first
lymphocyt
subset
recov
follow
cell
often
reach
supranorm
level
within
month
hct
subsequ
b
cell
ultim
cell
recov
pace
extent
recoveri
lymphocyt
subset
highli
depend
upon
sever
factor
ultim
determin
degre
extent
durat
immun
incompet
experienc
individu
hct
recipi
figur
regener
lymphocyt
human
ineffici
process
primarili
involv
distinct
pathway
first
pathway
lymphocyt
regener
bone
marrow
bm
lymphoid
progenitor
thu
recapitul
ontogeni
regener
immun
system
similar
found
newborn
child
nk
cell
recoveri
use
pathway
exclus
full
recoveri
nk
cell
count
typic
achiev
within
month
follow
hct
b
cell
also
primarili
regener
lymphoid
progenitor
cell
evidenc
appear
primit
b
cell
subset
harbing
b
cell
immun
reconstitut
unlik
nk
cell
recoveri
howev
b
cell
lymphopoiesi
highli
depend
upon
special
marrow
microenviron
term
bursal
equival
suscept
damag
prepar
regimen
exquisit
sensit
toxic
effect
gvhd
andor
treatment
inde
patient
experi
even
limit
episod
steroidrespons
gvhd
show
significantli
diminish
b
cell
reconstitut
long
term
compar
patient
experi
gvhd
although
recent
data
demonstr
matur
b
cell
also
contribut
b
cell
reconstitut
via
homeostat
expans
pathway
appear
minor
compar
marrowderiv
pathway
b
cell
regener
restor
full
humor
immun
compet
follow
hct
requir
reconstitut
b
cell
memori
b
cell
pool
well
latter
occur
result
environment
vaccinebas
exposur
common
pathogen
also
requir
help
cell
therefor
even
hct
recipi
experi
gvhd
demonstr
recoveri
total
b
cell
number
within
month
posttranspl
consid
regain
full
humor
immunocompet
time
least
year
follow
transplant
essenti
hct
recipi
remain
predispos
infect
encapsul
bacteria
virus
neutral
antibodi
provid
first
line
defens
serum
igg
level
provid
littl
insight
b
cell
reconstitut
longliv
radioresist
plasma
cell
surviv
mani
prepar
regimen
produc
substanti
circul
igg
without
provid
humor
respons
specif
pathogen
reliabl
mean
one
assess
humor
immun
compet
follow
transplant
document
clinic
signific
rise
antigenspecif
antibodi
follow
vaccin
infect
inde
medic
center
use
rise
antibodi
level
respons
administr
kill
vaccin
prerequisit
use
liveattenu
vaccin
cell
regener
predominantli
driven
thymicindepend
pathway
term
homeostat
peripher
expans
matur
cell
contain
within
graft
dramat
expand
vivo
respons
cell
lymphopenia
process
driven
combin
factor
among
increas
avail
homeostat
cytokin
includ
interleukin
il
accumul
lymphopenia
inflammatori
cytokin
associ
tissu
damag
induc
prepar
regimen
exposur
viral
antigen
either
environment
via
reactiv
period
profound
lymphopenia
peripher
homoeostat
expans
much
effici
cell
cell
result
chronic
reduc
ratio
hct
recipi
sever
month
follow
hct
memori
cell
first
expand
hct
may
either
donor
origin
case
nont
celldeplet
hct
origin
host
cell
surviv
condit
regimen
case
celldeplet
hct
memori
cell
respond
quickli
previous
encount
pathogen
herpesvirus
factor
analyz
thu
far
count
may
provid
readili
avail
predict
marker
restor
immun
compet
follow
hct
although
predict
valu
low
count
extens
studi
recipi
hct
hiv
infect
sever
studi
demonstr
recoveri
associ
diminish
infecti
risk
improv
transplant
outcom
cell
regener
occur
via
ontogen
thymicdepend
pathway
substanti
rise
cell
number
recoveri
cell
diversif
cell
repertoir
howev
microenviron
thymu
highli
suscept
damag
age
therapi
gvhd
mani
adult
hct
recipi
show
littl
thymicdepend
cell
regener
month
year
follow
hct
studi
adult
recipi
autolog
hct
breast
cancer
reveal
advanc
decad
patient
age
year
decreas
percentag
patient
achiev
effect
immun
reconstitut
year
followup
beyond
gener
rule
hct
recipi
experi
profound
immunosuppress
point
degre
immunosuppress
experienc
individu
patient
vari
greatli
influenc
sever
factor
first
foremost
profound
advers
effect
gvhd
overal
process
essenti
everi
seri
gvhd
sever
correl
degre
immunosuppress
infecti
complic
correl
varieti
factor
compound
one
anoth
includ
damag
lymphoid
microenviron
advers
effect
gvhd
homeostat
peripher
expans
well
obviou
impact
chronic
immunosuppress
reconstitut
immun
system
second
recipi
factor
age
comorbid
infecti
exposur
prior
transplant
contribut
substanti
risk
posttranspl
infecti
complic
illustr
studi
sever
combin
immunodefici
scid
patient
wherein
outcom
success
children
undergo
transplant
experienc
sever
lifethreaten
infect
third
graftassoci
factor
also
play
import
role
recent
studi
suggest
pbsc
graft
recipi
show
rapid
immun
reconstitut
measur
lymphocyt
subset
wherea
ucb
transplant
adult
transplant
profoundli
celldeplet
haploident
graft
result
poor
immun
reconstitut
high
rate
infecti
complic
dose
crucial
level
cellskg
associ
improv
hematopoiet
recoveri
decreas
incid
fungal
infect
improv
overal
surviv
os
recipi
unmanipul
bm
transplant
hlaident
sibl
donor
model
distinguish
infecti
complic
occur
differ
posttransplant
phase
put
forth
base
larg
upon
paradigm
model
shown
figur
phase
preengraft
phase
day
hct
phase
ii
postengraft
phase
day
hct
phase
iii
late
phase
day
hct
phase
prolong
neutropenia
break
mucocutan
barrier
result
substanti
risk
bacteremia
fungal
infect
involv
candida
speci
neutropenia
continu
aspergillu
speci
addit
herp
simplex
viru
hsv
reactiv
occur
phase
phase
ii
infect
relat
primarili
impair
cellmedi
immun
scope
impact
defect
determin
extent
gvhd
immunosuppress
therapi
herpesvirus
particularli
cytomegaloviru
cmv
common
infecti
agent
period
domin
pathogen
phase
includ
pneumocysti
jiroveci
aspergillu
speci
phase
iii
person
cgvhd
recipi
alternatedonor
allogen
transplant
remain
risk
infect
common
pathogen
includ
cmv
varicellazost
viru
vzv
infect
encapsul
bacteria
eg
streptococcu
pneumonia
rel
risk
infect
approxim
proport
sever
patient
gvhd
phase
ii
iii
recipi
nma
graft
substanti
differ
may
observ
phase
suscept
infect
phase
ii
iii
larg
similar
driven
primarili
statu
underli
diseas
histori
gvhd
andor
need
ongo
immunosuppress
risk
diseas
communityacquir
respiratori
virus
crv
elev
phase
phase
iii
howev
outpati
statu
hct
recipi
complic
effort
reduc
exposur
provid
time
intervent
thu
risk
infect
primarili
determin
time
transplant
presenc
absenc
gvhd
factor
includ
donorhost
histocompat
diseas
statu
graft
type
graft
content
condit
intens
neutrophil
engraft
tabl
unfortun
current
definit
laboratori
marker
immun
reconstitut
would
predict
infecti
risk
could
use
tailor
infect
prophylaxi
like
degre
immun
recoveri
measur
variou
assay
associ
clinic
outcom
includ
infect
rate
base
retrospect
studi
includ
rel
small
number
patient
tabl
howev
rigor
proof
associ
lack
moreov
publish
studi
focus
associ
immun
assay
result
outcom
clearli
defin
captur
eg
surviv
nrm
rather
infect
addit
inform
publish
studi
limit
public
bia
ie
tendenc
publish
studi
find
associ
rather
neg
studi
tool
avail
precis
monitor
viralspecif
epsteinbarr
viru
ebv
cmv
immun
respons
hla
tetram
interferong
product
assay
may
help
understand
issu
larg
ideal
prospect
studi
need
first
conclus
determin
immun
monitor
test
prognost
valu
ultim
determin
whether
outcom
would
improv
test
use
tailor
infect
prophylaxi
summari
hct
character
variabl
period
earli
infecti
complic
caus
larg
neutropenia
mucos
damag
prepar
regimen
complic
readili
predict
base
upon
clinic
find
mucos
absolut
neutrophil
count
anc
addit
essenti
hct
recipi
experi
prolong
period
immunosuppress
character
profound
defect
cellmedi
humor
immun
unfortun
readili
avail
surrog
marker
accur
measur
rel
risk
individu
patient
consequ
patient
must
monitor
care
receiv
earli
intervent
sign
symptom
infecti
diseas
patient
immunocompet
improv
progress
increas
time
transplant
observ
led
current
recommend
revaccin
month
includ
live
vaccin
month
patient
longer
receiv
immunosuppress
show
sign
gvhd
howev
import
realiz
mani
hct
recipi
remain
immunocompromis
far
beyond
year
transplantespeci
individu
cgvhd
infect
remain
import
caus
morbid
mortal
futur
work
need
augment
degre
immun
reconstitut
toward
pathogen
malign
identifi
accur
surrog
marker
immunocompet
guid
longterm
manag
highrisk
popul
confer
r
gress
tomblyn
g
ehning
allogen
hct
life
recipi
may
depend
time
select
accept
hlamatch
donor
limit
number
hlamatch
donor
might
identifi
henc
transplant
physician
may
accept
higher
risk
transmiss
infecti
agent
hct
would
permit
routin
blood
transfus
section
provid
strategi
hct
physician
minim
transmiss
infecti
diseas
whenev
possibl
donor
recipi
gener
strategi
dictat
nation
regul
therefor
rate
includ
addit
recipi
safeti
clinician
must
recogn
donor
role
potenti
impact
upon
donor
product
safeti
determin
assess
donor
includ
element
relat
safeti
donor
eg
uncontrol
hypertens
diabet
mellitu
coronari
arteri
diseas
addit
determin
product
safeti
donor
may
clear
donat
product
safeti
perspect
unsuit
medic
condit
render
donat
unsaf
potenti
risk
individu
donat
must
provid
inform
consent
assess
product
safeti
complic
high
frequenc
intern
exchang
survey
world
marrow
donor
associ
found
adult
product
ucb
unit
ship
countri
transplant
center
anoth
countri
robust
intern
activ
creat
challeng
ensur
product
safeti
relat
region
differ
diseas
risk
regulatori
structur
medic
practic
desir
hla
tissu
match
presum
underli
much
intern
exchang
result
potenti
need
recruit
poorli
repres
popul
given
individu
outsid
immedi
famili
highest
likelihood
hla
match
occur
among
person
similar
ethnic
strong
ethic
impetu
pariti
likelihood
hla
match
regardless
patient
ethnic
origin
may
necessit
recruit
hct
donor
geograph
region
endem
condit
would
make
resid
unsuit
routin
blood
tissu
donor
unit
state
fda
issu
regul
cover
product
safeti
donor
elig
includ
screen
relev
communic
diseas
agent
diseas
well
laboratori
test
kit
requir
fda
guidanc
document
topic
found
http
wwwfdagov
cberindexhtml
european
union
gener
requir
defin
european
commiss
direct
donor
elig
defin
commiss
direct
requir
similar
fda
european
union
develop
canada
http
wwwhcscgccadhpmpsbrgtherap
reginitcellctodraftgdctoebaucheldengphp
australia
japan
elsewher
disord
pertin
hct
categor
accord
preval
sever
preval
concern
likelihood
disord
within
potenti
donor
popul
may
highli
depend
upon
donor
geograph
locat
sever
refer
usual
consequ
disord
eas
manag
consequ
highli
pertin
disord
includ
infect
caus
hiv
hepat
b
viru
hbv
hepat
c
viru
hcv
human
cell
leukemia
virus
type
ii
htlvi
htlvii
west
nile
viru
pertin
disord
includ
transmiss
spongiform
encephalopathi
tse
cmv
infect
ebv
infect
syphili
toxoplasmosi
vaccinia
well
virus
use
liveattenu
vaccin
person
acut
infect
cmv
ebv
donat
similarli
acut
toxoplasmosi
donat
acut
ill
resolv
howev
physician
awar
rare
case
person
asymptomat
seroposit
toxoplasma
gondii
might
transmit
infect
hct
uncommon
disord
includ
malaria
tickborn
diseas
rocki
mountain
spot
fever
babesiosi
q
fever
infect
caus
coxiella
speci
colorado
tick
fever
prospect
hct
donor
resid
travel
area
endem
rickettsia
tickborn
pathogen
suspect
acut
tickborn
infect
temporarili
defer
donor
infect
pathogen
exclud
blood
bank
standard
strongli
recommend
deferr
past
histori
q
fever
babesiosi
infect
chronic
babesia
parasit
might
persist
despit
appropri
therapi
addit
research
recommend
defer
person
acut
human
ehrlichiosi
eg
activ
human
granulocyt
anaplasmosi
human
monocyt
ehrlichiosi
well
infect
speci
within
genu
ehrlichia
hct
donat
chaga
diseas
transmiss
transfus
potenti
donor
resid
emigr
endem
area
screen
serolog
trypanosoma
cruzi
infect
research
also
recommend
deferr
hct
donat
past
histori
exist
parasit
persist
despit
therapi
prospect
donor
symptom
activ
tuberculosi
tb
evalu
diseas
activ
tb
donat
tb
well
control
eg
longer
contagi
determin
donor
primari
physician
appropri
medic
therapi
howev
transplant
marrow
untreat
tuberculin
skin
testposit
donor
evid
activ
diseas
pose
known
risk
screen
potenti
donor
tb
tuberculin
skin
test
necessari
prospect
hct
donor
evalu
determin
gener
state
health
whether
pose
risk
transmit
infecti
diseas
recipi
evalu
donor
achiev
screen
laboratori
test
screen
test
autolog
donor
recommend
ensur
safeti
laboratori
personnel
prevent
cross
contamin
autolog
donor
screen
test
autolog
unit
special
label
handl
potenti
infect
detect
transmiss
infect
hct
donor
collect
site
personnel
follow
uptod
publish
guidelin
standard
donor
screen
test
complet
donor
screen
includ
histori
physic
examin
review
medic
record
must
perform
within
month
preced
donat
prior
donat
procedur
screen
must
repeat
updat
abbrevi
screen
may
use
complet
screen
perform
within
previou
month
abbrevi
screen
inquiri
chang
histori
risk
factor
physic
find
practic
critic
new
risk
find
develop
potenti
donor
might
requir
evalu
deferr
donor
month
age
younger
includ
ucb
donat
infant
mother
screen
donor
histori
includ
direct
question
donor
done
telephon
document
donor
respons
review
avail
medic
record
complet
risk
factor
questionnair
eg
nmdp
questionnair
physic
examin
donor
target
detect
stigmata
associ
transfusiontransmiss
diseas
highrisk
activ
addit
donor
screen
laboratori
test
must
perform
assess
relev
infecti
diseas
unit
state
lymphocyt
ucb
donat
specimen
test
must
obtain
within
day
donat
pbsc
bm
donat
specimen
may
obtain
day
donat
european
union
test
specimen
must
obtain
time
donat
within
day
donat
unless
product
store
storag
possibl
sampl
may
obtain
day
prior
donat
howev
invok
requir
retest
donor
day
donat
retest
requir
howev
nucleic
acid
test
hiv
hcv
hbv
includ
initi
specimen
unit
state
pbsc
bm
store
specimen
may
obtain
day
donat
requir
retest
unit
state
posit
result
screen
test
use
determin
diseas
risk
regardless
result
obtain
confirmatori
test
sole
except
test
syphili
syphilisspecif
test
use
determin
elig
oversight
govern
unrel
donor
registri
gener
preclud
use
volunt
unrel
donor
risk
infecti
diseas
transmiss
hct
whether
select
relat
donor
risk
infecti
diseas
transmiss
hct
determin
casebycas
basi
final
respons
hct
physician
possibl
donor
risk
known
infect
bloodborn
pathogen
patient
like
succumb
rapidli
diseas
hct
receiv
physician
must
care
weigh
risk
benefit
use
potenti
infect
donor
cell
person
deni
potenti
lifesav
hct
procedur
sole
basi
risk
infecti
diseas
howev
hct
physician
avoid
transplant
hematopoiet
cell
product
infect
infecti
donor
unless
stem
cell
product
obtain
risk
death
transplant
perform
deem
greater
risk
morbid
death
infect
may
transmit
hct
physician
judg
circumst
case
justifi
use
product
follow
note
recipi
chart
knowledg
author
recipi
hct
physician
regard
potenti
transmiss
infecti
agent
hct
inform
consent
recipi
recipi
legal
guardian
acknowledg
possibl
transmiss
infecti
agent
transplant
subsequ
hct
physician
includ
infecti
agent
differenti
diagnosi
ill
hct
recipi
experi
infect
transmit
diagnos
earli
treat
preemptiv
possibl
infecti
product
except
cmv
seroposit
evid
infecti
label
biohazard
untest
biohazard
applic
warn
label
list
diseas
agent
diseas
donor
shown
reactiv
test
result
tissu
intend
autolog
use
label
autolog
use
onlyus
patient
name
safe
handl
process
storag
donat
unit
personnel
donat
collect
transplant
center
cellprocess
laboratori
courier
servic
follow
current
standard
detect
prevent
extrins
bacteri
fungal
contamin
collect
stem
cell
unit
collect
site
process
transport
transplant
center
current
comprehens
discuss
issu
detail
food
drug
administr
fda
good
tissu
practic
regul
european
commiss
regul
intern
standard
establish
profession
organ
addit
gener
recommend
regard
bacteri
infect
section
provid
specif
recommend
regard
pneumonia
viridan
streptococci
mainli
miti
anginosu
group
h
influenza
type
b
central
lineassoci
blood
stream
infect
clabsi
recommend
regard
specif
nosocomi
infect
includ
legionella
speci
methicillinresist
staphylococcu
aureu
mrsa
staphylococcu
speci
reduc
suscept
vancomycin
vancomycinresist
enterococcu
vre
clostridium
difficil
found
infect
prevent
control
health
care
facil
section
health
care
worker
hcw
other
contact
hematopoiet
cell
transplant
hct
recipi
routin
follow
appropri
hand
hygien
practic
avoid
expos
recipi
bacteri
pathogen
aiii
see
infect
prevent
control
health
care
facil
addit
precaut
patient
colon
certain
contagi
pathogen
eg
mrsa
vre
special
situat
eg
diarrhea
respiratori
diseas
instruct
regard
visitor
pet
plant
describ
infect
prevent
control
health
care
facil
section
cdc
guidelin
guidelin
manag
neutropen
fever
publish
elsewher
prevent
earli
diseas
day
hct
antibacteri
prophylaxi
fluoroquinolon
ie
levofloxacin
prevent
bacteri
infect
strongli
consid
adult
hct
patient
anticip
neutropen
period
day
bi
appendix
lack
data
current
antimicrobi
prophylact
regimen
recommend
children
expert
use
levofloxacin
pediatr
antibacteri
prophylaxi
ciii
antibacteri
prophylaxi
gener
start
time
stem
cell
infus
continu
recoveri
neutropenia
initi
empir
antibacteri
therapi
fever
neutropenia
prophylaxi
continu
recoveri
neutropenia
local
epidemiolog
data
care
consid
appli
fluoroquinolon
prophylaxi
appli
emerg
resist
bacteri
pathogen
monitor
close
increas
quinolon
resist
worldwid
among
gramneg
bacteria
eg
escherichia
coli
klebsiella
pneumonia
pseudomona
aeruginosa
staphylococci
plasmidmedi
quinolon
resist
enterobacteriacea
close
relat
beta
lactamas
inactiv
thirdgener
cephalosporin
quinolonerel
develop
hypervirul
strain
c
difficil
aiii
addit
antigramposit
agent
prophylaxi
regimen
indic
diii
specif
glycopeptid
eg
vancomycin
teicoplanin
use
routin
bacteri
prophylaxi
either
system
prevent
catheterrel
infect
diii
agent
lack
benefit
prophylaxi
use
may
promot
emerg
resist
microorgan
growth
factor
eg
granulocytemacrophagecolonystimul
factor
gmcsf
gcsf
shorten
durat
neutropenia
hct
may
slightli
reduc
risk
infect
shown
reduc
mortal
therefor
routin
use
growth
factor
hct
controversi
recommend
use
made
ci
prophylaxi
metronidazol
shown
reduc
anaerob
bacteri
growth
gut
associ
reduct
acut
graftversushost
diseas
agvhd
recipi
transplant
hlaident
sibl
donor
donor
openlabel
random
trial
howev
evid
insuffici
recommend
routin
gut
decontamin
hct
candid
either
metronidazol
nonabsorb
antibiot
diii
although
intraven
immunoglobulin
ivig
recommend
use
produc
immun
system
modul
gvhd
prevent
ivig
routin
administ
hct
recipi
prophylaxi
bacteri
infect
within
first
day
transplant
di
center
check
total
igg
level
highrisk
hct
recipi
eg
unrel
marrow
graft
patient
sever
hypogammaglobulinemia
ie
igg
mgdl
ivig
prophylaxi
may
consid
appendix
ciii
ivig
dose
frequenc
hypogammaglobulinem
hct
recipi
individu
maintain
trough
serum
igg
concentr
mgdl
halflif
ivig
among
hct
recipi
gener
day
much
shorter
halflif
among
healthi
adult
gener
day
bii
prolong
antibiot
prophylaxi
recommend
prevent
infect
pneumonia
among
allogen
recipi
chronic
cgvhd
long
activ
cgvhd
treatment
administ
aiii
antibiot
select
guid
local
antibiot
resist
pattern
absenc
sever
hypogammaglobulinemia
ie
igg
level
mgdl
might
associ
bacteremia
recurr
sinopulmonari
infect
routin
monthli
ivig
administr
hct
recipi
day
allogen
autolog
hct
recommend
di
mean
prevent
bacteri
infect
recommend
prevent
late
bacteri
infect
among
pediatr
adult
hct
recipi
catheterassoci
infect
lead
caus
bloodstream
infect
hct
recipi
particularli
preengraft
phase
patient
gvhd
infect
often
result
cathet
remov
much
less
commonli
death
hct
recipi
central
venou
cathet
cvc
whether
tunnel
nontunnel
insert
use
maxim
steril
barrier
precaut
ai
prefer
approach
clabsi
prevent
bundl
consist
hand
hygien
full
barrier
precaut
clean
insert
site
chlorhexidin
avoid
femor
site
insert
remov
unnecessari
cathet
although
efficaci
clabsi
prevent
bundl
studi
hct
recipi
element
bundl
recommend
patient
popul
aii
measur
decreas
risk
clabsi
studi
cathet
impregn
minocyclinerifampin
shown
decreas
clabsi
patient
requir
nontunnel
subclavian
central
venou
access
includ
hct
patient
retrospect
studi
minocyclin
rifampin
impregn
cathet
affect
suscept
staphylococci
tetracyclin
rifampin
hct
center
high
clabsi
rate
per
cathet
day
despit
effect
implement
clabsi
bundl
element
use
addit
intervent
minocyclinerifampin
antimicrobialimpregn
cathet
prevent
clabsi
consid
biii
addit
prevent
strategi
eg
cathetersit
dress
regimen
antimicrobialantisept
ointment
antimicrobi
lock
prophylaxi
evalu
extens
assess
among
hct
patient
popul
review
found
similar
risk
infect
regardless
whether
cathet
dress
consist
transpar
semiperm
polyurethan
dress
steril
gauz
tape
povidoneiodin
ointment
mupirocin
ointment
antimicrobi
ointment
appli
cathet
insert
site
fail
show
consist
advantag
compar
antimicrobi
ointment
recent
data
shown
nonhct
patient
chlorhexadineimpregn
spong
decreas
rate
cathet
relat
infect
topic
antimicrobi
avoid
risk
antimicrobi
resist
increas
fungal
colon
immunosuppress
hct
patient
diii
antimicrobi
lock
prophylaxi
use
antimicrobi
solut
includ
contain
vancomycin
studi
patient
longterm
venou
access
devic
develop
neutropenia
metaanalysi
prospect
random
trial
test
vancomycinlock
solut
report
decreas
rate
bloodstream
infect
vancomycinsuscept
organ
delay
onset
first
bloodstream
infect
howev
use
vancomycincontain
lock
recommend
increas
risk
select
staphylococci
reduc
vancomycin
suscept
diii
altern
includ
lock
solut
contain
minocyclineedta
taurolidin
citrat
ethanol
shown
success
prevent
clabsi
salvag
vascular
access
approach
though
promis
recommend
routin
cathet
care
investig
complet
diii
adopt
prevent
practic
hct
program
institut
prospect
data
collect
report
allow
analysi
success
practic
hct
team
also
make
use
system
review
defin
benchmark
rate
clabsi
wide
rang
cathet
type
although
studi
includ
metaanalysi
conduct
exclus
among
hct
patient
hct
team
use
result
assess
center
rel
perform
aspect
qualiti
improv
effort
prevent
exposur
standard
precaut
taken
hospit
patient
infect
pneumonia
aiii
includ
patient
infect
caus
drugresist
strain
invas
pneumococc
infect
ipi
lifethreaten
complic
may
occur
month
year
hct
annual
incid
ipi
transplant
among
allogen
hct
recipi
higher
still
among
cgvhd
transplant
although
ipi
occur
less
frequent
autolog
hct
recipi
annual
incid
transplant
risk
remain
much
higher
immunocompet
popul
effort
prevent
ipi
includ
activ
immun
prophylact
antibiot
tabl
appendix
vaccin
pneumonia
recommend
hct
recipi
prefer
pneumococc
conjug
vaccin
bi
see
hct
recipi
vaccin
antibiot
prophylaxi
pneumococc
infect
indic
patient
cgvhd
low
igg
level
aiii
antibiot
prophylaxi
administ
even
patient
receiv
pneumococc
vaccin
strain
includ
vaccin
immunogen
vaccin
vaccin
strain
hct
patient
theoret
concern
strain
includ
vaccin
replac
vaccin
strain
oral
penicillin
remain
prefer
choic
antibiot
select
depend
local
pattern
pneumococc
resist
penicillin
antibiot
ie
secondgener
cephalosporin
macrolid
quinolon
earli
empir
antibiot
treatment
requir
hct
patient
suspect
ipi
regardless
time
sinc
transplant
immun
statu
use
chemoprophylaxi
aiii
prevent
exposur
viridan
streptococci
normal
commens
primarili
oral
surfac
henc
prevent
effort
must
focu
prevent
system
infect
diseas
rather
prevent
exposur
chemotherapyinduc
oral
mucos
potenti
sourc
viridan
streptococc
bacteremia
sepsi
consequ
start
condit
dental
consult
consid
hct
candid
assess
state
oral
health
perform
need
dental
procedur
decreas
risk
oral
infect
transplant
aiii
mani
expert
recommend
antibiot
activ
viridan
streptococci
given
time
transplant
minimum
day
afterward
ciii
howev
approach
systemat
studi
penicillin
quinolon
vancomycinresist
strain
viridan
streptococci
report
empir
treatment
hct
recipi
fever
sever
mucos
neutropenia
includ
agent
activ
viridan
streptococci
prevent
complic
potenti
fatal
infect
prevent
exposur
vaccin
campaign
markedli
reduc
incid
h
influenza
type
b
hib
diseas
howev
rare
event
patient
hospit
hib
standard
precaut
recommend
droplet
precaut
ad
first
hour
initi
appropri
antibiot
therapi
biii
vaccin
hib
recommend
hct
recipi
least
onethird
hct
recipi
protect
antibodi
level
hib
capsular
polysaccharid
antibodi
hct
hib
conjug
vaccin
excel
efficaci
among
hct
recipi
bii
see
hct
recipi
vaccin
hct
recipi
expos
person
hib
diseas
receiv
prophylaxi
day
rifampin
altern
antimicrobi
agent
rifampin
would
like
interfer
prophylact
agent
patient
receiv
eg
extendedspectrum
azol
biii
appendix
antibiot
prophylaxi
especi
indic
allogen
hct
recipi
cgvhd
increas
risk
develop
infect
hib
encapsul
organ
see
section
pneumonia
prevent
exposur
hct
recipi
may
expos
person
pertussi
diseas
increasingli
frequent
gener
commun
pertussi
adolesc
recipi
unrel
cord
blood
transplant
cbt
report
addit
standard
precaut
droplet
precaut
use
patient
hospit
pertussi
droplet
precaut
recommend
day
initi
effect
therapi
antibiot
treatment
given
week
onset
paroxysm
cough
biii
hct
recipi
expos
person
pertussi
receiv
prophylaxi
azithromycin
anoth
macrolid
trimethoprimsulfamethoxazol
tmpsmz
may
altern
antimicrobi
agent
regardless
age
immun
statu
biii
follow
hct
hct
recipi
receiv
vaccin
acellular
pertussi
see
hct
recipi
vaccin
hematopoiet
cell
transplant
hct
candid
test
presenc
serum
anticytomegaloviru
cmv
igg
antibodi
transplant
determin
risk
primari
cmv
infect
reactiv
hct
aii
cmv
shed
intermitt
oropharynx
genitourinari
tract
immunocompet
immunosuppress
subject
data
demonstr
avoid
bodi
fluid
feasibl
effect
prevent
acquisit
cmv
cmvseroneg
hct
recipi
cmvseroneg
pregnant
health
care
worker
may
risk
contract
cmv
patient
standard
univers
precaut
use
situat
proper
manag
cmvseroneg
patient
low
risk
contract
cmv
infect
reduc
risk
cmv
transmiss
blood
product
cmvseroneg
donor
leukocytedeplet
blood
product
use
cmvseroneg
allogen
hct
recipi
ai
benefit
use
either
product
autolog
hct
recipi
prevent
cmv
transmiss
less
clear
howev
mani
autolog
hct
recipi
receiv
previou
cell
suppress
therapi
fludarabin
flu
alemtuzumab
use
cmvsafe
blood
product
recommend
bii
mani
center
even
entir
countri
leukocyt
filtrat
blood
product
mandatori
control
studi
examin
potenti
benefit
combin
seroneg
blood
product
filter
blood
product
leukocyt
filtrat
perform
blood
bank
establish
qualiti
standard
residu
leukocytesunit
follow
aii
prevent
diseas
diseas
recurr
hct
recipi
risk
posttranspl
cmv
diseas
ie
cmvseroposit
hct
recipi
cmvseroneg
recipi
cmvseroposit
donor
place
cmv
diseas
prevent
program
time
engraft
least
day
hct
ie
phase
ii
ai
physician
use
either
prophylaxi
preemptiv
treatment
allogen
recipi
ai
select
cmv
diseas
prevent
strategi
physician
assess
risk
benefit
strategi
need
condit
patient
hospit
virolog
laboratori
support
capabl
prophylaxi
strategi
earli
cmv
replic
ie
day
hct
allogen
recipi
involv
administ
prophylaxi
allogen
recipi
risk
throughout
period
engraft
day
hct
appendix
ai
ganciclovir
highdos
acyclovir
valacyclovir
shown
efficaci
random
studi
reduc
risk
cmv
infect
hct
ganciclovir
use
induct
cours
usual
start
engraft
ai
although
brief
prophylact
cours
ad
pretranspl
condit
ciii
acyclovir
valacyclovir
use
patient
must
also
undergo
viral
monitor
receiv
preemptiv
antivir
therapi
evid
cmv
replic
found
ai
ivig
recommend
cmv
diseas
prophylaxi
among
hct
recipi
eiii
patient
cmv
diseas
document
transplant
transplant
delay
diseas
adequ
treat
bii
use
secondari
anticmv
prophylaxi
hct
consid
biii
patient
close
monitor
hct
procedur
includ
preengraft
phase
transplant
center
usual
start
monitor
cmv
reactiv
follow
engraft
low
threshold
preemptiv
treatment
use
biii
preemptiv
strategi
target
antivir
treatment
patient
evid
cmv
replic
hct
appendix
requir
use
sensit
specif
laboratori
test
rapidli
diagnos
cmv
replic
hct
enabl
immedi
administr
effect
antivir
therapi
cmv
replic
detect
allogen
recipi
risk
screen
presenc
cmv
blood
sampl
timeweek
day
least
day
hct
ie
phase
ii
aiii
cmvseroposit
cord
blood
transplant
cbt
recipi
increas
risk
cmv
reactiv
diseas
thu
research
use
acyclovir
valacyclovir
prophylaxi
combin
preemptiv
therapi
patient
ciii
preemptiv
strategi
earli
cmv
replic
ie
day
hct
allogen
recipi
prefer
prophylaxi
cmvseroneg
hct
recipi
seroposit
donor
cell
ie
dposit
rneg
low
attack
rate
cmv
replic
screen
filter
blood
product
support
use
bii
diagnost
test
determin
need
preemptiv
treatment
includ
detect
cmv
antigen
leukocyt
antigenemia
cmv
dna
quantit
polymeras
chain
reaction
pcr
detect
cmv
rna
hct
center
perform
allogen
transplant
capac
perform
test
aiii
viral
cultur
urin
saliva
blood
bronchoalveolar
wash
rapid
shellvial
cultur
routin
cultur
today
rare
use
techniqu
less
sensit
cmvdna
pcr
cmv
antigenemia
test
howev
recogn
cmv
antigenemia
test
may
fals
neg
patient
neutropenia
ganciclovir
often
use
firstlin
drug
preemptiv
therapi
although
foscarnet
effect
ganciclovir
current
commonli
use
secondlin
drug
practic
reason
eg
requir
prehydr
electrolyt
monitor
allogen
recipi
day
hct
begin
preemptiv
treatment
cmv
viremia
antigenemia
dna
detect
ai
preemptiv
therapi
given
minimum
week
cmv
still
detect
week
therapi
mainten
therapi
given
cmv
undetect
continu
day
ai
discontinu
preemptiv
therapi
routin
weekli
screen
necessari
least
day
recurr
episod
cmv
viremia
commonli
occur
bii
present
intraven
formul
ganciclovir
approv
use
cmv
prophylact
preemptiv
strategi
ai
valganciclovir
prodrug
ganciclovir
increasingli
use
preemptiv
therapi
interim
analysi
random
control
studi
shown
compar
result
patient
treat
iv
ganciclovir
valganciclovir
dose
adjust
renal
insuffici
necessari
either
drug
avoid
hematolog
toxic
patient
ganciclovirintoler
treat
foscarnet
ai
hct
recipi
receiv
ganciclovir
absolut
neutrophil
count
anc
check
timesweek
biii
expert
report
manag
ganciclovirassoci
neutropenia
ad
granulocyt
colonystimul
factor
gcsf
temporarili
stop
ganciclovir
day
patient
anc
ciii
ganciclovir
restart
patient
anc
consecut
day
altern
foscarnet
substitut
ganciclovir
cmv
still
detect
blood
neutropenia
accompani
ganciclovir
administr
usual
brief
patient
requir
antifung
antibacteri
prophylaxi
diii
true
cmv
antivir
resist
quit
rare
hct
patient
especi
patient
never
previous
treat
antivir
agent
increas
antigenemia
cmv
dna
load
earli
initi
antivir
therapi
usual
sign
treatment
failur
patient
previous
treat
antivir
agent
therefor
necessit
chang
therapi
howev
patient
develop
sign
cmv
diseas
level
antigenemia
cmv
dna
load
continu
rise
week
therapi
resist
cmv
suspect
chang
therapi
consid
biii
develop
cmv
drug
resist
earli
hct
observ
children
transplant
immunodefici
receiv
celldeplet
graft
antit
cell
antibodi
ganciclovir
foscarnet
consid
altern
drug
secondlin
preemptiv
therapi
ai
cidofovir
nucleosid
analog
consid
secondlin
preemptiv
therapi
care
monitor
renal
function
requir
note
crossresist
ganciclovir
occur
bii
possibl
sampl
sent
laboratori
capabl
document
antivir
resist
ciii
certain
cmvseroposit
autolog
recipi
increas
risk
symptomat
cmv
replic
diseas
includ
patient
undergo
condit
regimen
includ
total
bodi
irradi
tbi
patient
receiv
graft
manipul
remov
cell
patient
recent
eg
within
month
prior
hct
receiv
alemtuzumab
flu
cda
patient
may
benefit
use
preemptiv
strategi
includ
monitor
cmv
reactiv
day
hct
cii
patient
transplant
select
graft
treat
level
antigenemia
bii
autolog
recipi
high
risk
experi
moder
high
level
cmv
antigenemia
ie
blood
level
posit
cellsslid
cmv
dna
receiv
week
preemptiv
treatment
ganciclovir
foscarnet
ciii
prophylact
approach
cmv
diseas
prevent
recommend
cmvseroposit
autolog
recipi
dii
hct
recipi
might
develop
reactiv
patient
consid
increas
risk
late
cmv
diseas
routin
screen
evid
cmv
reactiv
long
substanti
immunocompromis
persist
bii
appendix
risk
factor
late
cmv
diseas
includ
allogen
hct
accompani
chronic
graftversushost
diseas
cgvhd
steroid
use
low
count
mm
use
graft
cmvseroneg
donor
cmvseroposit
recipi
use
unrel
haploident
cb
celldeplet
hct
indic
antivir
therapi
cmv
detect
day
determin
individu
basi
depend
patient
risk
factor
develop
late
cmv
diseas
biii
choic
durat
antivir
therapi
similar
cmv
infect
occur
first
day
posttranspl
strategi
prevent
late
cmv
diseas
highrisk
patient
includ
use
continu
surveil
preemptiv
antivir
therapi
well
prophylaxi
antivir
drug
cellular
immunotherapi
patient
defici
absent
cmvspecif
immun
system
function
sever
small
phase
iii
studi
publish
use
adopt
transfer
cmvspecif
andor
cell
especi
patient
develop
repeat
episod
cmv
diseas
howev
none
adopt
cell
transfer
techniqu
routin
clinic
practic
therefor
recommend
prevent
exposur
hct
donor
candid
test
presenc
serum
antiebv
igg
antibodi
transplant
determin
risk
primari
epsteinbarr
viru
ebv
hct
recommend
stronger
pediatr
patient
aii
adult
bii
although
fever
mononucleosi
occur
primari
ebv
infect
signific
clinic
syndrom
associ
ebv
replic
hct
recipi
particularli
follow
primari
infect
posttranspl
lymphoprolif
diseas
ptld
disord
occur
princip
recipi
profound
cell
cytopenia
eg
cell
deplet
tcd
use
antit
cell
antibodi
ucb
transplant
haplo
ident
transplant
assess
blood
ebv
dna
load
quantit
pcr
test
identifi
risk
ptld
ebv
diseas
hct
recipi
typic
result
reactiv
endogen
infect
transmiss
ebv
graft
nevertheless
transplant
candid
particularli
ebvseroneg
advis
behavior
would
decreas
likelihood
ebv
exposur
aii
see
strategi
safe
live
hct
prevent
ebvrel
ptld
appendix
import
monitor
highrisk
eg
cell
deplet
use
antit
cell
antibodi
ucb
transplant
haploident
transplant
patient
ebv
dna
load
use
blood
ebv
pcr
assay
bii
ebv
dna
load
shown
rise
earli
week
prior
diseas
onset
monitor
blood
ebv
dna
load
allow
preemptiv
reduct
immunosuppress
possibl
first
part
patient
manag
variabl
pcr
techniqu
differ
risk
ebvrel
ptld
depend
degre
cell
lymphopenia
firm
recommend
threshold
initi
preemptiv
therapi
made
respons
reduct
immunosuppress
preemptiv
treatment
rituximab
prevent
ptld
bii
infus
donorderiv
ebvspecif
ctl
demonstr
promis
prophylaxi
ebv
lymphoma
among
recipi
celldeplet
unrel
mismatch
allogen
recipi
cii
addit
expand
donorderiv
ebvspecif
cell
use
control
blood
ebv
dna
load
set
procedur
remain
experiment
cii
use
b
cell
deplet
minim
risk
ebv
ptld
also
propos
cii
final
prophylaxi
preemptiv
therapi
current
avail
antivir
agent
recommend
lack
efficaci
dii
prevent
exposur
hct
candid
test
serum
antihsv
igg
transplant
aii
howev
typespecif
antihsv
igg
serolog
test
necessari
hct
candid
particularli
hsv
seroneg
inform
import
avoid
hsv
infect
immunocompromis
advis
behavior
decreas
likelihood
hsv
exposur
aii
see
strategi
safe
live
hct
person
dissemin
primari
sever
mucocutan
hsv
diseas
place
contact
precaut
durat
ill
aii
prevent
transmiss
hsv
hct
recipi
prevent
diseas
diseas
recurr
acyclovir
acyclovir
prophylaxi
offer
hsvseroposit
allogen
recipi
prevent
hsv
reactiv
earli
posttranspl
period
ai
standard
approach
begin
acyclovir
prophylaxi
start
condit
therapi
continu
engraft
occur
mucos
resolv
whichev
longer
approxim
day
hct
ai
appendix
continu
use
acyclovir
appear
prevent
hsv
reactiv
diseas
patient
receiv
vzv
cmv
prophylaxi
cii
routin
acyclovir
prophylaxi
indic
hsvseroneg
hct
recipi
even
donor
hsv
seroposit
diii
use
ganciclovir
prophylaxi
cmv
hct
recipi
suffici
prevent
hsv
drug
vitro
activ
aii
although
ganciclovir
approv
use
hsv
acyclovirresist
hsv
infect
occur
mainli
set
lowdos
prophylaxi
intermitt
treatment
hsvseroneg
donor
foscarnet
treatment
choic
resist
diseas
bi
cidofovir
may
serv
altern
ciii
postengraft
acyclovir
prophylaxi
given
expert
recommend
suffici
high
dose
prevent
emerg
resist
appendix
valacyclovir
although
valacyclovir
approv
use
prevent
hsv
diseas
among
hct
recipi
compar
studi
shown
valacyclovir
acyclovir
equal
effect
suppress
hsv
autolog
hct
patient
toler
oral
medic
ciii
regard
safeti
valacyclovir
use
year
hct
recipi
suppress
vzv
without
toxic
physician
wish
use
valacyclovir
among
recipi
renal
impair
exercis
caution
decreas
dose
need
foscarnet
substanti
renal
infusionrel
toxic
foscarnet
recommend
routin
hsv
prophylaxi
among
hct
recipi
diii
howev
patient
receiv
foscarnet
reason
eg
cmv
prophylaxi
requir
addit
acyclovir
prophylaxi
diii
famciclovir
present
data
regard
safeti
efficaci
famciclovir
among
hct
recipi
limit
therefor
recommend
hsv
prophylaxi
famciclovir
made
hsv
prophylaxi
last
day
hct
might
consid
person
frequent
recurr
hsv
infect
biii
appendix
acyclovir
valacyclovir
use
phase
preengraft
administr
hsvseroposit
autolog
recipi
like
experi
substanti
mucos
condit
regimen
ciii
acyclovir
prophylaxi
dose
modifi
use
among
children
appendix
limit
publish
data
regard
valacyclovir
safeti
efficaci
among
children
recommend
pediatr
popul
made
prevent
exposur
hct
candid
test
presenc
serum
antivaricella
zoster
viru
vzv
igg
antibodi
aii
howev
test
reliabl
particularli
among
sever
immunosuppress
patient
hct
candid
recipi
particularli
vzv
seroneg
inform
potenti
serious
vzv
diseas
among
immunocompromis
person
advis
strategi
decreas
risk
vzv
exposur
aii
although
major
vzv
diseas
hct
caus
reactiv
endogen
vzv
hct
candid
recipi
vzv
seroneg
vzv
seroposit
immunocompromis
avoid
exposur
person
activ
vzv
infect
aii
health
care
worker
hcw
famili
member
household
contact
visitor
healthi
report
histori
varicella
infect
vzvseroneg
receiv
vzv
vaccin
allow
visit
direct
contact
hct
recipi
aiii
ideal
vzvsuscept
famili
member
household
contact
potenti
visitor
immunocompromis
hct
recipi
vaccin
soon
decis
made
perform
hct
vaccin
schedul
complet
week
hct
perform
biii
date
seriou
diseas
report
among
immunocompromis
patient
transmiss
vzv
vaccin
viru
vzv
vaccin
strain
suscept
acyclovir
howev
hct
recipi
undergo
condit
therapi
avoid
contact
vzv
vaccin
recipi
experi
rash
vaccin
biii
rash
vaccin
wildtyp
vzv
median
day
rang
day
vzv
vaccin
strain
median
day
rang
day
hct
recipi
multidermatom
vzv
diseas
place
airborn
contact
precaut
aii
prevent
transmiss
hct
recipi
dermatom
zoster
requir
contact
precaut
skin
lesion
crust
aii
research
also
recommend
airborn
precaut
immunocompromis
patient
high
risk
dissemin
zoster
rash
cii
airborn
precaut
institut
day
exposur
vzv
continu
day
last
exposur
aii
day
postexposur
patient
receiv
varicellazost
immunoglobulin
vzig
bii
person
infect
vzv
inecti
rash
appear
vzig
product
current
avail
unit
state
varizig
prevent
diseas
antivir
drug
longterm
acyclovir
prophylaxi
prevent
recurr
vzv
infect
routin
recommend
first
year
hct
vzvseroposit
allogen
bi
autolog
cii
hct
recipi
appendix
regimen
acyclovir
highli
effect
reduc
risk
vzv
diseas
year
acyclovir
administr
bi
acyclovir
prophylaxi
may
continu
beyond
year
allogen
hct
recipi
cgvhd
requir
system
immunosuppress
bii
optim
durat
prophylaxi
poorli
defin
patient
cgvhd
appear
persist
risk
vzv
reactiv
diseas
even
acyclovir
continu
system
immunosuppress
drug
discontinu
count
exce
cellsml
clinician
advoc
continu
acyclovir
prophylaxi
month
discontinu
system
immunosuppress
agent
ciii
valacyclovir
prodrug
acyclovir
may
use
altern
acyclovir
time
oral
medic
use
valacyclovir
may
provid
higher
drug
level
sever
immunosuppress
patient
acyclovir
bii
although
valacyclovir
licens
unit
state
use
hct
recipi
larg
random
trial
hct
recipi
found
safeti
issu
valacyclovir
even
use
high
dose
data
famciclovir
hct
recipi
found
consequ
recommend
made
regard
use
place
acyclovir
valacyclovir
resist
acyclovir
rare
document
date
hct
recipi
howev
clinic
suspect
virolog
document
acyclovir
resist
occur
among
patient
hct
physician
use
foscarnet
preemptiv
treatment
vzv
diseas
biii
hct
recipi
candid
undergo
condit
therapi
experi
vzvlike
rash
whether
exposur
person
wildtyp
varicella
shingl
exposur
vzv
vaccine
rash
receiv
preemptiv
intraven
acyclovir
day
lesion
crust
bii
treatment
may
complet
oral
valacyclovir
patient
toler
oral
medic
high
morbid
vzvassoci
diseas
among
sever
immunocompromis
hct
recipi
data
publish
situationspecif
indic
administr
vzig
varizig
avail
vzvseroneg
hct
recipi
immunocompromis
hct
recipi
ie
allogen
patient
month
hct
month
hct
immunosuppress
therapi
cgvhd
receiv
vzig
varizig
soon
possibl
later
hour
close
household
contact
person
either
chickenpox
shingl
aii
postexposur
acyclovir
valacyclovir
appendix
may
use
altern
vzig
varizig
avail
cii
vzig
varizig
acyclovir
valacyclovir
also
administ
vzvseroneg
hct
recipi
undergo
condit
therapi
expos
vzv
vaccine
varicellalik
rash
biii
vzvseroneg
hct
recipi
undergo
condit
therapi
close
expos
varicella
week
receiv
vzig
varizig
receiv
anoth
dose
vzig
varizig
anoth
cours
valacyclovir
vzig
varizig
avail
biii
passiv
immun
vzvseroposit
hct
recipi
vzig
varizig
acyclovir
valacyclovir
use
follow
vzv
exposur
includ
exposur
vzv
vaccine
varicellalik
rash
hct
recipi
vzvseroposit
hct
highli
immunosuppress
ie
highdos
steroid
therapi
cd
ciii
recommend
made
vaccine
might
unknowingli
incub
wildtyp
varicella
particularli
first
day
varicella
vaccin
vaccinestrain
vzv
rare
transmit
vzv
vaccine
postvaccin
vesicular
rash
furthermor
varicella
vaccin
approxim
effect
thu
vaccin
recipi
may
still
becom
infect
wildtyp
viru
year
vaccin
may
thu
sourc
transmiss
immunocompromis
patient
vzv
vaccin
use
vzv
vaccin
varivax
zostavax
discuss
hct
recipi
vaccin
section
vaccineassoci
rash
occur
approxim
recipi
varicella
zoster
vaccin
respect
rash
potenti
sourc
transmiss
vaccin
viru
strain
hct
recipi
risk
vaccin
viru
transmiss
low
particularli
absenc
vaccineassoci
rash
household
member
receiv
varicella
vaccin
protect
hct
recipi
potenti
exposur
wildtyp
diseas
aiii
individu
experi
vaccineassoci
rash
avoid
close
contact
hct
recipi
home
set
biii
contact
occur
hct
recipi
consid
postexposur
prophylaxi
valacyclovir
outlin
earlier
ciii
inactiv
vzv
vaccin
use
investig
among
hct
recipi
studi
ongo
defin
util
recommend
regard
use
made
time
recommend
vzv
prevent
allogen
autolog
recipi
recommend
also
allograft
recipi
differentintens
condit
regimen
recommend
prevent
vzv
diseas
among
pediatr
adult
hct
recipi
except
appropri
dose
adjust
acyclovir
deriv
vzig
made
pediatr
hct
recipi
aiii
appendix
prevent
crv
exposur
critic
prevent
crv
diseas
measur
prevent
nosocomi
crv
transmiss
present
infect
prevent
control
health
care
facil
recommend
regard
crv
infect
section
use
pcr
test
donor
respiratori
infect
remain
investig
ciii
viral
cultur
asymptomat
hct
candid
unlik
use
whether
multiplex
pcr
test
identifi
asymptomat
shedder
hct
present
studi
pcrbase
routin
surveil
asymptomat
patient
hct
remain
investig
hct
recipi
symptom
upper
respiratori
infect
uri
lower
respiratori
infect
lri
place
contact
precaut
avoid
transmit
infect
hct
candid
recipi
hcw
visitor
etiolog
ill
identifi
biii
optim
isol
precaut
modifi
need
etiolog
identifi
biii
hct
recipi
candid
famili
member
visitor
hcw
inform
regard
crv
infect
control
measur
potenti
sever
crv
infect
among
hct
recipi
biii
hct
physician
determin
etiolog
uri
hct
recipi
possibl
respiratori
syncyti
viru
rsv
influenza
parainfluenza
adenoviru
uri
progress
seriou
lri
certain
crv
treat
biii
appropri
diagnost
sampl
includ
nasopharyng
wash
swab
aspir
throat
swab
combin
nasal
sampl
bronchoalveolar
lavag
bal
fluid
hct
candid
uri
symptom
time
condit
therapi
schedul
start
postpon
condit
regimen
uri
resolv
possibl
certain
uri
might
progress
lri
immunosuppress
biii
clinic
relev
recent
discov
virus
eg
human
bocaviru
nonsar
coronavirus
human
rhinovirus
human
metapneumoviru
detect
molecular
method
current
undefin
recommend
made
routin
screen
virus
ciii
lifelong
season
influenza
vaccin
trival
inactiv
vaccin
recommend
hct
candid
recipi
see
vaccin
section
aii
addit
influenza
vaccin
famili
member
close
household
contact
strongli
recommend
influenza
season
eg
octobermay
northern
hemispher
start
season
hct
continu
month
hct
aii
prevent
influenza
famili
member
close
household
contact
hct
recipi
continu
vaccin
annual
long
hct
recipi
immunocompromis
persist
even
beyond
month
hct
aii
season
influenza
vaccin
strongli
recommend
hcw
hct
recipi
ai
hcw
famili
member
close
contact
hct
recipi
receiv
influenza
vaccin
influenza
outbreak
receiv
chemoprophylaxi
feasibl
week
influenza
vaccin
bi
immunolog
respons
vaccin
develop
howev
outbreak
occur
influenza
strain
contain
avail
influenza
vaccin
healthi
famili
member
close
household
contact
hcw
hct
recipi
candid
receiv
influenza
chemoprophylaxi
activ
agent
current
circul
strain
influenza
end
outbreak
biii
zanamivir
may
given
prevent
influenza
b
includ
influenza
strain
resist
oseltamivir
durat
prophylaxi
depend
type
exposur
zanamivir
administ
person
year
age
older
prevent
influenza
year
older
treatment
influenza
oseltamivir
administ
person
year
age
older
patient
influenza
place
droplet
standard
precaut
aiii
prevent
transmiss
influenza
hct
recipi
hcw
influenza
excus
patient
care
longer
infecti
aiii
hct
recipi
month
hct
receiv
chemoprophylaxi
neuraminidas
inhibitor
commun
influenza
outbreak
lead
nosocomi
outbreak
aii
commun
outbreak
hct
recipi
yet
receiv
current
influenza
vaccin
vaccin
influenza
immedi
month
hct
biii
addit
allow
suffici
time
patient
experi
immunolog
respons
influenza
vaccin
chemoprophylaxi
use
hct
recipi
week
vaccin
nosocomi
commun
influenza
outbreak
ciii
influenza
chemoprophylaxi
recommend
influenzaexpos
hct
recipi
month
hct
month
hct
substanti
immunocompromis
regardless
vaccin
histori
like
suboptim
immunolog
respons
influenza
vaccin
bii
drug
resist
pattern
circul
influenza
strain
guid
choic
prophylact
agent
healthi
children
receiv
influenza
vaccin
first
time
might
gener
protect
antibodi
week
receipt
second
dose
influenza
vaccin
therefor
influenza
outbreak
pediatr
recipi
year
old
month
hct
receiv
first
influenza
vaccin
given
week
influenza
chemoprophylaxi
first
dose
influenza
vaccin
biii
appendix
prevent
sever
diseas
hct
patient
influenza
uri
receiv
earli
preemptiv
therapi
drug
shown
suscept
circul
strain
aii
respiratori
secret
hospit
hct
candid
recipi
experi
sign
symptom
crv
infect
test
promptli
viral
cultur
rapid
diagnost
test
rsv
biii
diagnost
sampl
taken
day
apart
identifi
respiratori
pathogen
despit
persist
lower
respiratori
symptom
bal
test
advis
biii
test
critic
high
morbid
case
fatal
rsv
diseas
frequent
presenc
signific
copathogen
among
hct
recipi
occur
peritranspl
period
hct
recipi
particularli
preengraft
lymphopen
preexist
obstruct
airway
diseas
highest
risk
sever
rsv
pneumonia
patient
ill
diagnos
earli
ie
rsv
uri
receiv
aggress
treatment
prevent
fatal
rsv
diseas
biii
basi
retrospect
studi
well
prospect
trial
inadequ
accrual
research
recommend
preemptiv
aerosol
ribavirin
patient
rsv
uri
especi
lymphopenia
first
month
hct
preexist
obstruct
lung
diseas
late
hct
ciii
although
definit
uniformli
effect
preemptiv
therapi
rsv
infect
among
hct
recipi
identifi
certain
strategi
propos
includ
system
ribavirin
rsv
antibodi
ie
passiv
immun
highrsvtit
ivig
rsv
immunoglobulin
combin
aerosol
ribavirin
rsv
monoclon
antibodi
mab
random
trial
complet
test
efficaci
strategi
therefor
specif
recommend
regard
strategi
given
time
prevent
rsv
diseas
center
provid
monthli
palivizumab
prophylaxi
rsv
season
eg
novemberapril
northern
hemispher
pediatr
recipi
risk
primari
rsv
diseas
ie
children
year
old
ciii
routin
ivig
therapi
would
still
requir
indic
ie
hypogammaglobulinemia
appendix
immunoprophylaxi
withdraw
immunosuppress
prevent
progress
preemptiv
treatment
parainfluenza
viru
infect
among
hct
recipi
propos
howev
recommend
made
guidelin
insuffici
data
commerci
licens
drug
vaccin
parainfluenza
virus
current
avail
human
metapneumoviru
caus
pneumonia
hct
recipi
ribavirin
vitro
anim
model
activ
human
metapneumoviru
howev
recommend
made
guidelin
lack
treatment
data
recommend
prevent
crv
infect
recurr
allogen
autolog
recipi
gener
recommend
appli
children
adult
appropri
adjust
antivir
drug
influenza
vaccin
dose
children
appendix
progress
lower
tract
diseas
appear
less
common
hct
recipi
nonmyeloabl
nma
condit
specif
recommend
patient
made
time
adenoviru
infect
hct
result
reactiv
de
novo
acquisit
mani
differ
serotyp
exist
knowledg
crossreact
immun
limit
pretranspl
serolog
test
either
patient
donor
like
help
cellular
immun
respons
crossreact
across
variou
serotyp
like
provid
longterm
protect
adenoviru
reactiv
seriou
adenoviru
infect
adult
uncommon
hct
recipi
follow
similar
prevent
measur
respiratori
enter
virus
see
recommend
regard
crv
cmv
enter
virus
regard
contact
nosocomi
spread
see
infect
prevent
control
health
care
facil
safe
live
hct
hct
patient
stratifi
accord
risk
adenovir
diseas
lowest
riskautolog
hct
recipi
intermedi
riskt
cell
replet
relateddonor
allograft
recipi
without
gvhd
higher
riskrecipi
celldeplet
log
relatedor
unrelateddonor
transplant
hla
mismatch
transplant
recipi
allel
mismatch
patient
gvhd
receiv
system
steroid
pediatr
recipi
highest
riskrefractori
gvhd
ucb
transplant
haploident
transplant
stem
cell
graft
cell
deplet
log
use
antit
cell
antibodi
eg
antithymocyt
globulin
atg
alemtuzumab
patient
highest
risk
weekli
monitor
activ
adenoviru
infect
pcr
either
first
month
hct
durat
sever
immunosuppressionlymphopenia
could
consid
cii
quantit
pcr
test
strongli
consid
monitor
progress
adenoviru
infect
respons
treatment
bii
definit
data
critic
valu
viral
load
peripher
blood
indic
initi
intervent
thu
recommend
made
clearanc
adenoviru
shown
associ
recoveri
adenovirusspecif
cell
immun
possibl
rapid
taper
withdraw
immunosuppress
constitut
best
way
prevent
progress
adenoviru
infect
aii
howev
strategi
might
alway
feasibl
sever
gvhd
sever
lymphopenia
use
antit
cell
antibodi
cd
graft
antivir
agent
vivo
activ
adenovirus
random
placebocontrol
studi
antivir
drug
therapi
adenovir
infect
perform
avail
data
suggest
cidofovir
ribavirin
could
use
preemptiv
antivir
therapi
adenovir
diseas
select
highrisk
hct
patient
cii
appendix
reduct
dna
load
shown
mainli
cidofovir
evid
efficaci
prevent
mortal
hct
patient
inconsist
differ
respons
may
strainspecif
suscept
durat
preemptiv
therapi
subject
toler
clearanc
viral
load
current
evid
strongli
support
role
adenovirusspecif
cell
control
progress
adenovir
diseas
howev
approach
earli
stage
develop
use
outsid
context
clinic
trial
human
polyomaviru
type
commonli
call
bk
viru
bkv
human
polyomaviru
type
ii
commonli
call
jc
viru
jcv
infect
human
worldwid
age
year
without
known
symptom
sign
urinari
shed
bkv
andor
jcv
occur
healthi
immunocompet
blood
donor
bkv
jcv
nonenvelop
virion
found
urban
sewag
fairli
resist
environment
inactiv
polyomaviru
diseas
hct
patient
often
correspond
secondari
bkv
replic
impair
polyomavirusspecif
cellular
immun
urinari
shed
bkv
occur
hct
recipi
major
diseas
link
highlevel
polyomaviru
replic
bkvassoci
hemorrhag
cystiti
pvhc
affect
hct
recipi
ro
week
posttranspl
pvhc
occur
typic
engraft
must
distinguish
hemorrhag
cystiti
caus
pathogen
eg
adenoviru
cmv
earlyonset
hemorrhag
cystiti
aris
preengraft
link
urotox
condit
regimen
cyclophosphamid
cy
ifosfamid
busulfan
bu
andor
tbi
bkv
viruria
reach
high
viral
load
genom
equivalentsml
geqml
observ
hct
patient
less
onefifth
hct
recipi
develop
pvhc
pvhc
diagnos
hct
patient
postengraft
cystiti
pain
urinari
urgenc
togeth
hematuria
grade
ii
macrohematuria
higher
highlevel
bkv
replic
ie
geqml
exclus
pathogen
report
sporad
case
jcvassoci
pvhc
bkvor
jcvassoci
polyomaviru
nephropathi
pvan
jcvor
bkvmediat
polyomaviru
multifoc
leukoencephalopathi
pvml
evid
support
routin
test
hct
recipi
donor
presenc
bkvspecif
jcvspecif
antibodi
diii
commerci
avail
standard
fdaapprov
assay
measur
bkvor
jcvspecif
antibodi
role
primari
infect
donorrecipi
mismatch
bkvspecif
antibodi
titer
hct
recipi
present
unknown
evid
support
specif
infectioncontrol
measur
hct
patient
bkv
viruria
diii
patient
dissemin
bkv
replic
involv
respiratori
gastrointestin
gi
tract
separ
patient
signific
immunodefici
consid
ciii
evid
support
use
quinolon
cidofovir
specif
univers
prophylaxi
pvhc
polyomavirusassoci
complic
diii
insuffici
evid
support
use
quinolon
preemptiv
treatment
asymptomat
hct
patient
develop
bkv
viruria
viremia
diii
fluoroquinolon
inhibit
bkv
replic
tissu
cultur
report
reduc
bkv
load
hct
patient
signific
reduct
pvhc
demonstr
ciprofloxacin
levofloxacin
frequent
use
alon
combin
antibiot
patient
undergo
hct
antibacteri
prophylaxi
neutropenia
empir
specif
antibiot
therapi
seemingli
resist
bkv
isol
report
evid
support
use
cidofovir
preemptiv
treatment
asymptomat
hct
patient
develop
bkv
viruria
viremia
diii
cidofovir
administ
intraven
low
dose
ie
mgkg
time
weekli
without
probenecid
high
dose
ie
mgkg
per
week
probenecid
hct
patient
pvhc
random
trial
avail
prove
clinic
efficaci
ciii
seropreval
hav
vari
wide
higher
rate
resourcelimit
societi
test
hct
candid
donor
hav
igg
antibodi
gener
recommend
sole
posit
absenc
igm
indic
remot
exposur
impact
hct
outcom
diii
howev
test
igm
indic
part
workup
patient
sign
acut
hepat
aii
hct
candid
test
posit
hav
igm
transplant
delay
increas
risk
sinusoid
obstruct
syndrom
so
follow
livertox
myeloabl
condit
regimen
dii
hct
donor
test
posit
hav
igm
transplant
delay
high
risk
transmiss
increas
morbid
mortal
eii
hav
vaccin
recommend
hct
recipi
provid
tabl
hbv
caus
sever
hepat
follow
hct
howev
rate
hbvassoci
cirrhosi
hepatocellular
carcinoma
appear
higher
hct
patient
nonhct
patient
sever
hepat
b
observ
hct
recipi
follow
situat
hct
recipi
expos
hbv
via
infect
donor
infect
blood
product
sexual
contact
hct
recipi
chronic
hepat
b
experienc
prolong
immun
suppress
hct
recipi
serolog
evid
resolv
hbv
infect
revers
seroconvers
follow
prolong
immun
suppress
hct
patientsgener
countri
endem
hbvwith
latent
occult
hepat
b
serolog
marker
neg
activ
follow
prolong
immun
suppress
risk
factor
reactiv
exacerb
hbv
replic
hct
recipi
includ
treatment
highdos
steroid
flurituximab
alemtuzumab
clinic
hepat
may
becom
exacerb
immun
recoveri
discontinu
immunosuppress
test
recipi
potenti
donor
evid
activ
past
hbv
infect
critic
prevent
hbv
exposur
diseas
hct
recipi
appropri
assay
includ
hbv
surfac
antigen
hbsag
antibodi
hbv
surfac
antigen
antihb
antibodi
hbv
core
antigen
antihbc
aii
antihbc
posit
hbsagposit
donor
recipi
also
test
hbv
dna
aiii
hct
candid
receiv
transplant
hbsagposit
hbv
dnaposit
donor
anoth
equal
suitabl
donor
avail
aii
howev
use
donor
activ
hbv
replic
absolut
contraind
recipi
viral
transmiss
univers
biii
overrid
concern
must
hla
match
outcomerel
issu
vaccin
hct
candid
consid
aiii
attempt
made
provid
hepat
b
immun
hbvseroneg
hct
candid
hbsagposit
donor
prefer
prior
chemotherapi
initi
dose
week
apart
third
dose
month
later
ideal
prior
hct
biii
schedul
met
third
dose
administ
month
complet
chemotherapi
note
respons
vaccin
like
poor
patient
undergo
chemotherapi
postvaccin
antihb
titer
iul
pretransplant
vaccin
impract
hbig
mlkg
administ
immedi
prior
infus
stem
cell
aiii
hct
recipi
fail
respond
pretranspl
vaccin
remain
uninfect
posttranspl
ie
neg
hbsag
antihbc
antihb
hbv
dna
revaccin
immun
recoveri
dose
hepat
b
vaccin
bii
donor
detect
hbv
dna
load
follow
measur
recommend
biii
administ
antivir
treatment
donor
least
week
hbv
dna
undetect
time
permit
mani
expert
prefer
entecavir
purpos
ciii
reduc
harvest
volum
minimum
possibl
without
compromis
plan
cell
dose
test
aliquot
cell
product
hbv
dna
time
harvest
donor
harvest
cell
hbv
dnaneg
monitor
alanin
aminotransferas
alt
level
monthli
recipi
first
month
alt
level
increas
test
recipi
hbv
dna
aiii
hbv
dna
test
avail
test
hbsag
accept
altern
hbv
dna
detect
posit
hbsag
identifi
antivir
treatment
indic
aiii
donor
cell
product
posit
hbv
dna
time
harvest
provid
hct
recipi
prophylaxi
lamivudin
day
zero
least
month
follow
discontinu
immunosuppress
drug
consid
administr
second
dose
hbig
week
transplant
aiii
monitor
alt
hbv
dna
monthli
hbv
dna
posit
lamivudin
prophylaxi
treatment
may
modifi
detail
later
donor
antihbc
posit
neg
hbsag
antihb
donor
test
hbv
dna
biii
hbv
dna
assay
posit
treat
describ
bullet
earlier
donor
detect
hbv
viral
load
biii
hbv
dna
test
neg
repeat
test
donor
time
harvest
consid
hbv
dna
remain
neg
hct
perform
without
precaut
diii
repeat
test
posit
treat
describ
biii
hct
recipi
monogam
relationship
known
hbsag
carrier
sexual
activ
longterm
monogam
relationship
alway
use
latex
condom
sexual
contact
reduc
risk
primari
hbv
infect
aiii
hct
candid
evid
past
exposur
hbv
ie
antihbc
posit
specif
recommend
depend
pattern
test
result
risk
posthct
hepat
reduc
via
adopt
transfer
donor
natur
immun
equal
suitabl
donor
demonstr
natur
immun
antihb
posit
antihbc
posit
prefer
donor
without
natur
immun
recipi
evid
prior
hbv
exposur
hct
recipi
antihbc
posit
antihb
posit
risk
hbv
reactiv
consid
low
chemotherapycondit
higher
follow
prolong
treatment
prednison
gvhd
serum
alt
follow
patient
level
increas
hbv
dna
load
assess
patient
posit
hbv
dna
load
receiv
preemptiv
antivir
treatment
describ
later
aiii
prophylact
antivir
treatment
may
consid
antihbc
posit
antihb
posit
recipi
month
hct
ciii
addit
antihb
level
monitor
everi
month
reduct
antihb
titer
prompt
hbv
dna
test
biii
patient
lose
antihb
respons
hbv
dna
serum
receiv
activ
immun
attempt
restor
protect
level
antihb
biii
patient
posit
hbv
dna
assay
receiv
antivir
therapi
aiii
durat
antivir
treatment
set
studi
common
practic
continu
therapi
least
month
follow
discontinu
immun
suppress
drug
biii
rebound
hbv
replic
clinic
hepat
may
follow
discontinu
antivir
treatment
monitor
regular
measur
alt
hbv
dna
eg
biweekli
biii
hct
candid
evid
activ
hbv
replic
hbsag
posit
andor
hbv
dna
posit
liver
biopsi
prior
hct
preexist
biopsyproven
cirrhosi
hepat
fibrosi
increas
treatmentrel
morbid
mortal
trm
biii
antivir
therapi
initi
prior
condit
hct
urgent
antivir
treatment
administ
month
prior
condit
patient
persist
hbv
dna
therapi
lamivudin
treatment
may
modifi
detail
later
rebound
hbv
replic
fulmin
hepat
may
occur
follow
discontinu
antivir
treatment
therefor
discontinu
antivir
therapi
perform
judici
frequent
monitor
liver
function
hbv
dna
biii
hct
candid
posit
antihbc
neg
hbsag
antihb
test
hbv
dna
hbv
dna
undetect
patient
receiv
hbv
vaccin
describ
proceed
hct
manag
regard
monitor
antivir
treatment
perform
describ
antihbcposit
antihbsposit
hct
candid
biii
hbv
dna
posit
proceed
hct
preemptiv
antivir
therapi
describ
antivir
treatment
therapi
coordin
hct
physician
infecti
diseas
andor
hepatolog
specialist
expertis
chronic
viral
hepat
lamivudin
mgday
first
choic
antivir
therapi
ai
antivir
therapi
continu
least
month
posttranspl
autolog
hct
patient
month
follow
discontinu
immun
suppress
drug
allogen
hct
patient
longer
patient
receiv
immunosuppress
cgvhd
biii
extend
use
lamivudin
result
reduct
hbv
reactiv
result
complic
also
lower
hbvassoci
mortal
hct
donor
hcvrnaposit
invari
transmit
hcv
uninfect
recipi
develop
viremia
immedi
posttransplant
period
convers
risk
transmiss
decreas
hcvrna
undetect
time
hematopoiet
cell
donat
evid
advers
shortterm
effect
hcv
infect
hct
recipi
hcvinfect
hct
patient
similar
morbid
year
transplant
subsequ
howev
patient
risk
progress
cirrhosi
may
occur
rapidli
nonhct
patient
cumul
incid
biopsyproven
cirrhosi
year
posttranspl
respect
median
year
compar
year
nonhct
hcvinfect
patient
extrahepat
manifest
infect
hcv
genotyp
increas
risk
progress
hct
candid
assess
risk
hcv
infect
care
histori
physic
examin
serum
alt
test
biii
well
measur
antihcv
antibodi
titer
aii
even
antihcv
titer
neg
nucleic
acid
test
hcv
rna
undertaken
patient
whose
histori
indic
increas
risk
hcv
infect
eg
transfus
blood
test
hcvreliabl
test
blood
suppli
began
develop
countri
iv
inhal
drug
abus
tattoo
unexplain
elev
serum
alt
aii
hcvinfect
patient
requir
hct
altern
donor
proceed
hct
hcvposit
donor
provid
full
understand
longterm
side
effect
biii
donor
assess
chronic
liver
diseas
extrahepat
manifest
hcv
might
contraind
donat
eiii
similar
recipi
donor
screen
antihcv
antibodi
found
antihcvposit
high
risk
hcv
infect
test
hcvrna
aii
feasibl
viral
clearanc
standard
combin
antivir
therapi
prior
stem
cell
harvest
may
attempt
donor
detect
hcv
rna
howev
report
success
method
donor
recipi
counsel
individu
risk
biii
hct
candid
hcv
infect
must
assess
evid
chronic
liver
diseas
assess
risk
condit
hct
liver
biopsi
warrant
follow
clinic
situat
aiii
associ
iron
overload
histori
excess
alcohol
intak
histori
hepat
c
year
clinic
evid
chronic
liver
diseas
patient
evid
cirrhosi
hepat
fibrosi
consid
convent
condit
therapi
contain
either
cy
tbi
gy
diii
regimen
associ
increas
risk
fatal
so
patient
instead
regimen
contain
either
cy
tbi
pose
lower
risk
fatal
so
use
patient
cirrhosi
howev
even
ric
regimen
pose
mortal
risk
treatment
chronic
hcv
consid
hcvinfect
hct
recipi
limit
data
suggest
improv
outcom
respond
combin
therapi
biii
qualifi
antivir
treatment
patient
must
complet
remiss
origin
diseas
year
posttranspl
without
evid
either
protract
agvhd
cgvhd
immunosuppress
month
normal
blood
count
serum
creatinin
biii
treatment
consist
fulldos
peginterferon
ribavirin
biii
dose
modif
made
intoler
develop
eg
develop
cytopenia
survivor
whose
neutrophil
platelet
count
normal
baselin
daili
interferon
alpha
substitut
peginterferon
assess
hematolog
toxic
move
peginterferon
treatment
continu
week
depend
respons
prevent
exposur
human
herpesviru
caus
classic
childhood
ill
roseola
also
known
exanthema
subitum
sixth
diseas
clinic
diseas
associ
human
herpesviru
infect
remain
defin
nearli
children
infect
year
age
age
year
spectrum
complic
hct
complet
describ
reactiv
common
earli
allogen
hct
transplant
period
viremia
occur
approxim
patient
clinic
signific
detect
viremia
unknown
although
associ
posttranspl
set
hepat
fever
rash
idiopath
pulmonari
syndrom
delay
platelet
monocyt
engraft
also
chromosom
integr
potenti
result
falseposit
pcr
assay
result
posttransplant
acut
limbic
enceph
syndrom
associ
reactiv
cerebr
spinal
fluid
csf
report
syndrom
uncommon
occur
approxim
hct
patient
seri
typic
occur
month
posttransplant
appear
common
receipt
ucb
hlamismatch
graft
manifest
includ
profound
memori
loss
seizur
hyponatremia
mild
csf
pleocytosi
signific
mesial
tempor
lobe
abnorm
magnet
reson
imag
mri
addit
may
interfer
mhc
class
antigen
present
augment
local
immunosuppress
howev
implic
viral
properti
unknown
role
posttranspl
complic
remain
defin
time
data
guid
preemptiv
monitor
prophylact
antivir
strategi
prevent
potenti
diseas
diii
ganciclovir
cidofovir
foscarnet
variabl
vitro
activ
may
role
treat
diseas
data
support
recommend
monitor
potenti
diseas
diii
prevent
exposur
human
herpesviru
type
caus
kaposi
sarcoma
also
known
kshv
unlik
herpesviru
infect
infect
ubiquit
signific
geograph
variabl
preval
infect
high
infect
rate
report
subsaharan
africa
modest
rate
unit
state
low
rate
japan
unit
state
higher
rate
infect
identifi
men
sex
men
perhap
indic
sexual
transmiss
enhanc
transmiss
saliva
prevent
diseas
diseas
recurr
diseas
eg
kaposi
sarcoma
occur
rare
hct
time
data
guid
monitor
preemptiv
antivir
treatment
posttranspl
diseas
diii
patient
hiv
receiv
haart
therapi
cancer
lead
caus
death
consequ
hct
may
need
consid
patient
describ
hematopoiet
cell
graft
safeti
section
regul
place
unit
state
european
union
evalu
donor
minim
risk
transmiss
diseas
use
relat
donor
known
hiv
harbor
signific
risk
like
outweigh
benefit
transplant
seroneg
recipi
consid
diii
patient
hiv
malign
treat
transplant
automat
exclud
potenti
lifesav
therapi
report
autolog
transplant
suggest
feasibl
approach
patient
control
hiv
diseas
biii
outcom
allogen
transplant
quit
limit
although
report
suggest
current
era
haart
therapi
may
consid
ciii
signific
complex
manag
hivposit
patient
recommend
hivposit
patient
consid
hct
enrol
clinic
trial
patient
comanag
hiv
specialist
hematopoiet
cell
transplant
hct
recipi
candid
undergo
condit
therapi
avoid
substanc
includ
certain
food
tabl
increas
risk
exposur
fungi
diii
growth
factor
eg
granulocytemacrophag
colonystimul
factor
gmcsf
gcsf
shorten
durat
neutropenia
hct
howev
metaanalysi
show
use
growth
factor
reduc
attack
rate
invas
fungal
diseas
therefor
recommend
made
use
growth
factor
prophylaxi
invas
fungal
diseas
ci
topic
antifung
drug
appli
skin
mucosa
eg
nystatin
clotrimazol
might
reduc
colon
yeast
mold
area
applic
howev
agent
prove
concern
aris
detect
potenti
pathogen
food
support
document
evid
organ
sourc
opportunist
infect
immunocompromis
person
potenti
benefit
food
safeti
recommend
direct
specif
toward
hct
recipi
must
weigh
uncertain
valu
recommend
potenti
advers
affect
patient
nutrit
intak
andor
qualiti
life
shelfstabl
refer
unopen
can
bottl
packag
food
product
store
open
room
temperatur
contain
may
requir
refriger
open
packag
shelfstabl
tofu
pasteur
tofu
need
boil
nonpasteur
tofu
must
cut
cube
smaller
boil
minimum
minut
water
broth
eat
use
recip
clean
run
water
use
includ
produc
cook
peel
banana
orang
melon
tap
water
roll
boil
boil
minut
store
boil
water
refriger
discard
water
use
within
hour
day
use
boil
bottl
water
use
water
servic
citi
water
servic
pleas
see
water
safeti
guidelin
food
safeti
guidelin
see
water
safeti
guidelin
food
safeti
guidelin
approv
bottl
water
treatment
honey
product
allow
child
less
year
age
allow
children
scid
month
posttranspl
prevent
local
invas
dissemin
yeast
mold
infect
use
prophylaxi
unclear
ciii
perform
fungal
surveil
cultur
indic
asymptomat
hct
recipi
dii
patient
receiv
antifung
prophylaxi
develop
clinic
sign
symptom
infect
evalu
breakthrough
bloodstream
pulmonari
fungal
infect
aiii
infect
may
occur
prophylact
drug
activ
organ
organ
develop
resist
drug
factor
sever
immunosuppress
low
serum
level
prophylact
agent
risk
invas
candidiasi
significantli
higher
earli
posttranspl
period
phase
neutropenia
sever
mucos
presenc
central
venou
cathet
cvc
phase
ii
risk
factor
invas
candidiasi
presenc
cvc
sever
gastrointestin
gi
graftversushost
diseas
gvhd
among
autolog
hct
recipi
risk
invas
candidiasi
minim
neutropenia
mucos
resolv
invas
candidiasi
usual
caus
dissemin
endogen
candida
speci
colon
patient
gi
tract
consequ
method
prevent
exogen
yeast
exposur
usual
prevent
invas
yeast
infect
hct
howev
candida
speci
carri
hand
hcw
other
contact
hct
recipi
follow
appropri
handwash
practic
avoid
expos
patient
fungal
pathogen
aii
fluconazol
drug
choic
prophylaxi
invas
candidiasi
engraft
allogen
hct
recipi
may
start
begin
end
condit
regimen
ai
lowdos
fluconazol
variabl
efficaci
therefor
dose
lower
mg
mump
rubella
vaccin
usual
given
togeth
combin
vaccin
femal
pregnanc
potenti
vaccin
rubella
vaccin
either
singl
combin
vaccin
indic
children
dose
favor
recommend
dii
optim
durat
fluconazol
prophylaxisspecif
whether
prophylaxi
confer
signific
benefit
continu
postengraftmenti
defin
post
hoc
analysi
random
clinic
trial
shown
fluconazol
given
day
posttranspl
associ
prolong
protect
invas
candidiasi
even
beyond
period
prophylaxi
fluconazol
effect
candida
krusei
variabl
activ
c
glabrata
becom
resist
moreov
use
fluconazol
prophylaxi
may
result
select
azoleresist
candida
speci
princip
c
glabrata
c
krusei
therefor
fluconazol
recommend
prevent
infect
di
may
consider
patient
known
colon
fluconazoleresist
candida
speci
crossresist
azol
ie
fluconazol
voriconazol
posaconazol
may
occur
among
candida
speci
particularli
c
glabrata
therefor
clinician
alert
possibl
breakthrough
infect
resist
organ
patient
receiv
prophylaxi
azol
drug
ciii
micafungin
altern
prophylact
agent
studi
shown
compar
fluconazol
prevent
possibl
document
fungal
hct
indic
hematopoiet
cell
transplant
gvhd
graftversushost
diseas
current
advisori
committe
immun
practic
acip
american
academi
pediatr
guidelin
postexposur
human
rabi
immunoglobulin
vaccin
administr
follow
includ
administ
dose
rabi
vaccin
administ
day
postexposur
infect
bi
use
micafungin
prophylact
agent
limit
necess
iv
infus
cost
case
report
sporad
resist
echinocandin
antifung
agent
itraconazol
oral
solut
shown
prevent
invas
fungal
infect
use
drug
limit
poor
toler
toxic
ci
antimold
activ
warrant
antifung
prophylaxi
posaconazol
voriconazol
option
posaconazol
studi
preengraft
phase
hct
hct
recipi
requir
prophylaxi
candida
postengraft
period
phase
ii
iii
need
eg
presenc
gvhd
option
includ
voriconazol
bi
posaconazol
bi
oral
nonabsorb
antifung
drug
includ
oral
amphotericin
b
mg
suspens
everi
hour
nystatin
clotrimazol
troch
might
reduc
superfici
colon
control
local
mucos
candidiasi
demonstr
reduc
invas
candidiasi
ciii
hct
candid
candidemia
invas
candidiasi
safe
receiv
transplant
infect
diagnos
earli
treat
immedi
aggress
effect
anticandida
therapi
evid
infect
control
transplant
biii
patient
continu
receiv
therapeut
dose
appropri
antifung
drug
throughout
phase
bii
care
review
clinic
laboratori
serial
comput
tomographi
scan
verifi
resolut
candidiasi
bii
radiograph
abnorm
may
persist
long
period
time
among
patient
hepatosplen
candidiasi
complet
resolut
necessari
transplant
provid
patient
receiv
appropri
therapi
show
clinic
improv
autolog
recipi
gener
overal
lower
risk
invas
fungal
infect
allogen
recipi
autolog
recipi
requir
routin
antiyeast
prophylaxi
ciii
howev
expert
recommend
administ
antiyeast
prophylaxi
subpopul
autolog
recipi
underli
hematolog
malign
eg
lymphoma
leukemia
myeloma
prolong
neutropenia
mucos
damag
intens
condit
regimen
graft
manipul
receiv
fludarabin
flu
within
month
prior
hct
biii
recommend
regard
prevent
invas
yeast
infect
among
pediatr
adult
hct
recipi
except
appropri
dose
adjust
prophylact
drug
made
pediatr
recipi
appendix
consid
continu
antifung
therapi
patient
prior
infect
hct
clinician
mind
drug
interact
especi
calcineurin
inhibitor
particularli
drug
azol
class
affect
cytochrom
metabol
result
recent
studi
suggest
differenti
toxic
effect
cyclophosphamid
cy
metabolit
coadministr
differ
azol
drug
specif
coadministr
fluconazol
associ
fewer
earli
toxic
differ
metabolit
compar
itraconazol
hypothes
fluconazol
inhibit
cytochrom
provid
protect
effect
compar
itraconazol
inhibit
gener
clinician
care
coadminist
drug
impact
cytochrom
subunit
activ
condit
metabol
nosocomi
mold
infect
among
hct
recipi
result
primarili
respiratori
exposur
direct
contact
fungal
spore
measur
minim
exposur
mold
hct
candid
recipi
discuss
infect
prevent
control
health
care
facil
section
addit
air
water
may
also
sourc
pathogen
fungi
opportunist
mold
eg
aspergillu
fusarium
speci
present
water
waterrel
surfac
hospit
care
cancer
patient
molecular
studi
suggest
potenti
related
environment
clinic
strain
among
patient
aspergillosi
fusariosi
therefor
hospit
water
consid
potenti
sourc
nosocomi
invas
mold
infect
although
investig
believ
necessari
decreas
patient
exposur
period
sever
immunosuppress
current
data
insuffici
support
formul
definit
recommend
clean
waterrel
structur
patient
bathroom
may
attempt
invas
mold
infect
trimod
incid
distribut
among
allogen
hct
recipi
engraft
ie
phase
main
risk
factor
prolong
neutropenia
therefor
risk
higher
bone
marrow
bm
umbil
cord
blood
ucb
transplant
lower
peripher
blood
pb
nonmyeloabl
nma
transplant
addit
risk
higher
among
patient
prolong
lowlevel
neutropenia
prior
transplant
aplast
anemia
aa
patient
phase
ii
iii
main
risk
factor
sever
cellmedi
immunodefici
caus
gvhd
treatment
therefor
recipi
transplant
higher
risk
sever
gvhd
unrel
donor
mismatch
transplant
haploident
greater
risk
mold
infect
patient
high
risk
mold
infect
consid
prophylaxi
moldact
drug
period
risk
bi
trial
assess
efficaci
cyclodextrin
oral
solut
intraven
formul
itraconazol
shown
efficaci
prevent
mold
infect
bi
benefit
offset
poor
toler
toxic
oral
formul
discontinu
gi
side
effect
one
studi
shown
micafungin
effect
prevent
invas
fungal
infect
includ
fever
administ
neutropenia
incid
invas
aspergillosi
low
preengraft
phase
antimold
efficaci
could
show
display
activ
rather
efficaci
bi
experi
echinocandin
eg
caspofungin
demonstr
efficaci
cii
breakthrough
mold
infect
echinocandin
prophylaxi
report
fluconazol
activ
mold
base
result
studi
present
date
abstract
form
voriconazol
appear
altern
fluconazol
prophylaxi
result
studi
present
detail
committe
assign
recommend
specif
mold
resist
certain
drug
eg
voriconazol
activ
zygomycet
scedosporium
prolifican
resist
avail
antifung
agent
patient
gvhd
posaconazol
report
prevent
invas
mold
infect
bi
studi
patient
gvhd
random
receiv
either
fluconazol
mg
posaconazol
mg
time
daili
result
show
trend
toward
lower
incid
invas
fungal
infect
particular
differ
mold
infect
optim
durat
prophylaxi
set
gvhd
defin
aerosol
liposom
amphotericin
b
found
effect
reduc
invas
pulmonari
aspergillosi
random
trial
includ
leukemia
hct
patient
consid
altern
moldact
azol
bii
howev
administr
drug
interrupt
cough
mani
patient
optim
aerosol
dose
deliveri
devic
yet
determin
thu
studi
need
role
determin
patient
prior
invas
aspergillosi
receiv
secondari
prophylaxi
moldact
drug
aii
optim
drug
determin
voriconazol
shown
benefit
indic
aii
absorpt
itraconazol
posaconazol
poor
patient
eat
metaanalys
suggest
efficaci
itraconazol
associ
bioavail
blood
level
mgml
associ
effect
prevent
proven
invas
fungal
infect
posaconazol
level
therapeut
effect
establish
median
level
posaconazol
rel
lower
patient
agvhd
symptomat
diarrhea
voriconazol
blood
level
least
mgml
thought
requir
efficaci
low
voriconazol
level
report
patient
document
breakthrough
infect
rel
controversi
util
routin
monitor
azol
drug
level
clinician
agre
measur
level
consid
patient
document
breakthrough
infect
chang
addit
antifung
agent
differ
class
advis
blood
level
determin
level
found
low
consider
given
resum
earlier
drug
higher
dose
ciii
section
cover
infect
preval
certain
geograph
area
occur
uncommonli
among
hematopoiet
cell
transplant
hct
recipi
diseas
cover
tuberculosi
pneumocysti
jiroveci
pneumonia
pcp
toxoplasmosi
strongyloidiasi
chaga
diseas
leishmaniasi
malaria
nocardia
infect
infect
babesiosi
transmit
cours
transplant
via
blood
product
addit
hematopoiet
cell
graft
guidelin
prevent
grafttransmiss
infect
found
hematopoiet
cell
safeti
section
tuberculosi
tb
uncommon
among
hct
recipi
main
risk
factor
undergo
transplant
countri
high
endem
rate
tb
countri
tb
uncommon
tb
preval
among
patient
come
hct
countri
born
countri
higher
rate
endem
tb
patient
household
member
risk
eg
recent
immigr
correct
facil
discharg
also
deserv
particular
attent
must
alway
rememb
definit
test
exclud
tb
high
level
clinic
awar
must
maintain
immunosuppress
patient
rate
tb
report
hct
time
less
solid
organ
transplant
hct
patient
receiv
lifelong
immunosuppress
howev
patient
prolong
immunosuppress
chronic
graftversushost
diseas
cgvhd
remain
risk
tb
control
tb
cell
mediat
restor
cell
function
time
cessat
immunosuppress
reduc
patient
risk
tb
patient
develop
tb
hct
clearli
identifi
risk
factor
normal
pretranspl
chest
radiograph
direct
histori
contact
tb
transplant
leukemia
receiv
total
bodi
irradi
tbi
base
condit
allograft
recipi
receiv
treatment
gvhd
day
posttranspl
although
case
tb
occur
allogen
hct
recipi
occur
autolog
recipi
despit
low
rate
diagnost
vigil
must
maintain
exampl
mycobacteri
infect
may
occur
frequent
patient
undergon
autolog
hct
chronic
lymphocyt
leukemia
cll
prior
therapi
fludarabin
flu
alemtuzumab
induc
profound
cell
defici
suscept
varieti
opportunist
infect
hct
candid
recipi
avoid
exposur
person
environ
substanti
risk
respiratori
contact
individu
activ
tb
prudent
advis
hct
candid
recipi
certain
occup
eg
volunt
work
employ
health
care
facil
correct
institut
shelter
homeless
increas
risk
tb
exposur
biii
evalu
patient
hct
expert
recommend
evalu
latent
activ
tb
patient
candid
hct
bii
assess
includ
histori
prior
activ
tb
prior
exposureevalu
highprior
contact
per
cdc
guidelin
result
previou
tuberculin
skin
test
tst
interferongamma
releas
assay
igra
expert
disagre
conveni
benefit
routin
obtain
tst
igra
everi
transplant
candid
interpret
tst
may
also
complic
histori
prior
bacillu
calmettegu
erin
bcg
vaccin
although
tuberculin
reactiv
follow
bcg
tend
wane
time
american
thorac
societi
at
state
posit
tst
may
consid
diagnost
latent
tuberculosi
infect
bcg
recipi
risk
recent
tuberculosi
infect
medic
condit
increas
risk
progress
activ
tb
ciii
prior
chemotherapyinduc
immunosuppress
tst
sensit
hct
candid
healthi
popul
igra
specif
tb
neg
test
exclud
latent
tb
infect
particularli
immunocompromis
patient
metaanalysi
igra
found
sensit
tst
immunocompromis
patient
suspect
tb
particularli
case
among
patient
autoimmun
diseas
receiv
antitumor
necrosi
factor
therapi
eg
infliximab
particular
risk
tb
studi
specif
hct
patient
await
howev
canada
unit
state
made
recommend
use
igra
immunocompromis
patient
patient
recent
posit
tst
igra
histori
posit
test
prior
prevent
therapi
evalu
activ
tb
minimum
patient
ask
symptom
system
diseas
respiratori
symptom
cough
short
breath
chest
radiograph
assess
aii
activ
tb
detect
therapi
appropri
isol
initi
hct
delay
activ
infect
deem
control
base
clinic
judgment
object
definit
adequ
control
formul
tst
igra
posit
activ
tb
identifi
treatment
latent
tb
infect
appendix
initi
hct
need
delay
high
risk
reactiv
new
infect
prophylaxi
administ
immunocompromis
hct
recipi
candid
expos
someon
activ
infecti
ie
sputumsmear
posit
pulmonari
laryng
tb
regardless
hct
recipi
candid
tst
igra
statu
biii
posit
tst
resultregardless
prior
bcg
vaccinationwithout
previou
treatment
evid
activ
tb
diseas
bii
posit
tst
histori
bcg
vaccin
still
consid
at
indic
prophylaxi
patient
medic
condit
increas
risk
diseas
presum
includ
hct
ciii
posit
igra
result
without
previou
treatment
evid
activ
tb
bii
report
high
frequenc
reactiv
previous
treat
tb
follow
transplant
especi
part
world
endem
preval
tb
high
suggest
patient
may
high
risk
therefor
isoniazid
inh
prophylaxi
consid
ciii
valu
prophylaxi
countri
high
rate
tb
hct
patient
countri
consid
institut
level
high
preval
multidrugresist
tb
countri
singleag
prophylaxi
may
ineffect
consequ
maintain
high
index
suspicion
provid
earli
intervent
may
prefer
univers
prophylaxi
hct
candid
recipi
expos
activ
case
extrapulmonari
therefor
noninfecti
tb
requir
prevent
therapi
diii
inh
well
toler
posthct
even
concurr
fluconazol
use
concurr
use
itraconazol
recommend
impact
voriconazol
posaconazol
known
inh
pyridoxin
continu
least
month
immunosuppress
dosag
substanti
reduc
ie
prednisolon
mgkg
children
mg
daili
adult
appendix
inh
start
complet
condit
therapi
prior
condit
feasibl
clinic
situat
put
patient
higher
risk
infect
rifampin
given
month
effect
potenti
substanti
drugdrug
interact
rifampin
immunosuppress
agent
gener
make
option
impract
combin
pyrazinamid
rifampin
pza
rif
known
signific
liver
toxic
use
posthct
recommend
eii
vaccin
bcg
vaccin
contraind
hct
candid
eii
dissemin
bcg
infect
report
among
immunocompromis
person
receiv
bcg
donor
live
origin
countri
tb
endem
increas
risk
tb
latent
tb
similar
rest
popul
known
risk
transplant
hematopoiet
progenitor
cell
untreat
donor
latent
activ
tb
howev
would
prudent
prospect
donor
activ
tb
defer
donat
tb
well
control
determin
donor
primari
physician
eiii
case
pcp
tradit
thought
occur
reactiv
latent
infect
howev
suggest
anim
data
welldocu
human
case
indic
clinic
diseas
result
recent
infect
moreov
previous
infect
patient
reinfect
new
strain
pneumocysti
observ
intrigu
cluster
pcp
case
suggest
persontoperson
transmiss
possibl
neither
cdc
hospit
mandat
respiratori
precaut
regard
patient
pcp
howev
mani
clinician
consid
logic
hct
recipi
avoid
exposur
patient
pcp
ciii
databas
guidelin
long
pcp
patient
isol
prevent
diseas
diseas
recurr
allogen
stem
cell
transplant
sct
recipi
pcp
gener
prevent
complic
hct
program
must
vigor
system
assur
pcp
prophylaxi
prescrib
provid
adher
patient
aii
pcp
prophylaxi
usual
prescrib
allogen
recipi
engraft
least
month
hct
aii
health
care
provid
initi
pcp
prophylaxi
prior
transplant
depend
underli
diseas
pretranspl
condit
regimen
prior
chemotherapi
cii
prophylaxi
continu
longer
month
patient
continu
receiv
immunosuppress
drug
aii
prefer
regimen
pcp
prophylaxi
trimethoprimsulfamethoxazol
tmpsmx
superior
efficaci
compar
aerosol
pentamidin
oral
dapson
oral
atovaquon
aii
tmpsmx
also
provid
protect
pathogen
includ
toxoplasma
nocardia
enter
pathogen
plasmodium
speci
urinari
pathogen
respiratori
pathogen
although
dapson
atovaquon
probabl
provid
protect
toxoplasma
broader
spectrum
activ
tmpsmx
among
reason
drug
prefer
tmpsmx
delay
engraft
thu
usual
administ
engraft
occur
tmpsmx
variabl
toler
toxic
includ
myelosuppress
hypersensit
hyperkalemia
nephriti
hepat
pancreat
optim
dosag
defin
hct
patient
mani
hct
program
use
onceor
twicedaili
regimen
singlestrength
doublestrength
tablet
day
per
week
ciii
appear
efficaci
properli
power
trial
base
recommend
altern
regimen
oral
dapson
aerosol
pentamidin
oral
atovaquon
use
cii
howev
none
effect
tmpsmx
pcp
prophylaxi
therefor
everi
effort
made
administ
tmpsmx
oral
desensit
regimen
use
success
hivinfect
patient
other
rash
similar
protocol
use
hct
recipi
success
rate
approxim
desensit
attempt
feasibl
cii
appendix
oral
dapson
conveni
substanti
number
patient
allerg
tmpsmx
also
intoler
dapson
therefor
drug
recommend
patient
lifethreaten
reaction
tmpsmx
advers
reaction
dapson
includ
hypersensit
hemolysi
especi
patient
dehydrogenas
defici
hepat
methemoglobinemia
patient
defici
receiv
drug
aerosol
pentamidin
well
toler
bronchospasm
common
advers
effect
may
less
effect
regimen
atovaquon
expens
well
toler
howev
well
absorb
unless
ingest
fatti
food
thu
atovaquon
might
optim
choic
patient
gut
gvhd
recurr
pcp
hct
recipi
rare
nevertheless
patient
recov
pcp
continu
chemoprophylaxi
immunosuppress
resolv
aii
although
clear
paramet
defin
endpoint
autolog
sct
recipi
pcp
develop
autolog
hct
recipi
although
rate
much
lower
among
allogen
recipi
pcp
prophylaxi
consid
autolog
hct
recipi
whose
immunosuppress
substanti
either
underli
condit
treatment
patient
includ
underli
lymphoma
leukemia
myeloma
especi
intens
treatment
condit
regimen
includ
purin
analogu
flu
cladribin
highdos
corticosteroid
biii
durat
pcp
prophylaxi
set
evalu
common
practic
extend
prophylaxi
month
posttransplant
ciii
patient
ongo
immunomodulatori
therapi
posttransplant
longer
durat
prophylaxi
may
necessari
immunocompet
host
initi
acquisit
toxoplasma
often
occur
exposur
cat
fece
undercook
meat
hct
recipi
provid
inform
regard
strategi
reduc
risk
exposur
toxoplasma
speci
see
strategi
safe
live
although
unusu
sourc
toxoplasmosi
hct
potenti
donor
allogen
hct
could
test
igg
antibodi
gondii
antibodi
gondii
report
transmit
leukocyt
transfus
hct
ciii
toxoplasmosi
among
hct
recipi
caus
diseas
reactiv
candid
allogen
hct
test
igg
antibodi
determin
whether
risk
diseas
reactiv
hct
biii
howev
toxoplasmosi
occur
limit
number
hct
patient
seroneg
gondii
pretranspl
case
observ
allogen
hct
occur
week
posttranspl
later
occurr
also
report
patient
receiv
longterm
immunosuppress
incid
gondii
diseas
vari
accord
seropreval
geograph
area
clinic
reactiv
occur
among
seroposit
prior
hct
cb
transplant
recipi
may
higher
risk
hct
recipi
allogen
recipi
seroposit
toxoplasmosi
risk
reactiv
vari
kind
transplant
degre
immunosuppress
prospect
studi
spain
weekli
screen
quantit
pcr
test
blood
allogen
seroposit
hct
recipi
first
month
transplant
shown
reactiv
occur
seroposit
allogen
hct
recipi
nucleicacid
base
reactiv
typic
preced
clinic
symptom
day
facilit
earli
identif
reactiv
infect
pcr
screen
consid
patient
high
risk
ie
patient
seroposit
transplant
receiv
cb
graft
develop
gvhd
requir
immunosuppress
treatment
receiv
tmpsmx
bii
pcr
prefer
perform
refer
laboratori
quantit
method
use
strict
measur
reduc
risk
fals
posit
result
contamin
fals
neg
result
presenc
inhibitor
biii
brain
mri
ct
scan
hct
patient
toxoplasmosi
may
demonstr
characterist
ringenhanc
lesion
diseas
therefor
diagnost
workup
eg
pcr
test
cerebrospin
fluid
csf
bronchoalveolar
lavag
bal
sampl
andor
blood
initi
patient
brain
pulmonari
lesion
seroposit
toxoplasma
ciii
gondii
reactiv
diseas
rare
report
patient
receiv
tmpsmx
p
jiroveci
prophylaxi
highrisk
patient
intoler
tmpsmx
specif
strategi
gondii
implement
p
jiroveci
prophylact
drug
either
penetr
bodi
site
reactiv
ie
aerosol
pentamidin
prophylact
efficaci
hct
unknown
ie
dapson
atovaquon
patient
either
treat
prophylact
drug
effect
gondii
ie
clindamycin
pyrimethamin
plu
leucovorin
pyrimethamin
plu
sulfadiazin
pyrimethamin
sulfadoxin
plu
leucovorin
monitor
pcr
test
given
preemptiv
treatment
appendix
ciii
publish
prospect
studi
benefitrisk
ratio
strategi
therapi
toxoplasmosi
hct
recipi
continu
receiv
suppress
dose
tmpsmz
altern
regimen
durat
immunosuppress
biii
appendix
except
rare
patient
pretranspl
toxoplasm
chorioretin
may
benefit
secondari
prophylaxi
recipi
autolog
transplant
neglig
risk
toxoplasmosi
reactiv
prophylaxi
screen
toxoplasmosi
infect
recommend
autolog
transplant
recipi
ciii
indic
toxoplasmosi
prophylaxi
children
adult
children
receiv
pediatr
dose
appendix
prevent
exposur
hct
recipi
provid
inform
way
reduc
risk
exposur
nocardia
spp
specif
inform
includ
ubiquit
natur
gramposit
weakli
acidfast
aerob
actinomycet
nocardia
spp
found
primarili
dirt
stagnant
water
patient
advis
avoid
garden
soil
plant
receiv
immunosuppress
therapi
ciii
infect
occur
via
inhal
patient
wish
continu
garden
may
minim
exposur
wear
protect
gear
mask
glove
ciii
incid
nocardia
infect
increas
patient
hct
compar
gener
popul
personyear
versu
case
personyear
median
time
onset
approxim
day
follow
transplant
risk
factor
diseas
includ
immunosuppress
corticosteroid
use
neutropenia
activ
gvhd
concomit
opportunist
infect
especi
cytomegaloviru
cmv
one
studi
suggest
may
decreas
risk
infect
patient
receiv
tmpsmx
prophylaxi
ciii
notabl
case
hct
patient
occur
patient
receiv
tmpsmx
pcp
prophylaxi
interestingli
breakthrough
case
success
treat
highdos
tmp
smx
howev
therapi
nocardia
infect
chosen
basi
appropri
identif
nocardia
isol
avail
suscept
test
becvaus
treatment
option
possibl
prevent
exposur
allogen
hct
recipi
avoid
contact
outhous
cutan
exposur
soil
surfac
might
contamin
human
fece
aiii
allogen
hct
recipi
work
set
could
expos
fecal
matter
eg
hospit
institut
wear
glove
work
patient
area
potenti
fecal
contamin
aiii
histori
obtain
patient
hct
identifi
potenti
exposur
strongyloid
travel
resid
highrisk
area
ie
moist
temper
area
tropic
subtrop
southeastern
unit
state
europ
biii
hct
candid
unexplain
peripher
eosinophilia
resid
travel
area
endem
strongyloidiasi
even
distant
past
screen
asymptomat
strongyloidiasi
hct
biii
option
avail
screen
includ
stool
examin
serolog
test
enzymelink
immunosorb
assay
elisa
indirect
immunofluoresc
antibodi
test
ifat
gener
elisa
prefer
screen
method
sensit
may
rel
low
immunocompromis
patient
biii
although
stool
examin
strongyloidiasi
specif
sensit
achiev
stool
examin
sensit
achiev
concentr
stool
exam
best
total
stool
examin
perform
serolog
test
unavail
strongyloidiasi
clinic
suspect
seroneg
patient
biii
hct
candid
pretranspl
screen
test
posit
strongyloid
speci
unexplain
eosinophilia
travel
resid
histori
indic
exposur
strongyloid
stercorali
receiv
empir
treatment
transplant
prefer
ivermectin
appendix
biii
evid
support
univers
preemptiv
treatment
given
ivermectin
favor
safeti
profil
low
cost
clinician
advoc
preemptiv
treatment
patient
endem
area
symptom
eosinophilia
neg
screen
test
result
ciii
prevent
recurr
among
hct
candid
parasit
clearanc
therapi
verifi
consecut
neg
stool
examin
proceed
hct
aiii
data
insuffici
recommend
drug
prophylaxi
regimen
hct
prevent
recurr
strongyloidiasi
hct
recipi
strongyloidiasi
hct
monitor
care
sign
symptom
recurr
infect
least
month
treatment
biii
unlik
allogen
hct
hyperinfect
strongyloidiasi
report
rare
autolog
hct
howev
screen
precaut
use
among
autolog
recipi
biii
indic
empir
treatment
strongyloidiasi
hct
among
children
adult
except
children
weigh
kg
prefer
drug
albendazol
biii
appendix
prevent
exposur
trypanosoma
cruzi
etiolog
agent
chaga
diseas
transmit
blood
transfus
transfusionassoci
transmiss
cruzi
wellknown
phenomenon
endem
countri
instanc
report
unit
state
canada
immunocompromis
patient
fulmin
cours
acut
chaga
diseas
serolog
screen
donat
blood
cruzi
unit
state
began
januari
although
fda
mandat
screen
donat
unit
current
screen
sleep
sick
brucei
rhodesiens
tb
gambiens
leishmaniasi
variou
speci
belong
genu
leishmania
could
also
transmit
via
contamin
transfus
although
possibl
leishmania
african
trypanosom
caus
problem
hct
patient
extrem
remot
donor
recipi
nonendem
area
reactiv
cruzi
report
hct
patient
report
viscer
leishmaniasi
follow
hct
case
seem
acquir
year
transplant
preexist
transmit
stem
cell
product
donor
recipi
born
receiv
blood
transfus
ever
live
least
month
chaga
diseas
endem
area
eg
part
south
central
america
mexico
screen
serolog
antit
cruzi
serum
igg
antibodi
biii
similarli
donor
recipi
whose
mother
born
chaga
diseas
endem
area
extens
matern
famili
histori
cardiac
diseas
eg
cardiomegali
dysrhythmia
screen
risk
congenit
transmiss
ciii
person
live
month
chagasendem
area
highrisk
live
condit
eg
extens
exposur
chaga
diseas
vectorth
reduviid
bugor
live
dwell
mud
wall
unmil
log
stick
thatch
roof
also
screen
evid
cruzi
infect
biii
absenc
gold
standard
test
chaga
diseas
screen
infect
perform
least
serolog
test
eg
enzym
immunoassay
indirect
hemagglutin
indirect
fluoresc
antibodi
radioimmunoprecipit
assay
biii
person
activ
chaga
diseas
diii
past
histori
chaga
diseas
ciii
serv
hct
donor
hct
candid
risk
infect
cruzi
screen
serum
igg
antit
cruzi
antibodi
biii
cruzi
seroposit
contraind
hct
howev
acut
ill
occur
cruziseroposit
hct
recipi
particularli
neutropenia
cruzi
reactiv
includ
differenti
diagnosi
biii
expert
propos
use
benznidazol
nifurtimox
preemptiv
therapi
prophylaxi
recurr
cruzi
among
seroposit
hct
recipi
insuffici
data
found
make
recommend
addit
inform
regard
epidemiolog
chaga
diseas
question
regard
evalu
treatment
contact
cdc
nation
center
zoonot
vectorborn
enter
diseasesdivis
parasit
diseas
http
wwwcdcgovchaga
chaga
cdcgov
recommend
autolog
allogen
recipi
howev
recurr
chaga
diseas
probabl
less
like
occur
among
autolog
recipi
shorter
durat
immunosuppress
recommend
among
children
adult
estim
million
case
malaria
death
malaria
opportunist
diseas
increasingli
relev
sct
sever
reason
patient
either
histori
malaria
resid
endem
malaria
region
transplant
resid
endem
region
consid
donor
recipi
expos
malaria
transplant
prevent
exposur
prevent
transmiss
stem
cell
product
malaria
includ
falciparum
malaria
transmit
hct
even
donor
smear
pretranspl
reportedli
neg
donor
endem
region
ask
malaria
histori
donor
travel
area
malaria
transmiss
occur
defer
donat
year
return
former
current
resid
area
malaria
transmiss
occur
defer
year
deferr
time
feasibl
donor
receiv
empir
treatment
malaria
prior
donat
blood
smear
immunochromatogen
test
pcr
inappropri
test
evalu
asymptomat
potenti
donor
donor
diagnos
activ
infect
collect
stem
cell
product
delay
possibl
treatment
complet
neg
confirmatori
test
obtain
aiii
feasibl
preemptiv
treatment
recipi
seem
reason
evid
make
recommend
prevent
mosquito
bite
hct
recipi
avoid
area
malaria
tri
avoid
bite
plasmodiumcarri
mosquito
anophel
mosquito
activ
night
recommend
hct
recipi
travel
endem
malaria
area
use
insecticidetr
bed
net
itn
sleep
openair
set
aii
practic
shown
reduc
sever
malaria
children
recommend
cdc
world
health
organ
malaria
control
individu
infect
may
decreas
use
long
sleev
long
pant
mosquito
repel
ai
eg
deet
use
mosquito
repel
seem
add
protect
effect
itn
hctrecipi
endem
area
live
endem
area
hct
recipi
endem
area
screen
blood
smear
rapid
test
andor
pcr
activ
diseas
transplant
aiii
follow
hct
patient
screen
develop
fever
pancytopenia
hemophagocytosi
syndrom
hepatosplenomegali
symptom
suggest
malaria
aiii
howev
report
occurr
malaria
hct
recipi
rare
evid
insuffici
make
specif
recommend
prophylaxi
even
patient
live
endem
area
involv
malari
specialist
consid
addit
manag
hct
recipi
nonendem
area
travel
malaria
endem
area
hct
recipi
travel
area
endem
malaria
consult
physician
choos
antimalari
regimen
effect
preval
plasmodium
toler
free
interact
patient
current
medic
aiii
cdc
web
site
comprehens
inform
regard
travel
http
wwwncdcgovtraveldefaultaspx
hematopoiet
cell
transplant
hct
center
personnel
follow
publish
guidelin
hospit
room
design
ventil
biii
hct
recipi
ideal
place
protect
environ
room
incorpor
follow
featur
air
exchangeshour
central
pointofus
hepa
filter
effici
remov
particl
mm
diamet
aiii
correct
filtrat
particularli
critic
hct
center
ongo
construct
renov
filter
replac
regularli
base
manufactur
recommend
ongo
construct
filtrat
effici
monitor
frequent
best
determin
appropri
time
replac
aiii
direct
airflow
air
intak
occur
side
room
air
exhaust
occur
opposit
side
biii
consist
posit
air
pressur
differenti
patient
room
hallway
pa
ie
inch
water
gaug
biii
wellseal
room
eg
fill
gap
wall
window
outlet
floor
ceil
alway
use
hct
patient
prevent
infiltr
air
outsid
room
could
allow
entri
spore
hinder
mainten
proper
pressur
differenti
biii
continu
pressur
monitor
especi
room
occupi
biii
consider
given
use
monitor
system
set
alarm
pressur
differenti
protect
environ
room
adjac
hallway
anteroom
fall
less
pa
alert
staff
possibl
engin
failur
ciii
selfclos
door
maintain
constant
pressur
differenti
biii
enabl
nurs
staff
observ
hct
recipi
even
door
close
window
instal
either
door
wall
hct
recipi
room
ciii
shortag
protect
environ
room
accommod
hct
patient
exist
alloc
room
priorit
highest
risk
invas
mold
infect
eg
expect
prolong
neutropenia
receiv
treatment
gvhd
biii
situat
portabl
industrialgrad
hepa
filter
may
use
nonprotect
environ
room
accommod
vulner
patient
place
central
patient
room
space
avail
around
surfac
allow
free
air
circul
biii
portabl
hepa
filter
shown
remov
airborn
fungal
spore
mycobacteria
use
part
success
strategi
prevent
fungal
infect
construct
howev
whether
effect
central
point
use
hepa
filter
prevent
infect
studi
laminar
air
flow
laf
room
contain
hepafilt
air
move
parallel
unidirect
flow
air
enter
room
wall
exit
room
opposit
wall
studi
shown
laf
may
protect
patient
infect
aspergillosi
outbreak
relat
hospit
construct
howev
routin
laf
room
use
hct
recipi
shown
provid
substanti
overal
surviv
os
benefit
therefor
laf
system
recommend
newli
construct
room
hct
center
dii
recommend
regard
pressur
differenti
hct
center
adjoin
build
least
studi
demonstr
neg
pressur
respect
adjoin
build
contribut
aspergillu
outbreak
hct
center
mainten
personnel
prevent
bird
nest
near
hospit
airintak
duct
aii
hct
center
provis
backup
emerg
power
redund
airhandl
pressur
system
maintain
constant
number
air
exchang
room
pressur
central
ventil
system
shut
mainten
repair
biii
addit
infect
control
risk
assess
icra
creat
infect
control
personnel
mainten
personnel
develop
protocol
protect
hct
patient
time
burst
mold
spore
might
occur
airhandl
system
restart
routin
mainten
shutdown
biii
risk
airhandl
system
never
shut
hct
unit
energi
conserv
purpos
anteroom
hct
center
room
option
except
case
hct
recipi
requir
airborn
precaut
certain
infect
biii
anteroom
use
ensur
appropri
air
balanc
rel
protect
environ
hallway
independ
exhaust
contamin
air
outsid
provid
hepa
filter
place
exhaust
duct
return
air
must
recircul
biii
protect
environ
airborn
infect
isol
room
anteroom
avail
patient
place
standard
airborn
infect
isol
room
portabl
industrialgrad
hepa
filter
use
enhanc
remov
spore
room
biii
hospit
construct
renov
may
result
increas
risk
health
careassoci
invas
mold
infect
particularli
aspergillosi
among
hct
recipi
therefor
person
respons
hct
center
construct
renov
consult
publish
recommend
regard
environment
control
construct
aiii
construct
renov
undertaken
plan
includ
intensifi
moldcontrol
measur
icra
plan
prior
construct
facil
design
new
facil
aiii
construct
renov
infect
control
plan
committe
includ
engin
architect
housekeep
staff
infect
control
personnel
director
hct
center
administr
construct
project
manag
safeti
offic
close
coordin
among
particip
facilit
complianc
infect
control
measur
construct
renov
demolit
biii
whenev
possibl
hct
recipi
avoid
construct
renov
area
aiii
also
hct
center
staff
avoid
transport
equip
suppli
use
hct
recipi
construct
renov
area
construct
renov
hct
center
staff
take
step
minim
fungal
spore
count
patient
room
adher
room
ventil
recommend
outdoor
construct
demolit
intak
air
seal
biii
possibl
filter
check
frequent
verifi
wellseat
replac
necessari
addit
protect
hct
patient
care
area
fire
drill
emerg
weather
strip
place
around
stairwel
door
altern
stairwel
air
filter
level
safeti
adjac
hospit
air
biii
fals
ceil
avoid
whenev
possibl
bii
use
fals
ceil
avoid
area
fals
ceil
vacuum
routin
minim
dust
therefor
fungal
exposur
patient
biii
number
measur
use
minim
impact
construct
hct
recipi
hospit
construct
renov
hospit
construct
rigid
dustproof
barrier
airtight
seal
patient
care
construct
renov
area
prevent
dust
enter
patient
care
area
biii
go
wwwasheorgash
codescdcpdfsassessmenticrapdf
inform
barrier
eg
seal
drywal
imperm
aspergillu
spore
construct
renov
area
neg
air
pressurerel
hct
patient
care
area
ensur
air
flow
patient
care
area
toward
construct
area
aii
impervi
barrier
creat
around
construct
area
patient
move
area
renov
complet
area
clean
appropri
biii
hct
center
direct
pedestrian
traffic
occur
near
construct
renov
area
away
patient
care
area
limit
open
close
door
barrier
might
caus
dust
dispers
entri
contamin
air
track
dust
patient
area
particularli
hct
center
patient
care
area
biii
possibl
specif
access
rout
corridor
elev
entranc
exit
even
bathroom
dedic
construct
use
tacki
floor
mat
place
threshold
construct
area
minim
track
dust
visibl
dust
debri
track
construct
zone
vacuum
clean
hepa
filter
vacuum
exhaust
construct
worker
whose
cloth
might
contamin
mold
spore
use
construct
elev
avoid
contact
patient
patient
care
area
elev
nonconstruct
area
biii
portabl
industrialgrad
hepa
filter
use
construct
zone
hct
unit
larg
area
construct
neg
pressur
differenti
guarante
aii
monitor
air
qualiti
construct
may
includ
daili
particl
count
environment
air
sampl
frequent
measur
ventil
pressur
differenti
ciii
monitor
clinic
case
aspergillosi
invas
mold
infect
perform
enhanc
surveil
microbiolog
patholog
radiolog
data
identifi
trend
suggest
environment
mold
sourc
biii
see
surveil
section
routin
microbiolog
air
sampl
fungal
spore
hct
unit
recommend
role
establish
diii
howev
suspect
outbreak
may
role
microbiolog
air
sampl
patient
care
area
ciii
microbiolog
air
sampl
perform
part
outbreak
investig
sampl
volum
least
l
may
achiev
higher
degre
sensit
smaller
sampl
allogen
hct
recipi
avoid
construct
area
insid
outsid
health
care
facil
hct
recipi
may
benefit
wear
respir
outsid
hepafilt
area
especi
period
health
care
facil
construct
renov
ciii
although
util
patient
use
commerci
avail
mask
includ
respir
test
specif
efficaci
reduc
patient
exposur
aspergillu
mold
hospit
construct
renov
area
standard
surgic
mask
provid
neglig
protect
mold
spore
whether
addit
moldact
prophylaxi
would
provid
addit
protect
period
heavi
construct
specif
studi
therefor
recommend
made
newli
construct
renov
area
clean
disinfect
patient
allow
enter
aiii
fungalcontamin
materi
remov
replac
decontamin
clean
biii
also
area
drop
ceil
room
locat
adjac
construct
area
vacuum
biii
addit
ventil
direct
airflow
room
pressur
test
correctli
adjust
patient
allow
enter
biii
clean
hct
center
clean
least
daili
special
attent
dust
control
biii
wetdust
perform
dust
techniqu
aerosol
dust
avoid
biii
mani
studi
show
surfac
contamin
associ
nosocomi
infect
pauciti
data
show
routin
surfac
disinfect
reduc
rate
infect
nonetheless
exhaust
vent
window
sill
horizont
surfac
clean
cloth
mop
head
premoisten
approv
hospit
disinfect
biii
thorough
clean
construct
activ
includ
minor
renov
project
critic
biii
floor
surfac
finish
smooth
nonpor
scrubbabl
eg
vinyl
linoleum
tile
minim
dust
level
biii
carpet
instal
hct
center
hallway
outsid
patient
room
insid
room
diii
contamin
carpet
associ
outbreak
aspergillosi
among
hct
recipi
hct
recipi
expos
vacuum
could
caus
aerosol
fungal
spore
eg
aspergillu
speci
eiii
vacuum
cleaner
use
hct
center
fit
hepa
filter
approv
disinfect
use
daili
environment
disinfect
wet
vacuum
perform
hct
center
biii
hct
center
provid
care
infant
phenol
disinfect
use
clean
floor
provid
dilut
accord
product
label
phenol
compound
howev
use
clean
basinet
incub
diii
water
leak
clean
repair
soon
possibl
within
hour
prevent
mold
prolifer
floor
wall
cover
ceil
tile
cabinetri
around
hct
patient
care
area
biii
cleanup
repair
delay
hour
water
leak
involv
materi
assum
contain
fungi
handl
accordingli
eg
discard
prefer
clean
moistur
meter
detect
water
penetr
wall
use
whenev
possibl
guid
decis
make
biii
exampl
wall
moistur
content
hour
water
penetr
affect
portion
wall
remov
biii
design
select
furnish
focu
creat
maintain
dustfre
environ
upholsteri
smooth
nonpor
easili
disinfect
minim
contamin
potenti
nosocomi
pathogen
finish
ie
wall
cover
window
shade
countertop
use
hct
center
also
scrubbabl
nonpor
easili
disinfect
minim
dust
accumul
biii
hct
center
follow
publish
guidelin
hospit
isol
practic
includ
cdc
guidelin
prevent
healthcareassoci
infect
aiii
howev
efficaci
specif
isol
precaut
prevent
health
careassoci
infect
among
hct
recipi
evalu
hct
recipi
place
singlepati
room
biii
possibl
avail
singlepati
room
limit
use
priorit
sever
immunosuppress
patient
eg
hct
recipi
initi
transplant
admiss
particularli
allogen
hct
recipi
patient
receiv
immunosuppress
therapi
gvhd
readmiss
biii
gener
allogen
hct
recipi
like
benefit
protect
isol
measur
ie
protect
environ
includ
hepa
filtrat
andor
laminar
airflow
reduc
exposur
environment
fungi
eg
aspergillu
sp
reduc
treatmentrel
mortal
trm
see
ventil
section
biii
efficaci
protect
isol
measur
autolog
hct
recipi
well
establish
biii
individu
circumst
guid
priorit
protect
environ
room
set
number
room
limit
eg
patient
receiv
tandem
autolog
hct
may
immunosuppress
receiv
nonmyeloabl
nma
allogen
hct
biii
minimum
standard
precaut
follow
patient
contact
aiii
standard
precaut
includ
hand
hygien
wear
appropri
person
protect
equip
ie
glove
surgic
mask
eye
face
protect
gown
procedur
activ
like
gener
splash
spray
blood
bodi
fluid
secret
excret
caus
soil
cloth
center
use
addit
protect
precaut
eg
glove
mask
either
respiratori
season
year
round
attempt
reduc
risk
transmiss
respiratori
virus
health
care
worker
visitor
patient
howev
insuffici
data
provid
recommend
regard
use
addit
protect
precaut
indic
basi
coexist
condit
hct
recipi
also
place
airborn
droplet
contact
precaut
addit
standard
precaut
aiii
adher
isol
precaut
critic
prevent
transmiss
infecti
agent
among
hct
recipi
hcw
visitor
aiii
hct
recipi
ill
respiratori
gastrointestin
virus
prolong
episod
excret
organ
eg
rsv
adenoviru
rotaviru
guidanc
regard
durat
isol
precaut
specif
pathogen
provid
control
specif
healthcareassoci
infect
section
hct
recipi
may
benefit
wear
mask
respir
preengraft
period
outsid
hospit
room
especi
period
hospit
construct
renov
ciii
hct
recipi
immunocompromis
phase
iiii
immun
system
recoveri
candid
undergo
condit
therapi
minim
time
spent
crowd
area
avoid
exposur
person
crv
infect
biii
hand
hygien
mainstay
infect
prevent
hospit
essenti
element
standard
precaut
patient
aii
hand
hygien
includ
use
alcoholbas
hand
rub
handwash
soap
plain
antimicrobi
water
hct
center
hcw
whose
duti
includ
direct
patient
contact
wear
artifici
fingernail
extend
associ
outbreak
gramneg
bacillu
candid
infect
eiii
hct
center
polici
encourag
visitor
perform
hand
hygien
patient
visit
biii
hct
recipi
candid
household
contact
educ
import
hand
hygien
hct
hospit
hospit
discharg
biii
absenc
visibl
soil
hand
contact
sporeform
organ
see
recommend
regard
c
difficil
prefer
method
hand
hygien
alcoholbas
hand
rub
superior
microbicid
activ
reduc
dri
skin
conveni
aii
hand
visibl
dirti
soil
blood
bodi
fluid
hand
wash
use
soap
water
ai
hand
hygien
perform
follow
circumst
direct
contact
patient
contact
blood
bodi
fluid
excret
mucou
membran
nonintact
skin
wound
dress
contact
patient
skin
hand
move
contamin
clean
bodi
site
patient
care
contact
medic
equip
hospit
environ
immedi
vicin
patient
glove
worn
don
remov
glove
equip
devic
clean
disinfect
steril
maintain
direct
establish
guidelin
aiii
open
unopen
wounddress
suppli
eg
adhes
bandag
surgic
elast
adhes
tape
examin
factor
left
uncheck
could
result
mold
contamin
possibl
subsequ
cutan
transmiss
patient
bii
consist
discard
bandag
wound
dress
date
damag
packag
visual
contamin
construct
debri
moistur
biii
arm
board
use
provid
support
intraven
line
steril
dress
materi
use
arm
board
chang
frequent
eg
daili
biii
addit
nonsteril
tongu
depressor
insert
piec
foam
tube
use
splint
intraven
arteri
cathet
site
associ
outbreak
fatal
invas
nosocomi
rhizopu
microsporu
among
preterm
ie
low
birthweight
infant
dii
although
exposur
plant
flower
conclus
caus
invas
mold
infect
among
hct
recipi
expert
recommend
plant
dri
fresh
flower
allow
hospit
room
condit
hct
phase
iiii
immun
system
recoveri
aspergillu
speci
isol
soil
pot
ornament
plant
eg
cacti
surfac
dri
flower
arrang
fresh
flower
diii
addit
high
count
gramneg
bacteria
found
vase
water
cut
flower
pseudomona
frequent
isol
minim
risk
mold
infect
hct
recipi
candid
avoid
contact
soilbas
materi
eg
clay
pot
soil
diii
toy
commonli
colon
bacteria
eg
aureu
enterococcu
virus
associ
respiratori
gastrointestin
gi
ill
evid
date
toy
serv
sourc
mold
infect
waterretain
bath
toy
use
immunocompromis
hct
recipi
candid
associ
outbreak
pseudomona
aeruginosa
pediatr
oncolog
ward
dii
publish
recommend
wash
disinfect
toy
follow
biii
cloth
plush
toy
wash
hot
cycl
wash
machin
least
weekli
often
need
biii
altern
machin
wash
cold
cycl
accept
laundri
chemic
cold
water
wash
use
proper
concentr
hard
plastic
toy
scrub
warm
soapi
water
use
brush
clean
crevic
rins
clean
water
immers
mild
bleach
solut
made
fresh
daili
see
section
bleach
disinfect
minut
rins
allow
air
dri
altern
hard
plastic
toy
wash
dishwash
hot
cycl
wash
machin
biii
broviac
doll
use
demonstr
medic
procedur
eg
insert
cathet
children
lessen
fear
disassembl
upon
complet
play
wash
disinfect
children
allow
play
biii
infant
toddler
children
put
toy
mouth
share
toy
biii
toy
wash
disinfect
use
avoid
diii
occup
physic
therapi
item
clean
disinfect
previous
describ
biii
play
area
pediatr
hct
recipi
candid
undergo
condit
therapi
clean
disinfect
daili
frequent
need
biii
toy
game
video
allow
playroom
hct
center
kept
clean
disinfect
biii
toy
game
video
provid
individu
patient
room
thoroughli
wash
brought
room
thereaft
least
weekli
frequent
need
biii
dispos
play
item
offer
whenev
possibl
children
contact
precaut
biii
child
contact
precaut
use
toy
game
video
item
thoroughli
clean
disinfect
use
children
biii
child
longer
requir
contact
precaut
toy
game
video
use
period
isol
thoroughli
clean
disinfect
biii
cloth
plush
toy
use
child
contact
precaut
wash
wash
machin
toy
given
anoth
child
place
play
area
biii
toy
use
isol
room
thoroughli
disinfect
discard
biii
hct
center
provid
written
comprehens
polici
regard
immun
vaccin
hct
center
employe
meet
current
cdc
advisori
committe
immun
practic
healthcar
infect
control
practic
advisori
committe
recommend
biii
immun
hcw
recommend
vaccin
critic
prevent
transmiss
vaccineprevent
diseas
hct
recipi
candid
undergo
condit
therapi
equival
effect
option
exist
hcw
care
hct
recipi
preferenti
receiv
inactiv
vaccin
eg
trival
inactiv
influenza
vaccin
inactiv
polio
vaccin
rather
live
vaccin
minim
theoret
risk
transmiss
vaccin
viru
hct
recipi
see
famili
member
receiv
live
vaccin
section
aiii
everi
effort
made
restrict
direct
patient
care
activ
hcw
infect
potenti
transmiss
hct
recipi
candid
aii
extent
work
restrict
eg
leav
work
versu
temporari
reassign
nonpati
care
duti
depend
specif
infect
hcw
drain
skin
soft
tissu
infect
skin
mucou
membran
lesion
eg
hsv
lip
lesion
complet
cover
also
restrict
patient
contact
biii
publish
recommend
regard
durat
work
restrict
hcw
infecti
diseas
follow
biii
hct
center
hcw
bloodborn
viral
infect
ie
hiv
hepat
b
c
virus
hbv
hcv
restrict
patient
contact
diii
work
exclus
polici
design
encourag
hcw
report
ill
exposur
aii
hct
center
written
polici
regard
screen
visitor
communic
infect
biii
institut
train
personnel
eg
administr
nurs
personnel
perform
activ
screen
key
entri
point
hct
unit
particularli
respiratori
viru
season
minimum
sign
post
inform
public
visit
restrict
ideal
staff
activ
screen
visitor
daili
appendix
visitor
sign
symptom
suggest
communic
infect
eg
fever
upper
respiratori
infect
uri
flulik
symptom
diarrhea
vomit
recent
known
exposur
communic
infect
eg
chickenpox
mump
measl
pertussi
exclud
direct
contact
hct
recipi
candid
undergo
condit
therapi
bii
particularli
import
period
widespread
crv
activ
surround
commun
suspect
nosocomi
crv
outbreak
staff
request
affect
visitor
leav
hct
center
sign
symptom
infect
resolv
recent
exposur
communic
infect
incub
period
infect
pass
without
appear
sign
symptom
suggest
activ
infect
aii
visitor
also
screen
recent
receipt
live
vaccin
exclud
appropri
see
famili
member
receiv
live
vaccin
section
screen
process
includ
visitor
stay
overnight
room
hct
recipi
candid
absolut
minimum
age
requir
hct
center
visitor
exist
howev
visitor
must
abl
follow
appropri
hand
hygien
isol
precaut
aiii
number
hct
center
visitor
time
limit
number
permit
nurs
staff
perform
appropri
infect
screen
adequ
instruct
supervis
hand
hygien
glove
mask
use
appropri
biii
hospit
nearbi
famili
lodg
facil
eg
ronald
mcdonald
hous
share
inform
facil
regard
practic
prevent
spread
communic
infect
within
type
facil
health
care
facil
biii
optim
skin
care
hct
recipi
take
daili
shower
bath
use
mild
soap
transplant
biii
patient
gvhd
regular
lubric
dri
intact
skin
emolli
may
decreas
pruritu
maintain
skin
integr
ointment
cream
effect
lotion
less
like
sting
appli
sensit
skin
routin
inspect
skin
site
like
portal
infect
eg
perineum
intravascular
access
site
recommend
neutropenia
biii
hct
recipi
candid
undergo
condit
therapi
maintain
good
perin
hygien
minim
loss
skin
integr
risk
infect
biii
facilit
hct
center
develop
protocol
patient
perin
care
includ
recommend
gentl
thorough
perin
clean
bowel
movement
thorough
dri
perineum
episod
urin
biii
use
toilet
femal
alway
wipe
perineum
front
back
prevent
fecal
contamin
urethra
urinari
tract
infect
aiii
prevent
vagin
irrit
avoid
risk
cervic
vagin
abras
serv
portal
entri
infect
menstruat
hct
recipi
use
tampon
diii
use
rectal
thermomet
enema
suppositori
intern
rectal
exam
sexual
practic
involv
anal
penetr
contraind
among
hct
recipi
avoid
skin
mucos
breakdown
introduc
pathogen
diii
reduc
risk
oral
dental
infect
hct
candid
caregiv
educ
regard
import
maintain
good
oral
dental
hygien
least
first
year
hct
aiii
hct
candid
inform
establish
best
possibl
periodont
health
hct
substanti
benefit
avoid
shortand
longterm
oral
infect
mainten
oral
hygien
hct
minim
sever
infect
facilit
heal
mucos
particularli
engraft
biii
time
permit
hct
candid
undergo
dental
evalu
relev
treatment
start
condit
therapi
aiii
patient
prior
exposur
bisphosphon
treat
accord
establish
guidelin
prophylaxi
oral
mucos
keratinocyt
growth
palifermin
consid
patient
undergo
myeloabl
transplant
palifermin
reduc
incid
sever
durat
mucos
incid
febril
neutropenia
may
diminish
risk
bacteremia
follow
autolog
hct
elect
dentistri
postpon
patient
demonstr
substanti
immun
recoveri
patient
dentist
elimin
like
sourc
dental
infect
exampl
restor
teeth
moder
sever
cari
repair
illfit
dental
prosthes
biii
dentist
extract
teeth
compromis
moder
sever
periodont
diseas
nonrestor
cariou
teeth
partial
impact
teeth
ideal
least
day
elaps
complet
tissueinvas
oral
procedur
onset
condit
therapi
enabl
adequ
heal
monitor
postsurg
complic
aiii
hct
recipi
mucos
hct
candid
undergo
condit
therapi
maintain
oral
hygien
perform
oral
rins
timesday
steril
water
normal
salin
sodium
bicarbon
solut
aiii
hct
recipi
candid
brush
teeth
time
day
soft
regular
toothbrush
replac
regularli
recipi
toler
foam
tooth
swab
use
ciii
although
control
plaqu
prevent
cari
less
effect
toothbrush
must
use
gentli
exacerb
mucos
use
toothpast
option
depend
recipi
toler
ciii
hct
recipi
candid
undergo
condit
therapi
skill
dental
floss
floss
daili
done
without
trauma
biii
routin
dental
supervis
monitor
guid
patient
mainten
oral
dental
hygien
provid
encourag
biii
decreas
risk
mechan
trauma
infect
oral
mucosa
hct
patient
wear
fix
orthodont
applianc
space
maintain
start
condit
therapi
preengraft
mucos
resolv
subsequ
period
mucos
eiii
dental
transplant
team
patient
commun
dentist
coordin
remov
applianc
longterm
rehabilit
oral
lesion
biii
patient
minim
use
remov
dentur
condit
earli
posttransplant
period
reduc
potenti
mucos
injuri
recommend
hct
recipi
risk
mucos
wear
dentur
eat
clean
twice
daili
soft
toothbrush
wear
soak
dentur
antimicrobi
dentur
soak
solut
chang
daili
biii
patient
gvhd
oral
caviti
undergo
frequent
dental
evalu
acceler
pace
dental
cari
patient
biii
dental
cari
gingiv
periodont
diseas
must
manag
promptli
avoid
infecti
sequela
includ
periodont
dental
abscess
regular
brush
floss
rins
fluorid
treatment
manag
xerostomia
basic
element
oral
care
patient
gvhd
biii
hct
personnel
follow
establish
practic
prevent
infect
relat
intravascular
devic
see
bacteri
infect
recommend
regard
catheterassoci
infect
central
venou
access
among
children
nonimpl
devic
prefer
implant
devic
defin
central
venou
cathet
cvc
tunnel
beneath
skin
subcutan
port
access
needl
insuffici
number
lumen
optim
patient
manag
immedi
hct
aiii
addit
especi
among
year
old
skin
often
fragil
toler
repeat
punctur
port
site
patient
parent
caretak
train
care
intravascular
devic
aiii
devic
total
implant
contact
tap
water
central
venou
cathet
skin
site
avoid
biii
patient
cover
protect
cathet
tip
end
cap
bath
shower
avoid
contamin
tap
water
intraven
infus
given
outsid
clinic
start
caregiv
patient
bii
hct
physician
alway
includ
legionnair
diseas
ld
differenti
diagnosi
pneumonia
among
hct
recipi
aiii
legionella
outbreak
occur
transplant
ward
appropri
test
confirm
ld
includ
cultur
sputum
bal
tissu
specimen
test
bal
specimen
legionella
direct
fluoresc
antibodi
test
legionella
pneumophila
serogroup
antigen
urin
howev
sever
legionella
outbreak
immunocompromis
patient
describ
literatur
speci
l
pneumophila
serogroup
speci
therefor
would
detect
urin
antigen
assay
current
suffici
evid
lack
make
recommend
regard
legionella
pcr
test
incub
period
ld
usual
day
thu
laboratoryconfirm
legionellosi
occur
patient
hospit
continu
day
onset
ill
regard
definit
case
nosocomi
ld
laboratoryconfirm
infect
occur
day
hospit
admiss
possibl
case
nosocomi
ld
definit
possibl
case
laboratoryconfirm
nosocomi
ld
identifi
person
inpati
hct
center
part
day
ill
onset
case
laboratoryconfirm
ld
occur
among
patient
visit
outpati
hct
center
case
report
local
state
health
depart
diseas
report
state
countri
assist
need
aiii
addit
consult
hospit
infect
control
team
thorough
epidemiolog
environment
investig
conduct
determin
like
environment
sourc
legionella
speci
eg
shower
tap
water
faucet
cool
tower
hot
water
tank
ai
sourc
legionella
infect
identifi
decontamin
aiii
extens
hospit
investig
isol
case
possibl
nosocomi
ld
might
indic
patient
limit
contact
inpati
hct
center
incub
period
ciii
hct
center
follow
publish
recommend
regard
prevent
nosocomi
legionellosi
biii
hct
center
personnel
use
steril
water
ie
distil
nonsteril
water
fill
reservoir
nebul
devic
rins
nebul
devic
semicrit
respiratorycar
equip
clean
disinfect
bii
hct
center
use
largevolum
room
air
humidifi
creat
aerosol
eg
venturi
principl
ultrasound
spin
disk
thu
actual
nebul
di
unless
humidifi
steril
subject
daili
highlevel
disinfect
fill
steril
water
ciii
new
hospit
hct
center
construct
cool
tower
place
tower
drift
direct
away
hospit
airintak
system
cool
tower
design
volum
aerosol
drift
minim
bii
oper
hospit
cool
tower
hospit
instal
drift
elimin
regularli
use
effect
biocid
maintain
cool
tower
accord
manufactur
recommend
keep
adequ
mainten
record
bii
decor
fountain
instal
hct
unit
area
healthcar
facil
frequent
hct
recipi
biii
clonal
outbreak
ld
link
decor
fountain
despit
effort
prevent
legionella
contamin
recent
describ
avail
data
suggest
drink
tap
water
pose
risk
legionella
exposur
among
hct
recipi
absenc
outbreak
hct
recipi
higher
risk
diseas
death
legionellosi
compar
hospit
person
period
routin
cultur
legionella
speci
water
sampl
hct
center
potabl
water
suppli
could
includ
part
overal
strategi
prevent
ld
ciii
howev
optim
methodolog
ie
frequenc
number
site
environment
surveil
cultur
hct
center
determin
costeffect
strategi
evalu
safe
concentr
legionella
organ
potabl
water
establish
goal
maintain
water
system
detect
organ
aiii
legionella
speci
detect
water
suppli
hct
center
follow
measur
perform
legionella
speci
longer
detect
cultur
decontamin
water
suppli
aii
prevent
patient
shower
ldcontamin
water
instead
provid
hct
recipi
spong
bath
use
water
contamin
legionella
speci
eg
use
water
hct
center
potabl
water
system
biii
use
faucet
contain
ldcontamin
water
patient
room
hct
center
ambulatori
hct
clinic
avoid
creat
infecti
aerosol
diii
provid
hct
recipi
steril
water
instead
tap
water
drink
brush
teeth
flush
nasogastr
tube
proven
suspect
legionellosi
outbreak
biii
hct
center
follow
publish
recommend
prevent
healthcareassoci
transmiss
mrsa
prevent
mrsa
transmiss
adher
follow
infect
control
practic
recommend
perform
hand
hygein
either
alcoholbas
hand
rub
wash
hand
soap
water
soil
patient
contact
contact
patient
potenti
contamin
equip
environ
aii
use
contact
precaut
patient
colon
infect
mrsa
includ
use
glove
gown
aii
ensur
adher
standard
environment
clean
effect
disinfect
biii
insuffici
evid
present
recommend
routin
screen
hct
recipi
mrsa
use
topic
system
antimicrobi
therapi
patient
asymptomat
mrsa
colon
although
area
activ
research
high
rate
mrsa
persist
despit
implement
basic
infect
control
practic
hct
center
consid
adjunct
strategi
implement
program
obtain
mrsa
surveil
cultur
admiss
serial
eg
weekli
bii
without
decolon
therapi
biii
routin
bath
patient
chlorhexidin
biii
cohort
mrsa
patient
design
area
eg
bay
patient
care
area
assign
care
dedic
staff
ciii
potenti
impact
rapid
molecular
techniqu
identifi
aureu
nasal
carriag
prevent
mrsa
transmiss
anoth
area
activ
research
recommend
regard
use
rapid
techniqu
mrsa
provid
time
emerg
communityassoci
mrsa
infect
complic
prevent
control
mrsa
optim
strategi
prevent
transmiss
infect
communityassoci
mrsa
current
unknown
optim
durat
contact
precaut
patient
mrsa
unknown
although
studi
shown
patient
remain
persist
colon
extend
period
time
hct
center
may
opt
implement
mrsa
discontinu
criteria
eg
continu
contact
precaut
antimicrobi
activ
mrsa
isol
discontinu
consecut
screen
cultur
taken
separ
day
neg
ciii
patient
recurr
mrsa
infect
erad
carrier
state
attempt
appli
mupirocin
calcium
ointment
nare
use
topic
antisept
chlorhexidin
bath
administr
system
antimicrobi
although
strategi
shown
consist
effect
appendix
cii
highlevel
mupirocinresist
mrsa
report
europ
middl
east
south
america
less
common
unit
state
antimicrobi
agent
incorrect
use
overus
mupirocin
result
emerg
mupirocinresist
staphylococci
therefor
mupirocin
use
coordin
local
hospit
infect
control
team
select
system
antimicrobi
use
treat
mrsa
infect
guid
suscept
pattern
recommend
treatment
mrsa
infect
beyond
scope
guidelin
refer
publish
treatment
guidelin
hct
center
suffici
laboratori
capabl
identifi
staphylococcu
isol
antimicrobi
suscept
pattern
includ
vancomycin
suscept
aii
addit
hct
center
conduct
routin
surveil
emerg
staphylococcu
speci
strain
reduc
suscept
vancomycin
aiii
reduc
suscept
vancomycin
defin
aureu
strain
vancomycin
minimum
inhibitori
concentr
mic
mgml
coagulaseneg
staphylococci
vancomycin
mic
mgml
patient
hct
center
colon
infect
staphylococc
strain
reduc
suscept
vancomycin
infect
control
personnel
follow
publish
guidelin
control
speci
biii
avoid
overus
misus
antimicrobi
decreas
emerg
staphylococcu
speci
reduc
suscept
vancomycin
therefor
medic
ancillari
staff
member
respons
monitor
antimicrobi
use
pattern
facil
routin
review
vancomycin
use
pattern
aii
addit
hct
center
personnel
institut
prudent
use
antimicrobi
includ
vancomycin
prevent
emerg
staphylococcu
reduc
suscept
vancomycin
aii
hct
recipi
frequent
multipl
risk
factor
vre
colon
infect
vre
infect
associ
poor
outcom
among
hct
recipi
histori
resolv
vre
bacteremia
known
vre
colon
howev
contraind
hct
biii
reduc
risk
vre
infect
hct
clinician
minim
use
durat
treatment
vancomycin
antimicrobi
agent
antianaerob
coverag
eg
metronidazol
thirdgener
cephalosporin
aii
although
oral
vancomycin
metronidazol
promot
overgrowth
vre
stool
risk
acquir
vre
promot
vre
overgrowth
defin
consider
select
oral
vancomycin
treatment
sever
recurr
c
difficil
infect
biii
patient
colon
vre
typic
remain
colon
long
period
extend
beyond
hospit
initi
vreposit
cultur
result
obtain
vre
may
reemerg
prior
neg
cultur
patient
reexpos
antimicrobi
contact
precaut
hct
recipi
past
vre
colon
infect
continu
hospit
readmiss
aiii
although
insuffici
data
provid
recommend
regard
optim
durat
precaut
hct
recipi
histori
vre
individu
hct
center
consid
implement
criteria
discontinu
contact
precaut
eg
consecut
set
screen
cultur
neg
vre
obtain
separ
day
patient
receiv
antimicrobi
therapi
activ
vre
isol
prevent
vre
transmiss
follow
infect
control
measur
recommend
perform
hand
hygien
alcoholbas
hand
rub
wash
hand
soap
water
soil
patient
contact
contact
patient
potenti
contamin
equip
environ
aii
use
contact
precaut
patient
colon
infect
vre
includ
use
glove
gown
aii
ensur
adher
standard
environment
clean
appropri
disinfect
biii
antimicrobi
treatment
vre
carrier
adequ
studi
carri
potenti
risk
includ
toxic
develop
drugresist
organ
therefor
discourag
diii
effect
activ
surveil
cultur
vre
prevent
health
careassoci
transmiss
vre
unknown
vre
rectal
stoolact
surveil
cultur
identifi
colon
patient
consid
evid
ongo
transmiss
vre
hct
unit
ciii
mdrgnb
defin
gnb
resist
class
antimicrobi
agent
includ
produc
extendedspectrum
betalactamas
esbl
carbapenemas
addit
escherichia
coli
klebsiella
pneumonia
mdrgnb
includ
highli
resist
strain
acinetobact
baumannii
organ
stenotrophomona
maltophilia
burkholderia
cepacia
ralstonia
pickettii
intrins
broad
antimicrobi
resist
detail
discuss
mdrgnb
recommend
prevent
publish
judici
use
antimicrobi
agent
import
control
mdrgnb
bii
sever
studi
demonstr
tempor
associ
formulari
chang
decreas
incid
target
mdrgnb
multipli
drugresist
organ
adher
follow
infect
control
measur
import
prevent
health
careassoci
transmiss
perform
hand
hygien
alcoholbas
hand
rub
wash
hand
soap
water
soil
patient
contact
contact
patient
potenti
contamin
equip
environ
aii
use
contact
precaut
includ
gown
glove
patient
colon
infect
mdrgnb
epidemiolog
import
hct
center
aii
ensur
adher
standard
environment
clean
effect
disinfect
biii
base
current
evid
unclear
whether
addit
activ
surveillancecultur
asc
program
mdrgnb
basic
infect
control
practic
use
studi
report
success
reduct
extendedspectrum
betalactamaseproduc
enterobacteriacea
period
use
multifacet
control
program
includ
use
asc
report
suggest
use
asc
necessari
control
endem
mdrgnb
howev
cdc
health
care
infect
control
practic
advisori
committe
recommend
singl
round
surveil
conduct
high
risk
set
eg
unit
patient
expos
broad
spectrum
antimicrobi
previous
unidentifi
case
carbapenemresist
carbapenemaseproduc
klebsiella
spp
e
coli
identifi
review
mircobiolog
record
unit
experienc
high
rate
mdrgnb
infect
consid
use
asc
compon
control
prevent
program
ciii
although
insuffici
inform
provid
recommend
regard
use
asc
prevent
transmiss
mdrgnb
hct
center
follow
publish
recommend
prevent
control
treat
c
difficil
infect
cdi
ai
patient
cdi
place
contact
precaut
durat
ill
biii
hcw
contact
c
difficileinfect
patient
patient
environ
glove
ai
gown
biii
enter
patient
room
contact
precaut
continu
least
patient
asymptomat
biii
test
cure
determin
whether
contact
precaut
discontinu
discourag
dii
evid
ongo
transmiss
c
difficil
despit
implement
basic
prevent
practic
describ
hct
center
consid
maintain
contact
precaut
even
diarrhea
resolv
hospit
discharg
ciii
nosocomi
cdi
outbreak
hct
center
work
close
infect
prevent
control
staff
ensur
implement
appropri
control
measur
aiii
follow
practic
recommend
prevent
c
difficil
transmiss
perform
routin
stool
surveil
cultur
toxin
assay
c
difficil
among
asymptomat
patient
hcw
even
outbreak
diii
cultur
hcw
hand
c
difficil
eiii
treat
asymptomat
c
difficil
carrier
prevent
clinic
infect
eii
hand
hygien
complianc
may
decreas
soap
water
prefer
method
alcoholbas
hand
rub
associ
increas
hand
hygien
complianc
effect
remov
nonsporeform
organ
soap
water
howev
use
alcoholbas
hand
hygien
product
care
patient
cdi
remain
controversi
alcohol
sporicid
hand
wash
soap
water
shown
effect
remov
bacillu
atrophaeu
spore
presum
glove
worn
care
patient
c
difficil
infect
spore
physic
remov
glove
remov
set
outbreak
ongo
c
difficil
transmiss
hct
center
center
consid
instruct
visitor
hcw
wash
hand
soap
water
contact
patient
cdi
equip
environ
biii
soap
water
use
proper
techniqu
ie
minimum
second
hand
wash
ensur
bi
c
difficil
primarili
transmit
hand
hcw
howev
c
difficil
also
acquir
hospit
environ
current
approv
sporicid
hospit
disinfect
sodium
hypochloritebas
clean
agent
ie
household
bleach
water
dilut
least
ppm
avail
chlorin
sporicid
within
minut
one
studi
demonstr
signific
declin
cdi
rate
hct
unit
use
bleachbas
clean
agent
use
bleachcontain
clean
agent
environment
disinfect
consid
evid
ongo
c
difficil
transmiss
bii
optim
frequenc
eg
daili
clean
clean
discharg
patient
room
extent
eg
room
patient
cdi
patient
room
unit
addit
area
outsid
patient
room
clean
bleachcontain
agent
unresolv
issu
hct
center
institut
appropri
precaut
infect
control
measur
prevent
transmiss
crv
among
hospit
hct
recipi
candid
undergo
condit
therapi
aiii
hct
recipi
candid
uri
lower
respiratori
infect
lri
symptom
suspect
crv
infect
empir
place
contact
plu
droplet
precaut
specif
pathogen
identifi
identif
precaut
adjust
base
publish
guidelin
avoid
transmit
infect
hct
candid
recipi
hcw
visitor
biii
pathogenspecif
crv
isol
precaut
includ
contact
precaut
rsv
parainfluenza
droplet
precaut
influenza
droplet
plu
contact
precaut
adenoviru
airborn
plu
contact
precaut
primari
dissemin
varicella
infect
person
protect
equip
eg
gown
glove
surgic
mask
eye
protect
don
prior
enter
discard
upon
exit
patient
room
ensur
person
protect
equip
alway
chang
patient
aiii
care
hct
recipi
candid
undergo
condit
therapi
uri
lri
hcw
visitor
disinfect
hand
alcoholbas
gel
hand
visibl
soil
soap
water
aii
contact
patient
handl
respiratori
secret
fomit
potenti
contamin
patient
secret
don
remov
glove
adher
hand
hygien
critic
respiratori
infect
transmit
direct
contact
particularli
hand
nose
eye
use
mask
without
appropri
hand
disinfect
glovewear
facial
protect
insuffici
prevent
transmiss
crv
infect
perform
aerosolgener
procedur
eg
bronchoscopi
open
suction
respiratori
tract
ie
unless
inlin
suction
cathet
use
endotrach
intub
hcw
wear
face
shield
fulli
cover
front
side
face
mask
attach
shield
mask
goggl
along
glove
gown
avoid
contamin
patient
respiratori
secret
regardless
presenc
absenc
crv
symptom
aiii
hct
center
consid
daili
screen
person
enter
center
includ
hcw
visitor
uri
symptom
especi
nosocomi
commun
outbreak
crv
infect
appendix
biii
hct
center
hcw
uri
symptom
restrict
patient
contact
reassign
nonpati
care
duti
symptom
resolv
bii
visitor
uri
symptom
ask
defer
visit
hct
center
uri
symptom
resolv
aii
hcw
visitor
infecti
conjunct
restrict
direct
patient
contact
drainag
resolv
aii
respiratori
secret
hospit
hct
candid
recipi
sign
symptom
crv
infect
test
promptli
viral
cultur
rapid
diagnost
test
crv
biii
see
viral
infect
section
appropri
sampl
includ
nasopharyng
wash
swab
aspir
without
throat
swab
bal
fluid
practic
permit
time
initi
isol
precaut
prevent
transmiss
patient
hcw
well
preemptiv
treatment
certain
crv
eg
influenza
might
prevent
sever
diseas
death
among
hct
recipi
hct
center
obtain
nasopharyng
swab
throat
swab
aspir
cultur
pcr
rapid
antigen
test
help
determin
whether
patient
stop
shed
viru
biii
prevent
nosocomi
transmiss
crv
hct
center
recogn
prolong
crv
shed
may
occur
viral
shed
report
last
month
influenza
year
adenoviru
day
rsv
mainli
patient
treat
steroid
dose
mgkg
rsv
viral
shed
report
last
day
child
sever
combin
immunodefici
hct
recipi
crv
infect
place
appropri
precaut
least
durat
ill
aii
precaut
continu
durat
hospit
viral
shed
prevent
transmiss
within
unit
ciii
hct
center
conduct
routin
crv
surveil
among
asymptomat
hct
recipi
detect
outbreak
implement
infect
control
measur
earli
possibl
date
howev
data
insuffici
provid
recommend
regard
routin
surveil
test
asymptomat
patient
crv
infect
period
widespread
rsv
influenza
activ
surround
commun
suspect
health
careassoci
crv
outbreak
hct
recipi
candid
sign
symptom
respiratori
infect
test
rsv
influenza
infect
ie
presenc
rsv
andor
influenza
antigen
respiratori
secret
test
enzymelink
immunosorb
assay
viral
cultur
outbreak
health
careassoci
rsv
infect
manag
cohort
health
care
personnel
much
practic
ie
restrict
personnel
care
rsvinfect
patient
give
care
uninfect
patient
ciii
recommend
made
cohort
personnel
outbreak
health
careassoci
crv
infect
hcw
close
contact
hct
recipi
receiv
yearli
influenza
vaccin
start
influenza
season
prefer
trival
inactiv
influenza
vaccin
rather
live
attenu
influenza
vaccin
avoid
concern
transmiss
vaccin
viru
tabl
ai
use
influenza
vaccin
along
prophylaxi
earli
antivir
therapi
among
atrisk
healthcar
worker
highrisk
patient
reduc
spread
influenza
within
healthcar
facil
outbreak
health
careassoci
influenza
infect
addit
use
droplet
precaut
patient
suspect
confirm
influenza
rapid
influenza
viru
test
symptomat
patient
hct
center
consid
rapid
influenza
viru
test
symptomat
hct
staff
administr
inactiv
influenza
vaccin
unvaccin
hct
staff
appropri
patient
see
hct
recipi
vaccin
section
administr
influenza
antivir
chemoprophylaxi
hct
staff
patient
accord
current
recommend
biii
healthcar
personnel
influenza
exclud
work
day
follow
onset
symptom
aiii
prevent
crv
exposur
among
hct
recipi
hospit
discharg
challeng
high
crv
preval
prevent
measur
individu
accord
immunolog
statu
toler
patient
outpati
wait
room
patient
crv
infect
separ
extent
possibl
patient
instruct
use
respiratori
hygien
cough
etiquett
biii
adenoviru
caus
larg
outbreak
hospit
set
chronic
care
facil
outbreak
diarrheal
ill
adenoviru
previous
describ
among
adult
hct
recipi
transmiss
occur
via
inhal
aerosol
droplet
direct
indirect
contact
contamin
surfac
fecalor
spread
exposur
infect
tissu
blood
rare
contamin
water
sputum
oral
secret
infect
adult
contain
particlesml
nonimmun
adult
infect
inhal
viral
particl
prolong
fecal
shed
demonstr
hivinfect
patient
without
diarrhea
immunocompromis
host
known
asymptomat
shed
adenoviru
gi
respiratori
tract
month
initi
infect
furthermor
immunosuppress
individu
may
either
reactiv
endogen
infect
acquir
new
infect
adenoviru
surviv
nonpor
surfac
day
recommend
isol
precaut
hospit
set
depend
type
syndrom
caus
adenoviru
hct
recipi
adenovir
gastroenter
place
contact
precaut
least
durat
ill
aiii
precaut
continu
durat
hospit
viral
shed
ciii
prevent
transmiss
within
unit
case
respiratori
ill
dissemin
infect
associ
adenoviru
droplet
contact
precaut
maintain
least
durat
ill
aiii
case
adenovir
conjunct
immunosuppress
patient
contact
precaut
aiii
droplet
precaut
ciii
institut
least
durat
ill
usual
day
ciii
hand
hygien
either
alcoholbas
hand
rub
soap
water
shown
effect
adenoviru
biii
environment
disinfect
surfac
hospitalapprov
disinfect
eg
chlorinebas
product
ethyl
alcohol
ethanol
mix
quaternari
ammonium
compound
import
limit
spread
adenovir
infect
viral
gastroenter
commonli
spread
fecalor
rout
common
pathogen
includ
rotaviru
noroviru
astroviru
adenoviru
see
adenoviru
section
adenovirusspecif
recommend
prevent
acquisit
spread
viral
gastroenter
among
hct
recipi
hct
center
ensur
adher
hand
hygien
appropri
isol
precaut
environment
disinfect
aii
appropri
precaut
maintain
least
durat
ill
aii
hct
recipi
may
continu
shed
viru
symptom
resolv
hct
center
may
choos
continu
precaut
durat
hospit
durat
viral
shed
diagnost
laboratori
test
avail
ciii
rotaviru
common
caus
sever
gastroenter
infant
young
children
worldwid
viru
shed
high
concentr
stool
infect
children
transmit
primarili
fecalor
rout
persontoperson
contact
fomit
environment
contamin
common
rotaviru
surviv
nonpor
surfac
day
health
careassoci
transmiss
rotaviru
infect
link
toy
contamin
hand
contact
precaut
implement
hct
recipi
suspect
confirm
rotaviru
gastroenter
prevent
transmiss
health
care
set
aiii
alcoholbas
hand
gel
virucid
activ
rotaviru
suffici
routin
hand
hygien
unless
hand
visibl
soil
prolong
shed
occur
immunocompromis
patient
hct
staff
ensur
consist
environment
clean
disinfect
remov
soil
diaper
aiii
soil
diaper
need
weigh
outsid
patient
room
import
ensur
environment
disinfect
item
contact
soil
diaper
eg
cover
scale
paper
appropri
discard
soil
diaper
paper
disinfect
scale
use
biii
norovirus
common
caus
outbreak
nonbacteri
gastroenter
fecalor
transmiss
common
although
environment
fomit
contamin
also
import
sourc
infect
aerosol
vomitu
result
droplet
contamin
surfac
swallow
also
contribut
transmiss
infect
individu
contagi
hour
recoveri
low
infecti
dose
particl
multipl
mode
transmiss
prolong
durat
viral
shed
even
among
asymptomat
peopl
abil
surviv
high
level
chlorin
vari
temp
freez
heat
c
contribut
eas
noroviru
transmiss
detect
viral
rna
stool
use
rtpcr
assay
show
viru
isol
long
day
symptom
onset
reduc
transmiss
highli
infecti
organ
sever
strategi
need
employ
includ
hand
wash
soap
water
contact
precaut
wear
mask
clean
area
contamin
fece
vomitu
minim
handl
soil
linen
cloth
biii
use
alcoholbas
hand
rub
may
inadequ
prevent
noroviru
transmiss
norovirus
resist
usual
clean
disinfect
agent
hypochloritebas
clean
agent
recommend
use
hard
nonpor
environment
surfac
concentr
ppm
cup
bleach
gallon
water
dilut
ppm
cup
bleach
gallon
water
dilut
depend
level
soil
type
environment
surfac
bii
hct
center
without
access
predilut
bleach
product
staff
prepar
fresh
dilut
bleach
daili
discard
unus
portion
environment
clean
disinfect
hypochloritebas
clean
agent
perform
minimum
patient
discharg
room
ie
termin
clean
frequent
need
biii
quaternari
ammonium
compound
signific
activ
norovirus
nonenvelop
viru
particl
phenolicbas
disinfect
activ
norovirus
may
requir
concentr
time
higher
manufactur
recommend
routin
use
heat
disinfect
pasteur
c
suggest
item
clean
bleachbas
disinfect
outbreak
astroviru
gastroenter
occur
hospit
nurs
home
daycar
center
infect
also
occur
hct
recipi
astrovirus
transmit
via
fecalor
rout
direct
indirect
contact
possibl
via
contamin
water
furthermor
viru
persist
fecal
contamin
surfac
sever
month
rel
low
humid
contact
precaut
environment
disinfect
use
control
spread
astroviru
infect
among
hct
recipi
known
outbreak
aii
quaternari
ammonium
compound
chlorin
solut
effect
inactiv
enter
virus
provid
clean
step
remov
organ
matter
preced
termin
disinfect
institut
follow
standard
guidelin
surveil
epidemiolog
signific
nosocomi
pathogen
eg
mrsa
vre
mdrgnb
c
difficil
invas
mold
infect
suscept
pattern
biii
absenc
epidemiolog
cluster
infect
need
perform
routin
bacteri
surveil
cultur
hct
center
environ
equip
devic
use
respiratori
therapi
pulmonaryfunct
test
deliveri
inhal
anesthesia
diii
furthermor
absenc
nosocomi
fungal
outbreak
necessari
perform
routin
fungal
cultur
devic
dust
eg
settl
plate
room
hct
recipi
candid
undergo
condit
therapi
diii
howev
hct
center
personnel
perform
routin
surveil
case
invas
mold
diseas
includ
aspergillosi
occur
among
hct
recipi
biii
optim
surveil
definit
nosocomi
invas
mold
diseas
unclear
hct
recipi
frequent
contact
ambulatori
healthcar
facil
incub
period
invas
mold
diseas
unknown
case
invas
mold
infect
track
regardless
time
onset
admiss
biii
case
invas
mold
diseas
onset
symptom
day
hospit
admiss
like
hospit
acquir
surveil
definit
includ
definit
proven
probabl
possibl
case
criteria
includ
cultur
histolog
host
factor
indirect
test
detect
fungal
antigen
cellwal
constitu
clinic
includ
radiolog
data
biii
increas
number
case
incid
invas
mold
diseas
among
hct
recipi
trigger
care
evalu
hct
center
environ
sourc
mold
exposur
addit
ventil
system
evalu
ensur
adequ
filtrat
air
flow
air
pressur
differenti
see
ventil
section
biii
hematopoiet
cell
transplant
hct
recipi
caregiv
educ
regard
strategi
avoid
environment
exposur
opportunist
pathogen
aiii
hct
recipi
candid
perform
frequent
consist
hand
hygien
aii
especi
relat
follow
eat
prepar
food
chang
diaper
touch
plant
dirt
urin
defec
touch
anim
touch
bodi
fluid
excret
item
might
contact
human
anim
fece
eg
cloth
bed
toilet
bedpan
go
outdoor
public
place
remov
glove
collect
deposit
garbag
touch
cathet
wound
conscienti
hand
hygien
use
alcoholbas
hand
gel
soap
water
especi
critic
first
month
hct
period
substanti
immunosuppress
eg
treatment
gvhd
system
steroid
use
relaps
underli
diseas
transplant
perform
pediatr
hct
recipi
candid
supervis
adult
hand
disinfect
ensur
thorough
clean
hand
hygien
perform
alcoholbas
hand
gel
soap
water
aii
hct
recipi
visit
live
farm
follow
publish
recommend
prevent
cryptosporidiosi
hct
recipi
avoid
chang
diaper
whenev
possibl
biii
even
glove
worn
hand
alway
wash
glove
remov
glove
may
defect
easili
visibl
aiii
prevent
infect
primarili
transmit
respiratori
exposur
crv
infect
caus
sever
diseas
mortal
hct
recipi
prevent
respiratori
infect
hospit
discharg
hct
recipi
observ
follow
precaut
perform
frequent
thorough
hand
hygien
biii
avoid
touch
eye
nose
mouth
unless
disinfect
hand
avoid
inocul
crv
avoid
close
contact
person
respiratori
ill
biii
close
contact
unavoid
hct
recipi
symptomat
contact
encourag
disinfect
hand
frequent
shown
reduc
transmiss
respiratori
ill
symptomat
contact
also
consid
wear
surgic
mask
minimum
cover
mouth
nose
dispos
tissu
sneez
cough
tissu
avail
use
upper
sleev
although
hct
recipi
wear
mask
contact
symptomat
person
degre
protect
wear
mask
determin
exercis
particularli
care
hand
hygien
crowd
area
eg
shop
mall
public
elev
close
contact
person
respiratori
ill
like
especi
autumn
winter
month
aii
visitor
hct
center
introduc
communic
infect
environment
contamin
direct
spread
visitor
perform
hand
hygien
visit
visitor
screen
symptom
infect
fever
rash
vomit
diarrhea
upper
respiratori
symptom
conjunct
allow
visit
hct
recipi
symptomat
biii
hct
recipi
candid
undergo
condit
therapi
also
risk
infect
caus
fungal
parasit
bacteri
pathogen
associ
exposur
soil
plant
aerosol
eg
toxoplasma
gondii
histoplasma
capsulatum
cryptococcu
neoforman
nocardia
speci
aspergillu
speci
prevent
infect
hct
recipi
candid
follow
follow
precaut
first
month
hct
period
substanti
immunosuppress
eg
treatment
gvhd
system
steroid
use
relaps
underli
diseas
transplant
perform
hct
recipi
candid
undergo
condit
therapi
avoid
garden
direct
contact
soil
plant
aerosol
biii
activ
unavoid
individu
wear
protect
glove
prevent
abras
lacer
surgic
mask
touch
plant
soil
although
effect
glove
mask
protect
infect
associ
exposur
soil
unknown
hct
recipi
avoid
creat
plant
soil
aerosol
activ
spread
mulch
hct
recipi
alway
thoroughli
wash
hand
soap
water
soil
plant
contact
hct
recipi
avoid
construct
excav
site
dustladen
environ
first
month
hct
period
substanti
immunosuppress
avoid
exposur
mold
outpati
hct
recipi
advis
travel
rout
hct
center
avoid
minim
exposur
construct
site
ciii
coccidioidomycosi
uncommon
allogen
hct
present
sever
diseas
hct
recipi
travel
resid
area
coccidioidomycosi
endem
eg
american
southwest
mexico
central
south
america
avoid
activ
caus
exposur
dust
minim
exposur
dust
disturb
soil
includ
construct
excav
site
area
recent
earthquak
farm
rural
area
ciii
histoplasmosi
histoplasma
capsulatum
infect
allogen
hct
also
rare
howev
hct
recipi
histoplasmosisendem
area
avoid
exposur
birdroost
site
cave
avoid
exposur
bird
bat
drop
ciii
hct
candid
recipi
advis
certain
activ
occup
eg
work
healthcar
set
prison
jail
homeless
shelter
increas
risk
tuberculosi
tb
exposur
decid
whether
hct
recipi
continu
activ
set
physician
evalu
patient
specif
duti
precaut
use
prevent
tb
exposur
workplac
preval
tb
commun
decis
continu
termin
activ
made
jointli
patient
physician
hct
recipi
avoid
exposur
person
activ
tb
particularli
first
month
hct
period
substanti
immunosuppress
biii
person
whose
occup
involv
anim
contact
eg
veterinarian
pet
store
employe
farmer
slaughterhous
worker
may
increas
risk
toxoplasmosi
q
fever
brucellosi
zoonot
diseas
although
data
insuffici
justifi
gener
recommend
hct
recipi
work
set
exposur
avoid
first
month
hct
period
substanti
immunosuppress
biii
hct
recipi
exercis
caution
handl
household
trash
air
surround
solid
wast
shown
contain
cultur
aerosol
bacteria
fungi
although
case
infect
definit
link
routin
handl
solid
wast
recommend
hct
recipi
wear
mask
use
glove
handl
substanti
volum
wast
ciii
household
member
receiv
recommend
vaccin
prevent
ill
household
reduc
risk
transmiss
infect
hct
recipi
tabl
choic
liveattenu
vaccin
inactiv
vaccin
exist
eg
influenza
polio
household
member
receiv
inactiv
vaccin
reduc
potenti
risk
transmiss
vaccin
viru
ensur
hct
patient
optim
protect
vaccineprevent
diseas
vaccin
household
contact
minim
risk
transmiss
vaccin
viru
clinician
consid
follow
data
current
recommend
polio
vaccin
aii
household
member
hct
recipi
receiv
inactiv
polio
vaccin
ipv
oral
polio
vaccin
opv
liveattenu
vaccin
rare
associ
paralysi
healthi
recipi
contact
opv
vaccin
inadvert
given
household
contact
close
contact
avoid
approxim
week
vaccin
aii
feasibl
hct
recipi
perform
care
hand
hygien
contact
fece
vaccin
household
member
eg
chang
diaper
vaccin
child
avoid
contact
saliva
eg
share
food
utensil
reduc
risk
transmiss
vaccineassoci
polio
viru
infant
children
recent
receiv
opv
vaccin
exclud
visit
hct
unit
week
receipt
vaccin
minim
risk
transmiss
vaccineassoci
paralyt
poliomyel
among
hct
recipi
aii
rotaviru
vaccin
ciii
rotaviru
vaccin
current
avail
humanbovin
reassort
vaccin
avail
seri
use
infant
month
age
prevent
rotaviru
gastroenter
human
strain
avail
seri
use
children
month
age
shed
shown
occur
day
dose
day
although
document
case
transmiss
vaccin
viru
thu
routin
standard
precaut
current
recommend
recent
immun
infant
minim
risk
potenti
vaccin
viru
transmiss
hct
recipi
avoid
handl
diaper
possibl
feasibl
hct
recipi
perform
care
hand
hygien
contact
fece
vaccin
household
member
aiii
data
risk
transmiss
vaccin
viru
becom
avail
hct
unit
may
wish
exclud
infant
recent
receiv
rotaviru
vaccin
visit
week
receiv
vaccin
dose
ciii
liveattenu
influenza
vaccin
laiv
studi
demonstr
vaccin
recipi
month
age
shed
vaccin
viru
strain
mean
durat
day
thu
far
document
case
transmiss
immunocompromis
host
case
document
transmiss
occur
immunocompet
host
estim
transmiss
rate
popul
young
children
enrol
childcar
center
adult
shed
mostli
occur
within
first
day
continu
long
day
vaccin
hivinfect
individu
cdc
class
plasma
hiv
rna
count
count
none
shed
laiv
viru
longer
day
furthermor
clinic
trial
data
suggest
vaccin
viru
shed
vaccin
recipi
none
revert
wild
type
altern
trival
inactiv
influenza
vaccin
tiv
exist
household
member
hct
recipi
receiv
tiv
avoid
potenti
concern
transmiss
vaccin
viru
ai
health
care
center
personnel
hct
center
visitor
receiv
laiv
instead
tiv
avoid
contact
sever
immunosuppress
person
day
vaccin
ciii
zoster
vaccin
herp
zoster
vaccin
current
recommend
adult
year
age
older
unit
state
evid
date
transmiss
vaccineassoci
viru
occur
howev
hct
center
exclud
visitor
develop
varicellaor
zosterlik
rash
vaccin
aiii
household
member
develop
varicella
zosterlik
rash
vaccin
close
contact
hct
recipi
avoid
affect
area
cover
aiii
varicella
vaccin
aiii
small
studi
healthi
children
receiv
vaccin
immunocompromis
sibl
evid
vaccin
viru
transmiss
postlicensur
era
transmiss
immunocompet
person
vaccin
document
pcr
person
result
secondari
infect
million
dose
estim
given
risk
vaccin
viru
transmiss
low
particularli
absenc
vaccineassoci
rash
household
member
receiv
varicella
vaccin
protect
hct
recipi
potenti
exposur
wildtyp
diseas
aiii
individu
experi
vaccineassoci
rash
within
month
varicella
vaccin
exclud
visit
hct
center
avoid
close
contact
hct
recipi
home
set
biii
measur
remov
vaccine
transplant
recipi
domicil
studi
measl
mump
rubella
mmr
vaccin
aiii
household
member
receiv
ageappropri
mmr
vaccin
recommend
howev
vaccin
recipi
develop
fever
andor
rash
postvaccin
exclud
visit
hct
center
symptomat
avoid
close
contact
hct
recipi
home
set
biii
sexual
activ
patient
longterm
monogam
relationship
alway
use
latex
condom
sexual
contact
reduc
risk
exposur
cytomegaloviru
cmv
herp
simplex
viru
hsv
hiv
human
papilloma
viru
hpv
hepat
b
viru
hbv
hepat
c
viru
hcv
sexual
transmit
infect
sti
aii
howev
even
longtim
monogam
partner
discord
infect
reinfect
sti
report
seroposit
recipi
longterm
partner
year
transplant
therefor
sexual
activ
hct
recipi
longterm
monogam
relationship
consid
use
latex
condom
sexual
contact
reduc
risk
exposur
sti
ciii
addit
contact
oral
genit
secret
associ
acquisit
mani
sti
includ
hsv
cmv
epsteinbarr
viru
ebv
hpv
sever
immunosuppress
hct
recipi
consid
complet
avoid
unprotect
sexual
activ
ie
activ
involv
contact
hct
recipi
mucou
membran
saliva
semen
vagin
secret
long
remain
sever
immunodefici
ciii
sexual
activ
hct
recipi
avoid
sexual
practic
could
result
oral
exposur
fece
aiii
prevent
pettransmit
zoonot
infect
hct
physician
advis
recipi
candid
undergo
condit
therapi
potenti
infect
risk
pose
pet
ownership
howev
routin
advis
hct
recipi
part
pet
limit
except
immunocompromis
hct
recipi
candid
avoid
adopt
ill
juvenil
pet
eg
cat
month
old
stray
anim
biii
children
like
bitten
scratch
pet
thu
acquisit
new
pet
children
recent
hct
recipi
candid
hct
recommend
diii
gener
immunocompromis
hct
recipi
candid
undergo
condit
therapi
minim
direct
contact
anim
particularli
anim
ill
eg
diarrhea
biii
immunocompromis
person
choos
pet
awar
risk
infect
vari
type
anim
pet
acquir
larger
matur
anim
establish
vendor
pose
lower
risk
type
anim
immunocompromis
hct
recipi
candid
avoid
ownership
contact
reptil
eg
lizard
snake
turtl
iguana
risk
salmonellosi
bii
addit
patient
inform
salmonellosi
occur
fomit
contact
alon
therefor
hct
recipi
candid
avoid
contact
reptil
food
anyth
touch
contact
occur
recipi
candid
disinfect
hand
thoroughli
afterward
aiii
immunocompromis
hct
recipi
candid
avoid
ownership
contact
duckl
chick
risk
acquir
salmonella
campylobact
speci
infect
biii
immunocompromis
hct
recipi
candid
avoid
ownership
contact
exot
pet
eg
chinchilla
monkey
nonhuman
primat
bii
hct
recipi
candid
need
vigil
regard
mainten
pet
health
biii
pet
becom
ill
owner
seek
veterinari
care
promptli
minim
possibl
transmiss
pet
ill
owner
pet
experi
diarrhea
test
infect
biii
cryptosporidium
giardia
speci
salmonella
campylobact
owner
ensur
pet
date
recommend
vaccin
except
live
vaccin
biii
routin
screen
healthi
anim
zoonot
diseas
recommend
diii
feed
pet
highqual
commerci
pet
food
reduc
possibl
ill
caus
spoil
contamin
food
thu
reduc
possibl
transmit
ill
pet
hct
recipi
egg
poultri
meat
product
given
pet
supplement
well
cook
dairi
product
given
pet
pasteur
biii
pet
prevent
drink
toilet
bowl
water
scaveng
hunt
eat
anim
fece
access
garbag
biii
hct
recipi
handl
pet
clean
cage
perform
hand
hygien
alcoholbas
hand
gel
soap
water
prefer
hand
visibl
soil
contact
fece
adult
supervis
hand
disinfect
pediatr
hct
recipi
biii
hct
candid
recipi
avoid
contact
anim
fece
biii
reduc
risk
toxoplasmosi
cryptosporidiosi
salmonellosi
campylobacteriosi
clean
pet
litter
box
cage
dispos
anim
wast
diii
patient
unabl
find
assist
task
wear
dispos
glove
activ
wash
hand
thoroughli
afterward
biii
bird
cage
line
cat
litter
clean
regularli
eg
daili
person
particularli
immunocompromis
hct
candid
recipi
wear
glove
whenev
handl
item
contamin
bird
drop
biii
drop
sourc
cryptococcu
neoforman
mycobacterium
avium
h
capsulatum
minim
potenti
exposur
mycobacterium
marinum
immunocompromis
hct
recipi
candid
clean
fish
tank
diii
task
avoid
patient
wear
dispos
glove
activ
disinfect
hand
thoroughli
afterward
biii
hct
candid
recipi
may
also
come
contact
anim
medic
set
anim
typic
divid
categori
servic
therapi
visit
set
access
servic
anim
legal
restrict
anim
increasingli
use
adjunct
therapi
patient
cancer
chronic
ill
although
mani
studi
attest
overal
benefit
therapi
visit
anim
variou
clinic
set
risk
acquir
zoonot
infect
immunosuppress
hct
candid
recipi
need
care
consid
thu
recommend
given
mani
case
primari
toxoplasmosi
acquir
eat
undercook
meat
howev
hct
recipi
candid
particularli
gondii
seroneg
inform
risk
contract
toxoplasmosi
ingest
oocyt
contact
cat
fece
biii
although
need
requir
give
away
cat
dii
household
cat
litter
box
place
kitchen
dine
room
area
food
prepar
eat
occur
addit
litter
box
clean
daili
someon
hct
recipi
first
month
hct
period
substanti
immunosuppress
reduc
risk
transmit
toxoplasmosi
hct
recipi
biii
daili
litter
box
chang
minim
risk
fecal
transmiss
gondii
oocyst
fecal
oocyst
requir
day
incub
becom
infecti
hct
recipi
perform
task
first
month
hct
subsequ
period
substanti
immunocompromis
eg
gvhd
system
steroid
use
relaps
underli
diseas
transplant
perform
wear
dispos
glove
glove
discard
singl
use
biii
soil
dri
litter
dispos
care
prevent
aerosol
gondii
oocyst
biii
cat
fece
litter
flush
toilet
although
recommend
gondii
oocyst
consist
inactiv
sewag
system
diii
also
person
clean
cat
litter
particularli
hct
recipi
wash
hand
thoroughli
soap
water
afterward
reduc
risk
acquir
toxoplasmosi
biii
hct
recipi
candid
cat
keep
cat
insid
biii
adopt
handl
stray
cat
diii
cat
fed
can
dri
commerci
food
wellcook
tabl
food
raw
undercook
meat
elimin
possibl
caus
ill
could
transmit
cat
hct
recipi
biii
pet
cat
hct
recipi
need
test
toxoplasmosi
eii
playground
sandbox
kept
cover
use
prevent
cat
soil
biii
hct
recipi
candid
undergo
condit
therapi
avoid
drink
raw
goat
milk
decreas
risk
acquir
toxoplasmosi
diii
toxoplasmosi
may
also
acquir
contact
cat
fece
encount
garden
hct
recipi
avoid
walk
wade
swim
play
recreat
water
eg
pond
lake
like
contamin
cryptosporidium
e
coli
sewag
anim
human
wast
dii
hct
recipi
also
avoid
swallow
water
eg
swim
well
water
taken
directli
river
lake
eiii
water
beverag
may
pose
risk
immunocompromis
hct
candid
recipi
bacteri
viral
parasit
pathogen
hct
recipi
use
well
water
privat
well
public
well
commun
limit
popul
diii
test
microbi
contamin
perform
infrequ
eg
certain
locat
test
perform
timesmonth
detect
sporad
bacteri
contamin
howev
drink
well
water
municip
well
serv
highli
popul
area
regard
safe
bacteri
contamin
water
test
timesday
bacteri
contamin
hct
recipi
consum
tap
water
routin
monitor
mass
media
eg
radio
televis
newspap
area
immedi
implement
boilwat
advisori
might
issu
immunocompromis
person
state
local
govern
biii
boilwat
advisori
mean
tap
water
boil
minut
consum
although
municip
tap
water
gener
safe
may
complet
free
cryptosporidium
although
limit
data
exist
regard
risk
epidemiolog
cryptosporidium
diseas
among
hct
recipi
hct
recipi
avoid
possibl
exposur
cryptosporidium
diii
pathogen
report
caus
sever
chronic
diarrhea
malnutrit
death
among
immunocompromis
person
elimin
risk
cryptosporidium
exposur
tap
water
hct
recipi
boil
tap
water
minut
consum
ciii
altern
use
certain
type
water
filter
home
distil
reduc
risk
exposur
cryptosporidium
waterborn
pathogen
ciii
home
water
filter
use
capabl
remov
particl
mm
diamet
filter
revers
osmosi
list
filter
certifi
nation
sanit
foundat
nsf
standard
cyst
ie
cryptosporidium
remov
contact
nsf
intern
consum
line
http
wwwnsforg
howev
major
filter
capabl
remov
smaller
microb
eg
bacteria
virus
therefor
use
properli
treat
municip
water
major
devic
inappropri
use
water
unchlorin
privat
well
control
viral
bacteri
pathogen
bottl
water
consum
conform
region
standard
eg
fda
unit
state
direct
eu
process
remov
cryptosporidium
process
revers
osmosi
distil
particul
absolut
filtrat
hct
recipi
contact
bottler
directli
confirm
specif
bottl
water
undergon
process
intern
bottl
water
associ
contact
unit
state
pm
est
anytim
internet
site
http
wwwbottledwaterorg
obtain
contact
inform
regard
water
bottler
patient
take
precaut
absenc
boilwat
advisori
reduc
risk
cryptosporidiosi
extra
precaut
includ
avoid
fountain
beverag
ice
made
tap
water
restaur
bar
theater
fruit
drink
made
frozen
concentr
mix
tap
water
ice
tea
coffe
made
tap
water
drink
like
cryptosporidiumsaf
hct
recipi
includ
nation
distribut
brand
bottl
can
carbon
soft
drink
commerci
packag
noncarbon
drink
contain
fruit
juic
fruit
juic
requir
refriger
open
eg
store
unrefriger
groceri
shelv
can
bottl
soda
seltzer
fruit
drink
steam
hot
f
c
tea
coffe
juic
label
pasteur
nation
distribut
brand
frozen
fruit
juic
concentr
reconstitut
water
safe
sourc
hct
recipi
drink
nonpasteur
milk
fruit
veget
juic
eg
appl
cider
orang
juic
avoid
infect
brucella
speci
e
coli
salmonella
speci
cryptosporidium
pathogen
dii
recommend
food
safeti
base
larg
observ
gener
popul
concern
aris
detect
potenti
pathogen
food
support
document
evid
organ
sourc
opportunist
infect
immunocompromis
person
potenti
benefit
food
safeti
recommend
direct
specif
toward
hct
recipi
must
weigh
uncertain
valu
recommend
potenti
advers
affect
patient
nutrit
intak
andor
qualiti
life
hct
candid
person
prepar
food
hct
review
gener
food
safeti
practic
aiii
educ
regard
addit
food
safeti
practic
appropri
hct
recipi
review
educ
done
condit
regimen
ie
chemotherapi
radiat
begin
biii
adher
guidelin
decreas
risk
foodborn
diseas
among
hct
recipi
raw
poultri
meat
fish
seafood
handl
separ
surfac
eg
cut
board
counter
top
food
item
person
prepar
food
alway
use
separ
cut
board
wash
board
warm
water
soap
cut
differ
food
item
aiii
prevent
foodborn
ill
caus
campylobact
jejuni
salmonella
enteritidi
caus
sever
invas
infect
among
immunocompromis
person
uncook
meat
come
contact
food
diii
prepar
raw
poultri
meat
fish
seafood
prepar
food
food
handler
wash
hand
thoroughli
warm
soapi
water
cut
board
counter
knive
utensil
use
also
wash
thoroughli
warm
soapi
water
aiii
food
prepar
keep
shelv
countertop
refriger
freezer
utensil
spong
towel
kitchen
item
clean
aiii
fresh
produc
wash
thoroughli
run
water
serv
aiii
person
prepar
food
follow
publish
recommend
regard
safe
food
thaw
biii
person
cook
food
hct
recipi
follow
establish
guidelin
monitor
intern
cook
temperatur
meat
method
determin
meat
adequ
cook
aii
differ
kind
meat
cook
vari
intern
temperatur
f
c
aii
specif
food
oversight
agenc
us
depart
agricultur
recommend
poultri
cook
intern
temperatur
f
c
meat
eggcontain
casserol
souffl
es
cook
intern
temperatur
f
c
cold
food
store
f
c
hot
food
kept
f
c
biii
food
prepar
wash
hand
handl
leftov
aiii
use
clean
utensil
foodprepar
surfac
aiii
divid
leftov
small
unit
store
shallow
contain
quick
cool
aii
refriger
leftov
within
hour
cook
aii
discard
leftov
kept
room
temperatur
hour
aiii
reheat
leftov
heat
partial
cook
food
f
c
throughout
serv
aii
bring
leftov
soup
sauc
gravi
roll
boil
serv
aiii
follow
publish
guidelin
cold
storag
food
aii
leftov
food
place
refriger
date
discard
hour
addit
food
safeti
practic
appropri
hct
recipi
hct
recipi
diet
restrict
prior
engraft
decreas
risk
exposur
foodborn
infect
bacteria
yeast
mold
virus
parasit
lowmicrobi
diet
recommend
hct
recipi
prior
engraft
although
evid
efficaci
prevent
infect
lack
ciii
hct
recipi
engraft
follow
diet
balanc
risk
acquir
foodborn
ill
import
proper
nutrit
supplement
recommend
outlin
tabl
diet
continu
month
autolog
hct
allogen
hct
recipi
remain
diet
immunosuppress
drug
discontinu
patient
reach
mileston
receiv
live
viru
vaccin
howev
hct
physician
final
respons
determin
diet
discontinu
safe
hct
recipi
eat
raw
undercook
meat
includ
beef
poultri
pork
lamb
venison
wild
game
combin
dish
contain
raw
undercook
meat
sweetbread
anim
eg
sausag
casserol
eii
hct
recipi
candid
consum
meat
well
done
caretak
direct
control
food
prepar
eg
eat
restaur
ai
hot
dog
delistyl
readytoeat
meat
avoid
unless
heat
steam
aii
hct
recipi
consum
raw
undercook
egg
food
might
contain
eg
certain
prepar
hollandais
sauc
caesar
salad
dress
homemad
mayonnais
homemad
eggnog
risk
infect
salmonella
enteritidi
eii
hct
recipi
consum
raw
undercook
seafood
eg
oyster
clam
prevent
exposur
vibrio
speci
viral
gastroenter
cryptosporidium
parvum
eii
fruit
veget
provid
essenti
nutrit
element
hct
patient
certain
precaut
taken
prevent
acquisit
infect
gener
may
help
remind
patient
adag
ca
nt
peel
wash
nt
eat
infect
agricultur
product
acquir
either
contamin
item
field
subsequ
harvest
process
wash
fruit
veget
tap
water
advis
even
skin
rind
organ
food
prepackag
item
label
prewash
biii
wash
may
prevent
mani
contaminationrel
infect
hct
recipi
avoid
fruit
veget
may
confer
higher
risk
infect
includ
raw
veget
sprout
e
coli
salmonella
fresh
salsa
berri
eii
food
item
associ
foodborn
outbreak
past
therefor
hct
patient
avoid
includ
unroast
raw
nut
nut
shell
miso
product
raw
grain
product
nonpasteur
milk
product
milk
chees
yogurt
chees
contain
uncook
veget
chees
mold
ie
blue
stilton
roquefort
gorgonzola
soft
chees
eg
brie
feta
smoke
pickl
seafood
raw
honey
temp
product
eii
date
evid
exist
greater
risk
acquir
infect
eat
fast
food
restaur
convent
sitdown
restaur
sever
step
taken
ensur
safeti
food
consum
establish
aiii
ask
food
freshli
prepar
ie
avoid
food
sit
heat
lamp
ask
fruit
juic
pasteur
avoid
raw
fruit
veget
dine
ask
singleserv
condiment
packag
avoid
use
public
selfserv
condiment
contain
avoid
salad
bar
delicatessen
buffet
smorgasbord
etc
set
utensil
napkin
clean
tablecloth
placemat
rather
directli
tabl
plan
take
leftov
home
transfer
food
directli
box
tabl
similarli
although
consumpt
prepar
food
purchas
street
vendor
industri
countri
associ
infect
food
prepar
stringent
sanitari
condit
guarante
therefor
food
avoid
diii
true
food
brought
other
gather
potluck
picnic
consumpt
food
activ
live
yeast
cultur
probiot
promot
effect
mean
prevent
infect
studi
date
definit
support
literatur
possibl
consumpt
probiot
reduc
antibioticassoci
diarrhea
genitourinari
infect
use
probiot
examin
set
hct
dissemin
infect
probiot
administr
report
hct
patient
howev
hct
recipi
avoid
use
probiot
diii
hct
candid
undergo
condit
therapi
hct
recipi
neutropenia
ie
anc
period
substanti
immunocompromis
also
avoid
exposur
naturopath
medicin
might
contain
mold
diii
hct
recipi
wish
take
naturopath
medic
advis
use
prescrib
licens
naturopath
physician
work
consult
recipi
transplant
infecti
diseas
physician
ciii
hct
recipi
particularli
allogen
recipi
chronic
immunosuppress
travel
develop
countri
pose
substanti
risk
exposur
opportunist
pathogen
hct
recipi
plan
travel
develop
countri
without
consult
physician
eiii
undertak
travel
period
sever
immunosuppress
resolv
gener
allogen
recipi
plan
travel
develop
countri
month
hct
refrain
travel
set
immunosuppress
treatment
gvhd
autolog
recipi
travel
develop
countri
month
hct
hct
provid
agre
safe
appropri
hct
recipi
educ
regard
strategi
minim
risk
acquir
infect
travel
select
strategi
includ
follow
hct
recipi
obtain
updat
detail
health
inform
intern
travel
health
organ
aiii
adventur
travel
eg
kayak
particip
triathlon
associ
epidem
infect
leptospirosi
avoid
diii
air
travel
gener
safe
although
rare
may
associ
acquisit
respiratori
ill
eg
influenza
tuberculosi
measl
hct
recipi
use
techniqu
social
distanc
hand
hygien
avoid
infect
passeng
close
proxim
exhibit
respiratori
symptom
biii
cruis
ship
gener
consid
safe
may
associ
acquisit
gi
eg
noroviru
legionella
infect
hct
recipi
fastidi
wash
hand
soap
water
frequent
cruis
promptli
report
symptom
may
aris
transplant
team
aii
food
safeti
paramount
import
travel
develop
countri
hct
recipi
avoid
consum
diii
raw
fruit
veget
tap
water
potenti
untreat
contamin
water
ice
made
tap
water
potenti
contamin
water
nonpasteur
milk
nonpasteur
dairi
product
fresh
fruit
juic
food
drink
street
vendor
raw
undercook
egg
steam
hot
food
fruit
peel
oneself
bottl
can
process
drink
hot
coffe
tea
probabl
safe
travel
plan
treat
drink
water
develop
countri
bottl
water
avail
boil
best
method
make
water
safe
howev
boil
water
feasibl
travel
carri
suppli
disinfect
water
eg
commerci
avail
iodin
disinfect
tablet
portabl
water
filter
biii
referenc
food
safeti
section
water
disinfect
mitig
risk
cryptosporidiosi
viral
infect
antimicrobi
prophylaxi
travel
diarrhea
recommend
routin
hct
recipi
travel
develop
countri
diii
howev
hct
physician
wish
provid
prophylaxi
hct
recipi
travel
prescrib
fluoroquinolon
eg
ciprofloxacin
appendix
ciii
clinician
recommend
use
bismuth
subsalicyl
prevent
travel
diarrhea
adult
howev
data
found
regard
safeti
efficaci
among
hct
recipi
salicyl
recommend
use
among
person
younger
year
age
salicyl
associ
rey
syndrom
hct
recipi
immun
statu
assess
vaccin
updat
need
travel
tabl
influenza
chemoprophylaxi
oseltamivir
zanamivir
depend
circul
strain
suscept
use
immunocompromis
hct
recipi
could
expos
influenza
travel
ciii
travel
vigil
risk
pandem
influenza
sever
acut
respiratori
syndrom
sar
vaccin
recommend
previous
develop
publish
separ
ebmt
cdc
idsa
asbmt
purpos
vaccin
schedul
joint
updat
guidelin
provid
guidanc
hct
center
around
globe
antibodi
titer
vaccineprevent
diseas
eg
tetanu
polio
measl
mump
rubella
declin
year
allogen
autolog
hematopoiet
cell
transplant
hct
recipi
revaccin
clinic
relev
decreas
antibodi
vaccineprevent
diseas
among
hct
recipi
immedi
appar
limit
number
case
vaccineprevent
diseas
report
among
hct
recipi
howev
vaccineprevent
diseas
still
pose
risk
popul
addit
evid
exist
certain
vaccineprevent
diseas
pneumococc
infect
haemophilu
influenza
type
b
hib
infect
measl
varicella
influenza
pose
increas
risk
hct
recipi
therefor
hct
recipi
routin
revaccin
hct
experi
immun
vaccineprevent
diseas
other
tabl
although
sever
studi
evalu
safeti
immunogen
eg
serolog
studi
antibodi
titer
vaccin
differ
vaccin
allogen
hct
recipi
limit
indirect
data
found
regard
vaccin
efficaci
among
hct
recipi
ie
whether
vaccin
hct
recipi
decreas
attack
rate
infect
compar
unvaccin
hct
recipi
vaccin
mount
respons
thought
clinic
relev
eg
rise
specif
antibodi
level
rise
level
consid
protect
adapt
b
cell
immun
posttranspl
must
least
partial
reconstitut
b
cell
count
typic
zero
nearzero
first
month
hct
return
normal
month
posttranspl
patient
treat
rituximab
posttranspl
b
cell
recoveri
gener
delay
month
follow
last
dose
regardless
time
recoveri
newli
gener
b
cell
often
demonstr
impair
antigenspecif
respons
limit
capabl
b
cell
undergo
somat
mutat
isotyp
switch
first
year
transplant
cell
count
low
first
month
posttranspl
count
typic
thereaft
recoveri
cell
particularli
cell
influenc
patient
age
hct
substanti
cell
deplet
tcd
graft
presenc
absenc
cgvhd
patient
year
hct
without
cgvhd
recov
cell
count
month
transplant
wherea
adult
particularli
cgvhd
may
requir
year
circul
cell
first
year
transplant
particularli
adult
memoryeffector
cell
like
deriv
cell
infus
graft
capabl
respond
antigen
encount
donor
prior
transplant
cell
capabl
respond
new
antigen
start
gener
month
posttranspl
earlier
young
children
later
older
adult
hct
recipi
vari
immun
system
recoveri
hct
propos
differ
vaccin
schedul
recommend
recipi
differ
type
hct
rational
exampl
autolog
hct
patient
lose
immun
frequent
rapidli
patient
allogen
hct
exist
evid
suggest
howev
loss
immun
also
common
autolog
hct
particularli
patient
receiv
multipl
cours
chemotherapi
hct
respons
vaccin
similar
occur
allogen
hct
also
recogn
limit
inform
regard
vaccin
immunogen
exist
patient
transplant
umbil
cord
blood
ucb
haploident
graft
reducedintens
condit
ric
sake
simplic
therefor
committe
chosen
recommend
vaccin
schedul
hct
recipi
addit
data
publish
cell
respons
vaccin
pathogen
encount
pretranspl
eg
varicella
zoster
viru
vzv
observ
soon
month
posttranspl
antibodi
respons
vaccin
pathogen
encount
pretranspl
eg
tetanu
toxoid
observ
month
hct
cell
antibodi
respons
vaccin
pathogen
encount
pretranspl
eg
hepat
b
viru
hbv
european
american
adult
usual
observ
later
year
posttranspl
hct
recipi
similar
young
children
respond
poorli
pure
polysaccharid
antigen
includ
polysaccharid
pneumococc
vaccin
pure
polysaccharid
antigen
elicit
antibodi
respons
later
hct
protein
antigen
eg
diphtheria
toxoid
polysaccharideprotein
conjug
eg
hib
capsular
polysaccharid
conjug
carrier
protein
graftversushost
diseas
gvhd
andor
treatment
hamper
cell
antibodi
respons
vaccin
studi
shown
patient
chronic
gvhd
cgvhd
mount
respons
vaccin
clearli
need
protect
pneumococci
guidelin
recommend
postpon
vaccin
patient
gvhd
except
withhold
live
vaccin
howev
vaccin
patient
activ
gvhd
may
prudent
measur
specif
antibodi
level
vaccin
determin
level
protect
need
booster
immun
vaccin
administ
person
month
old
pregnant
immunocompromis
neg
uncertain
histori
varicella
diseas
neg
serolog
screen
note
two
dose
given
separ
least
day
aiii
hct
indic
hematopoiet
cell
transplant
children
age
month
year
receiv
influenza
vaccin
first
time
requir
dose
receiv
dose
first
year
receiv
dose
follow
year
hcw
famili
member
close
contact
hct
recipi
receiv
influenza
vaccin
influenza
outbreak
also
receiv
chemoprophylaxi
base
strain
suscept
bi
vaccine
develop
immunolog
respons
vaccin
howev
nosocomi
outbreak
occur
influenza
strain
contain
avail
influenza
vaccin
hcw
famili
member
close
contact
hct
recipi
candid
administ
influenza
chemoprophylaxi
base
strain
suscept
end
outbreak
biii
polio
viru
oral
polio
vaccin
transmit
person
person
therefor
oral
polio
vaccin
administr
contraind
among
household
contact
immunocompromis
person
oral
polio
vaccin
inadvert
administ
household
contact
hct
recipi
acip
american
academi
pediatr
recommend
follow
minim
close
contact
immunocompromis
person
week
vaccin
vaccineassoci
paralyt
poliomyel
report
among
hct
recipi
exposur
household
contact
inadvert
vaccin
oral
polio
vaccin
inactiv
polio
vaccin
use
among
famili
member
close
contact
hcw
avoid
persontoperson
transmiss
vaccinestrain
polio
viru
famili
member
close
contact
visitor
document
histori
varicellazost
infect
seroneg
receiv
varicella
vaccin
allow
visit
direct
contact
hct
recipi
aiii
ideal
varicellazostersuscept
hcw
famili
member
household
contact
potenti
visitor
immunocompromis
hct
recipi
vaccin
soon
decis
perform
hct
made
vaccin
dose
dose
complet
week
condit
regimen
begin
week
day
contact
hctrecipi
plan
biii
varicella
vaccine
develop
postvaccin
rash
within
day
vaccin
vaccine
avoid
contact
hct
recipi
rash
lesion
crust
rash
resolv
children
month
year
receiv
two
dose
month
apart
adolesc
year
adult
receiv
dose
week
apart
committe
split
recommend
differ
categori
tabl
vaccin
list
evid
exist
regard
safeti
immunogen
gener
recommend
use
hct
recipi
sinc
previou
version
vaccin
guidelin
publish
new
vaccin
introduc
addit
clinician
hct
center
get
question
patient
famili
member
hcw
regard
vaccin
special
situat
diseas
exposur
travel
area
endem
infect
previous
consid
recommend
therefor
comment
made
regard
vaccin
situat
tabl
although
limit
data
exist
final
situat
vaccin
famili
member
household
contact
hcw
recommend
minim
exposur
vaccineprevent
diseas
among
hct
recipi
tabl
vaccin
donor
shown
improv
posttranspl
immun
patient
case
tetanu
toxoid
pcv
hibconjug
vaccin
recommend
made
regard
donor
vaccin
practic
ethic
difficulti
surround
issu
hct
patient
immunosuppress
vari
degre
therefor
prudent
test
immun
infect
vaccin
test
vaccin
test
antibodi
measl
recommend
adult
vaccin
perform
patient
seroneg
ciii
tabl
vaccin
varicella
contempl
test
immun
perform
vaccin
given
seroneg
patient
ciii
tabl
test
vaccin
test
vaccin
indic
either
assess
respons
vaccin
need
addit
dose
check
durabl
respons
longterm
followup
test
assess
respons
vaccin
pneumococc
diseas
recommend
month
later
third
fourth
dose
pneumococc
vaccin
biii
tabl
differ
method
assess
pneumococc
antibodi
level
advantag
disadvantag
thu
specif
method
recommend
likewis
wide
accept
definit
adequ
respons
pneumococc
vaccin
lack
guidelin
revaccin
nonrespond
given
test
assess
respons
hbv
vaccin
also
recommend
test
done
month
later
third
vaccin
dose
biii
second
vaccin
schedul
recommend
nonrespond
ciii
interv
first
second
seri
determin
individu
nonrespons
hbv
vaccin
differ
caus
eg
cgvhd
case
may
prudent
revaccin
gvhd
abat
regular
test
longterm
hct
survivor
mainten
antibodi
level
recommend
biii
test
conduct
approxim
everi
year
assess
immun
hbv
measl
tetanu
diphtheria
polio
biii
test
immun
pneumococcu
might
reason
repeat
everi
year
first
year
biii
need
revaccin
assess
individu
basi
type
pneumococc
vaccin
conjug
vaccin
pcv
polysaccharid
vaccin
conjug
vaccin
compar
polysaccharid
vaccin
pcv
immunogen
howev
spectrum
protect
narrow
cover
strain
pneumococci
wherea
cover
strain
given
first
year
transplant
elicit
inadequ
respons
four
prospect
trial
demonstr
better
respons
pcv
hct
recipi
thu
pcv
prefer
vaccin
like
benefici
use
fourth
dose
dose
pcv
bii
broaden
immun
respons
fourth
dose
pcv
might
increas
respons
rate
patient
cgvhd
less
like
respond
ciii
microbiolog
document
pneumococc
infect
occur
pneumococc
vaccin
document
serotyp
strain
recommend
biii
know
whether
serotyp
among
includ
vaccin
indic
nonrespons
vaccin
patient
receiv
addit
dose
pneumococc
vaccin
choic
vaccin
ie
pcv
depend
document
strain
biii
time
posttranspl
initi
routin
vaccin
pcv
controversi
one
trial
show
similar
antibodi
respons
vaccin
start
month
earli
month
late
posttranspl
thu
earli
vaccin
may
prefer
may
protect
late
also
earli
pneumococc
diseas
note
earli
vaccin
may
prime
boost
effici
late
vaccin
also
earli
vaccin
may
result
shorter
last
antibodi
respons
therefor
vaccin
start
earli
may
particularli
import
determin
pneumococc
antibodi
level
low
revaccin
biii
gener
type
diphtheria
tetanu
vaccin
contain
full
dose
diphtheria
toxoid
combin
tetanu
toxoid
dt
contain
reduc
dose
diphtheria
toxoid
td
lower
case
indic
reduc
diphtheria
toxoid
tetanu
content
essenti
td
td
use
reduc
diphtheria
toxoid
vaccin
follow
transplant
associ
lack
respons
therefor
posttranspl
patient
view
never
vaccin
full
toxoid
vaccin
use
possibl
dt
vaccin
approv
individu
year
age
unit
state
side
effect
although
experi
adult
hct
recipi
receiv
dt
vaccin
indic
lower
risk
side
effect
previous
vaccin
healthi
adult
adult
transplant
recipi
might
adequ
respons
diphtheria
portion
td
howev
whether
respons
equal
td
studi
check
diphtheria
antibodi
level
vaccin
td
might
therefor
warrant
situat
increas
risk
diphtheria
might
envisag
gener
popul
advisori
committe
immun
practic
cdc
recommend
use
acellular
rather
whole
cell
pertussi
vaccin
pediatr
vaccin
regimen
sinc
steadi
increas
pertussi
last
decad
licens
vaccin
contain
tetanu
reduc
dose
diphtheria
reduc
dose
pertussi
tdap
cdc
recommend
adolesc
year
age
adult
year
age
receiv
singl
dose
tdap
replac
routin
adult
tetanu
diphtheria
toxoid
td
booster
adolesc
prefer
age
rang
year
adult
year
singl
tdap
recommend
replac
routin
td
booster
given
year
earlier
recommend
interv
year
td
tdap
concern
local
site
reaction
howev
adult
contact
infant
month
hcw
commun
outbreak
pertussi
interv
short
year
last
td
recommend
aim
decreas
reservoir
pertussi
affect
infant
immunocompromis
individu
regardless
age
hct
recipi
may
particularli
vulner
complic
pertussi
pulmonari
damag
chemotherapi
andor
tbi
even
absenc
cgvhd
posttranspl
patient
view
never
vaccin
receiv
full
dose
toxoid
dt
vaccin
includ
fulldos
reduc
dose
acellular
pertussi
toxoid
dtap
avail
unit
state
dtap
avail
children
year
adult
pertussi
vaccin
use
frequent
commun
physician
tdap
contain
tetanu
toxoid
reduceddos
diphtheria
toxoid
reduceddos
acellular
pertussi
toxoid
tdap
differ
dtap
vaccin
current
given
babi
young
children
contain
lesser
quantiti
diphtheria
pertussi
protein
much
less
like
dtap
caus
side
effect
pain
red
tender
preliminari
data
autolog
allogen
transplant
recipi
demonstr
respons
reduc
dose
pertussi
tdap
poor
regardless
vaccin
given
use
tdap
initi
tetanuscontain
vaccin
adult
autolog
hct
recipi
associ
lack
respons
tetanu
well
pertussi
portion
suggest
vaccin
use
booster
vaccin
rather
part
primari
seri
vaccin
higher
tetanu
pertussi
content
may
immunogen
hct
recipi
thu
consid
initi
vaccin
lifelong
season
influenza
vaccin
inactiv
influenza
vaccin
recommend
hct
candid
recipi
aii
vaccin
initi
hct
depend
epidemiolog
situat
like
effect
better
later
hct
whether
influenza
vaccin
benefici
first
month
follow
nonmyeloabl
condit
unknown
vaccin
given
earlier
month
hct
regardless
condit
intens
second
dose
could
contempl
ciii
live
intranas
influenza
vaccin
use
inactiv
altern
exist
eiii
commun
outbreak
hct
recipi
yet
receiv
current
influenza
vaccin
vaccin
influenza
immedi
month
hct
biii
second
dose
also
given
especi
first
dose
month
hct
ciii
pediatr
hct
recipi
candid
month
old
annual
season
influenza
vaccin
recommend
biii
children
year
old
receiv
influenza
vaccin
first
time
requir
dose
administ
month
apart
ai
main
varicella
vaccin
direct
prevent
chickenpox
varivax
shingl
zostavax
differ
vaccin
number
plaqu
form
unit
attenu
viru
chickenpox
vaccin
lower
viral
titer
use
hct
recipi
met
criteria
live
viru
vaccin
new
shingl
vaccin
use
much
higher
viral
titer
vaccin
recommend
hbsag
hbcabposit
patient
vaccin
reduc
risk
revers
seroconvers
bii
hbsag
hbcabneg
hct
patient
recommend
gener
popul
countri
resid
follow
polysaccharidebas
conjug
vaccin
exist
reason
assum
true
vaccin
pneumococci
hib
conjug
meningococc
vaccin
give
stabl
immun
respons
polysaccharidebas
vaccin
although
compar
studi
vaccin
type
perform
first
choic
altern
prophylaxi
allogen
hct
recipi
b
autolog
hct
recipi
prolong
neutropenia
mucos
damag
intens
condit
regimen
graft
manipul
recent
receiv
purin
analogu
note
administ
prophylaxi
start
condit
day
transplant
advancedgener
azol
engraft
ie
approxim
day
hct
day
absolut
neutrophil
count
cell
mm
